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ABSTRACT
SEX-BASED DIFFERENCES IN MICROBIOTA COMPOSITION AND 
METABOLOMIC PROFILES ASSOCIATED WITH ALTERED MACROPHAGE 
FUNCTION AND PROTECTION FROM LUPUS IN BWF1 MICE 
James W. Harder 
January 14, 2021 
Systemic lupus erythematosus (SLE) is a complex and an insidious disease that is 
still not completely understood, and has very few treatment options. Those that are 
available are ineffective and/or have serious side effects. Both genetic and environmental 
factors contribute to the susceptibility and resistance to SLE, and understanding the 
environmental factors underlying this disease could lead to more effective prevention 
and/or treatment strategies. Like most autoimmune diseases, SLE is much more prevalent 
in females than males. While there are numerous factors that contribute to this lupus 
susceptibility, there is increasing evidence that the microbiota can strongly influence 
lupus progression, and that sex-based differences in microbiota composition and function 
may play a role in the sex bias (i.e., susceptibility in females and resistance in males) of 
disease. The NZBxNZW F1 (BWF1) mouse model of lupus has many of the same 
disease features seen in humans including the sex bias, making it an ideal model for 
studying sex-based differences in microbiota and how they affect lupus progression. 
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Previous findings from our laboratory have shown that not only do female and male 
BWF1 microbiota profiles differ significantly, but male BWF1 microbiota can suppress 
lupus when cecal contents are transferred into female BWF1 recipients. The overall goal 
of this dissertation was to identify the players involved and begin to understand the 
potential mechanisms underlying the suppressive effect of the male microbiota on 
disease. Three aims were designed to address these issues. The goal of aim 1 was to 
identify the bacterial populations in the microbiota of female and male BWF1 mice that 
may either cause or suppress disease. The goal of aim 2 was to analyze the function of 
female and male microbiota by identifying metabolites that may be involved in the 
suppression of disease. In aims 1 and 2, we also investigated the impact of androgens on 
bacterial populations and metabolite profiles, respectively, by comparing intact and 
castrated male mice. In aim 3, the goal was to investigate the potential immune 
mechanisms that could underlie the suppression of disease mediated by male microbiota. 
The results of the first aim indicate that changes in the abundances of Bacteroides, 
Clostridium, and Alistipes strongly correlated with the ability of transferred male BWF1 
microbiota to suppress disease in female BWF1 recipients. We took advantage of a 
change in animal facility that had a significant impact on our mouse colony and its 
microbiota populations, and gave us an opportunity to analyze and compare bacterial 
populations during periods of time when microbiota transfers had varying results. 
Specifically, we found that Bacteroides (primarily the Bacteroides acidifaciens species) 
abundance was high, Clostridium (primarily the Clostridium leptum species) abundance 
was low, and Alistipes was present during the periods when transfer of male microbiota 
was effective at suppressing disease in female BWF1 mice. Conversely, Bacteroides 
vii 
abundance was low, Clostridium abundance was high, and Alistipes was absent when 
male microbiota lost that capability. We concluded from our thorough microbiota 
analyses that a high Bacteroides/Clostridium ratio in the male microbiota may be a 
reliable predictor of disease-suppressing capability, since it correlated strongly with 
disease suppression in female recipients of male microbiota. The second aim of the 
project used analysis of metabolomic profiles to investigate functional differences in 
female and male BWF1 microbiota. Differential production of immunomodulatory 
metabolites is a major mechanism by which the gut microbiota influences the immune 
system. By measuring the fecal metabolite profiles, we identified phytol as a potential 
mediator of lupus suppression by male microbiota. Phytol is produced by the microbiota 
and converted into phytanic acid by host enzymes. Both phytol and phytanic acid were 
significantly more abundant in intact male than either female or castrated male BWF1 
mice. Both phytol and phytanic acid have potent RXR and PPARγ agonist properties, all 
of which can directly influence many different immune functions. The third aim of this 
project investigated the differences in female and male macrophage efferocytosis (i.e., 
phagocytosis of apoptotic cells) efficacy and how phytol and/or phytanic acid could 
affect this immune function. Deficiencies in efferocytosis, particularly by macrophages, 
are a major risk factor for SLE because they result in the accumulation of debris that 
stimulates autoantibody production. We found male BWF1 splenic macrophages were 
more efficient at efferocytosis than female splenic macrophages, and treatment with 
phytanic acid in vitro or in vivo could enhance female splenic macrophage efferocytosis. 
Overall, we found that higher Bacteroides and lower Clostridium abundances 
correlated with lupus suppression in female BWF1 recipients of male microbiota, and 
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speculate that this protection could be due, at least in part, to higher levels of phytol and 
phytanic acid production in males. Furthermore, phytol and phytanic acid produced by 
males may suppress disease, again at least in part, via enhancement of macrophage 
efferocytosis. Taken together, these data may provide the basis for a mechanistic 
understanding of the impact that the microbiota can have on autoimmune diseases such as 
lupus, and for the development of novel therapies.
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INTRODUCTION
Sex bias in systemic lupus erythematosus (SLE) 
The core characteristic of mammalian immune systems is the ability to 
differentiate between self and non-self-antigens. This self-tolerance is mediated by both 
central and peripheral mechanisms. Central mechanisms involve removal of autoreactive 
T and B cells before they fully mature, while peripheral mechanisms involve inducing 
tolerance to self-antigens to suppress immune responses against non-foreign cells and 
tissues. When these mechanisms fail and self-tolerance is lost, the result is autoimmunity. 
Most autoimmune diseases have a significant sex bias. Women comprise over 
80% of autoimmune disease patients in Western countries. For the multi-organ 
autoimmune disease, systemic lupus erythematosus, also called SLE or lupus, this sex 
difference is even more pronounced as about 9 in every 10 people affected by SLE are 
women [1,2]. SLE is characterized by the loss of tolerance to nuclear self-antigens such 
as double-stranded DNA (dsDNA), single-stranded DNA (ssDNA, dsRNA), single-
stranded RNA (ssRNA), histones, small nuclear ribonucleoproteins (snRNPs), and 
ribosomes. This results in the production of anti-nuclear antibodies, which bind nuclear 
antigens and form antigen-antibody complexes that are deposited in the joints, 
vasculature, skin lungs, kidneys, and other organs. These immune complex deposits 
cause inflammation and immune cell infiltration. Over time this leads to increasing levels 
of tissue damage that can result in organ failure if untreated. This can manifest as lupus 
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nephritis, vasculitis, pulmonary hypertension, or stroke, and over 50% of lupus patients 
develop one or more of these complications [3]. These complications are even more 
common in male SLE patients, who tend to have more severe and rapid disease 
progression despite being less likely to develop the disease [4-8]. However, despite lupus 
nephritis being more common in male SLE patients, the incidence of progression to end-
stage renal disease is not different between male and female SLE patients [5,9-13]. 
Musculoskeletal involvement, on the other hand, seems to be more common in women 
[14]. 
There are many mouse models of lupus, and many of them share the same sex 
bias as the human disease. The models can be divided into two major categories: 
spontaneous and induced [15]. The most well-established spontaneous mouse model of 
lupus is the NZBxNZW F1 (BWF1) model. Female BWF1 mice spontaneously develop 
anti-dsDNA autoantibodies, lymphadenopathy, splenomegaly, and glomerulonephritis in 
a manner that resembles the progression of disease in humans. Male BWF1 mice rarely 
develop the disease, and the disease is much milder in them if they do [16]. Androgen 
depletion of males by castration results in severe disease at a much younger age, 
indicating that androgens are as critical for the sex bias in BWF1 mice as they are in 
humans [17]. Backcrossing the BWF1 strain with the NZW strain has given rise to two 
additional strains that are used as lupus models, NZM2410 and NZM2328 [15]. 
NZM2410 mice develop lupus-like disease similar to BWF1, however, the pronounced 
sex bias seen in BWF1 mice is not present in the NZM2410 strain [18,19]. NZM2328, on 
the other hand, does display a sex bias closer BWF1 mice, with females developing a 
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more severe form of lupus-like disease at an earlier age, though the penetrance of disease 
is lower in female NZM2328 mice than in female BWF1 mice [15,20]. 
The SWRxNZB F1 (SNF1) mouse model of lupus shares the NZB parental strain 
with the BWF1 model. It spontaneously develops lupus-like disease in a manner very 
similar to BWF1, producing anti-nuclear autoantibodies that lead to glomerulonephritis 
[21-23]. Also, like the BWF1 model, the SNF1 has a distinct sex bias. Female SNF1 mice 
develop disease more often, more severely, and more quickly than male SNF1 mice 
[21,24,25]. Although interestingly, unlike the BWF1 model where castration causes 
severe disease and mortality in male mice, a recent study of SNF1 mice found that 
castration of male mice caused only a slight increase in disease that was not a statistically 
significant change [26]. 
Another mouse model of lupus is the MRL/lpr model, which lacks a functional 
Fas gene. This results in the accumulation of double negative CD4-CD8- T cells and 
levels of lymphadenopathy that is not seen in human SLE patients. However, it does 
develop autoantibodies and glomerulonephritis at a younger age than other lupus mouse 
models. This occurs in both male and female mice, with no sex bias in incidence [27], 
though female MRL/lpr mice do develop severe nephritis and organ failure a few weeks 
earlier than male MRL/lpr mice [28]. This contrasts with another mouse model, the 
BXSB/Yaa (BXSB) model. The X chromosomes of this strain have a translocated Y 
chromosome genetic locus that includes the gene for TLR7. Male BXSB mice thus have 
2 copies of the locus and consequently develop lymphadenopathy, anti-nuclear 
autoantibodies, and glomerulonephritis. Female BXSB mice do not develop disease [29]. 
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There are also mouse models of lupus that require specific treatment to develop 
disease. Pristane-induced lupus models of mice use intraperitoneal injections of the 
pristane, a naturally occurring hydrocarbon oil that induces chronic inflammation in the 
peritoneal cavity. This leads to the production of anti-nuclear autoantibodies and 
glomerulonephritis [30]. The exact responses depend on the strain of mice, and in some 
strains, such as the SJL strain, the induced disease is more severe in female mice [31,32] 
Another class of induced-lupus models uses chronic graft-versus-host disease 
(cGVHD) to mimic lupus. These models rely on transferring donor lymphocytes into 
MHC mismatched recipients. Disease is stimulated by the alloreactive donor CD4+ T 
cells reacting with the MHC class II expressing host B cells resulting in polyclonal 
activation and the development of autoantibody-producing B cells [15,33]. There are 
several variations of the cGVHD model based on what strains are used for donors and 
recipients. Two of the most common are the DBA/2 donor into (C57BL/6 X DBA/2) F1 
recipient model (DBA->BDF1) and the C57BL/6.bm12 donor into C57BL/6 recipient 
model (bm12->B6). While both models result in lupus-like disease, with anti-nuclear 
autoantibody production and glomerulonephritis, the DBA->BDF1 model exhibits a sex 
bias where female to female transfer recipients develop more severe renal disease than 
male to male transfer recipients, but the bm12->B6 model has no sex bias [33-35]. This is 
due to the fact that the bm12->B6 model only has an MHC II mismatch while the DBA-
>BDF1 has an MHC I and MHC II mismatch. While the MHC II mismatch drives 
disease as described above, the MHC I mismatch results in a graft vs host reaction where 
the donor CD8+ cytotoxic lymphocytes (CTL) recognize the host autoantibody-producing 
B cells as foreign and eliminate them. This graft vs host CD8+ T cell CTL response is 
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much stronger when the donor cells are from male mice. This stronger CD8+ T cell CTL 
has two significant outcomes. First, the reduction of numbers of host B cells results in 
lower autoantibody production and lower disease. Second, the strong response of the 
male donor CD8+ T cells results in subsequent contraction of the male donor CD8+ T cell 
population and lower engraftment of male donor CD8+ T cells. After the initial CTL 
response is over and the donor CD8+ T cells engraft, they promote disease via an IFN-γ 
production. Thus, the lower engraftment of CD8+ T cells in male mice leads to lower 
IFN-γ production and contributes to the milder disease seen in males. Conversely, the 
lower initial CD8+ T cell CTL responses and subsequent higher engraftment and IFN-γ 
production in female results in a more severe disease [33,35].  
Deficient CD8 CTL activity is also present in other mouse models, including 
BWF1 mice [36-38], MRL/lpr mice [39,40], and BXSB-Yaa mice [41,42]. Humans prone 
to SLE also exhibit dysfunctional CD8 T cells and lower cytolytic activity [43-49]. 
However, how this connects to the sex bias in humans is unclear. While studies have 
found males have higher CD8 T cell frequencies, some studies have also found PBMCs 
from women to have higher levels of CD8 cytotoxic activity [50-55]. These seemingly 
contradictory results may be due to differences in estrogen levels in the women who 
participated in the studies. Estrogen levels rise and fall during the menstrual cycle, and 
estrogen has repeatedly been shown to suppress CD8+ T cell CTL activity [56-58]. 
Further complicating comparisons between male and female patients is the fact that sex 
differences in levels of CD8 cells change with age [59]. This is interesting, as hormone 
levels also change with age, and the changes in these levels have been shown to have a 
significant impact on the incidence and progression of SLE. [60]. Together, these suggest 
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the possibility that age-related differences in hormone levels could cause age-related 
differences in CD8+ T cell activity. Since deficiencies in CD8+ T cells have been linked 
to SLE [43-49], it suggests that the differences in SLE susceptibility at different ages may 
be mediated by age-dependent hormonal suppression of CD8+ T-cells. 
Influence of genetics on the sex bias of SLE 
The wide variety of mouse models have benefitted lupus research because SLE is 
an extremely heterogeneous disease influenced by many genetic, hormonal, and 
environmental factors. Genome-wide association studies have identified many genetic 
polymorphisms in genes like ITGAM, CD40, and IRF5 that are linked to susceptibility to 
SLE [61-67]. However, twin studies have found concordance to be 24-35% in 
monozygotic twins and 2-4% in dizygotic twins [60,68,69], showing that while SLE has a 
strong genetic component, genetics alone is insufficient to account for disease 
development. Similarly, the mechanisms behind the sex bias of SLE are not completely 
understood, but differences in both sex-linked genes and sex hormones are believed to 
play major roles. 
The mammalian X chromosome contains many genes important for normal 
immune function [2,70]. Males, who carry only one copy of each X-linked gene, are 
much more susceptible to genetic immunodeficiencies [71]. In addition, the female’s 
heterozygosity for the X-linked genes allows for a more robust and diverse immune 
system [72]. Following viral exposure, peripheral mononuclear cells from women 
produce greater levels of pro-inflammatory factors such as interferon-γ (IFNγ), 
interferon- and tumor necrosis factor α (TNFα) [59,73]. In healthy controls, macrophages 
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and neutrophils from female rats and mice have higher phagocytic activity than those 
from male rats. [74,75]. Studies have found that circulating T-cells from women have a 
more robust proliferative response after stimulation and higher cytotoxic T-cell activity 
[76]. Parasitic infections provoke higher levels of T helper 1 (Th1) cytokine production in 
adult female mice, which may explain their greater resistance to parasites like 
Leishmania major [77]. Females also exhibit higher levels of basal immunoglobulin 
levels and larger antibody responses [2,78-80]. All of this likely contributes to women’s 
superior survival rates and outcomes after injury due to reduced susceptibility to sepsis 
and infections  [81,82]. 
However, this hyperreactive immune system does come with a downside, as 
increased copies of the X chromosome also result in higher incidence of autoimmune 
diseases in general, and lupus in particular. Men with Klinefelter’s syndrome (XXY) 
have 14-fold higher rates of SLE than XY males [83], and females with XXX karyotypes 
are 2.5 times more likely to develop the disease than XX females [84]. Conversely, 
females with Turner syndrome (XO) have a lower prevalence of SLE than XX females 
[85]. 
Women and men with Klinefelter’s syndrome have a compensatory mechanism to 
equalize the gene dosage and limit overexpression of X-linked genes. One of the X 
chromosomes is randomly silenced during female embryogenesis [2]. This process, called 
X chromosome inactivation, was at first believed to be largely complete and stable, with 
only a small number of genes not fully suppressed. However, studies since then have 
shown that 20-30% of X-linked genes are incompletely inactivated and that the level of 
inactivation varies widely between tissue and cell types [86-89]. This discovery has 
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opened a whole new avenue for understanding the differences in lupus between males 
and females. 
To investigate the link between incomplete X inactivation and overexpression of 
lupus-promoting genes, multiple studies have examined T cells from female lupus 
patients. Studies have found considerable overlap between genes that are incompletely 
silenced and genes that are upregulated T cells from lupus patients, including CD40L, 
CXCR3, OGT, miR-98, let-7f-2, miR-188-3p, miR-421 and miR-503 [90-92]. Since XY 
males, having only one X-chromosome, are not susceptible to increased lupus-promoting 
X-linked gene expression due to incomplete X-inactivation, incomplete silencing of X-
linked genes may contribute to the sex bias of lupus. This phenomenon is not limited to T 
cells, as a recent study found that in plasmacytoid dendritic cells (pDCs), B cells, and 
monocytes from healthy women and men with Klinefelter syndrome (XXY), both copies 
of the X-linked gene encoding Toll-like receptor 7 (TLR7) gene were transcribed 
resulting in higher expression than in cells from XY men. TLR7 is important for 
detecting viral RNA and promoting IFNα production, which drives antibody responses to 
viral infections [93]. However, TLR7 signaling can also be activated by RNA-containing 
immune complexes associated with advanced SLE [94]. Numerous studies of mouse 
models of lupus have identified TLR7 as essential for the development of spontaneous 
germinal centers and the production of autoantibodies [95-97]. This effect of TLR7 has 
been found to be gene-dosage dependent, with increased TLR expression promoting the 
development of lupus-like disease [98-100]. Incomplete inactivation of TLR7 has clear 
implications for the development of SLE. However, a recent study of female BWF1 mice 
found that TLR7 did not escape X inactivation in B cells and that, while the B cells did 
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express higher levels of autoimmunity-associated genes, none of them were on the X 
chromosome. This finding suggests that incomplete X inactivation may not be a major 
cause of the sex bias in the BWF1 mouse model [101] 
Contribution of sex hormones in the sex bias of SLE 
The other major mechanism by which sex is thought to affect SLE is via the 
production of sex hormones. The connection between sex hormones and immune 
responses is long established. Estrogens generally promote immune responses, while 
androgens typically suppress them [58,102,103]. There is ample evidence that higher 
levels of estrogens increase lupus severity. 
While estrogens are known to promote immune activation in general, at higher 
doses they can suppress certain immune responses [102,104,105]. However, importantly 
for SLE, both low and high concentrations of estrogen stimulate B cells to increase 
production of immunoglobulins in mice and humans [58,104,106,107]. Consequently, 
while high estrogen levels can suppress some aspects of disease that are more dependent 
on T cells, its overall effect is to increase SLE severity and progression [58,108]. Even in 
mice not prone to autoimmunity, high doses of estrogen increased the numbers of 
antibody producing B cells, including cells that produced autoantibodies [109]. Estrogen 
promotes B cell survival and activation, leading to the increased numbers of autoreactive 
B cells escaping negative selection [106,110]. Estrogen can also inhibit B cell tolerance 
and induce lupus-like phenotypes in mice [111]. Knocking out the estrogen receptor gene 
in B cells has an impact on autoantibody production in BWF1 mice [112,113]. 
Additionally, treating peripheral blood mononuclear cells taken from SLE patients with 
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estrogen enhanced their production of autoantibodies [114]. Female mice with graft-
versus-host induced glomerulonephritis had higher levels of autoantibodies against 
dsDNA and other nuclear antigens after treatment with 17-β-estradiol (E2), a form of 
estrogen [71,115].  
Estrogen’s effects are not limited to B cells. E2 causes dendritic cells (DCs) to 
upregulate CD40, a costimulatory molecule that is critical for the induction of humoral 
immunity [116]. A recent study found that proteinuria decreased in BWF1 lupus-prone 
mice after treatment with a CD40 antagonist antibody [117]. There are several CD40-
blocking therapies undergoing clinical trials for SLE and other autoimmune diseases 
[118]. Another type of dendritic cell, plasmacytoid DCs (pDCs), is a key producer of 
interferon-α (IFNα) which activates B cells and drives autoantibody production. Lupus 
immune complexes can activate pDCs via TLR7 and TLR9 and stimulate them to 
produce IFNα. Studies have found that treating human or mouse pDCs with E2 increases 
their IFNα production in response to TLR7 and TLR9 signaling [119,120]. Additionally,  
there is a positive regulatory feedback loop between interferon and estrogen signaling 
[121].  
Androgens, especially testosterone, are strongly immunosuppressive and anti-
inflammatory [103]. Men who have androgen deficiencies have higher serum antibody 
titers, CD4/CD8 T cell ratios, and higher levels of inflammatory cytokines including IL-
1β, IL-2, and TNFα  [122-125]. Consequently, androgen levels have a significant effect 
on autoimmune disease. Castration has been found to stimulate or exacerbate 
autoimmune symptoms in several mouse models of autoimmune diseases, including 
Experimental Autoimmune Encephalomyelitis (EAE), non-obese diabetic (NOD), and 
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rheumatoid arthritis [126-128]. In those same mouse models, treatment with androgens 
ameliorated disease symptoms [103,128-130]. In male rheumatoid arthritis patients, 
lower levels of testosterone have been found to correlate with disease severity. Also, 
testosterone supplementation reduces disease severity in postmenopausal men and 
women with rheumatoid arthritis [131]. 
Studies with mouse models have repeatedly found that androgens play a 
protective role in SLE. In a graft-versus-host induced glomerulonephritis mouse model, 
testosterone treatments decreased proteinuria [132]. In the BWF1 mouse model of lupus, 
treating disease-prone females with androgens delays disease onset and reduces serum 
anti-dsDNA titers and other markers of disease [133]. When BWF1 mice were treated 
with the androgen receptor-blocking drug flutamide, it accelerated mortality in both male 
and female mice [134]. Similarly, male BWF1 mice that undergo androgen depletion by 
castration develop more severe disease at an earlier age. Some studies have shown that 
these male BWF1 mice have a testosterone-dependent splenic Gr1+CD11b+F4/80- 
neutrophil population that inhibits autoantibody-producing germinal center reactions 
[135,136]. However, while depleting Gr1+ neutrophils in male BWF1 mice increased 
autoantibody levels, it did not have any impact on kidney disease progression [135]. This 
finding and the findings of a more recent study that showed neutrophil depletion 
accelerated both autoantibody production and kidney damage in female BWF1 mice, cast 
doubt on the Gr1+ neutrophils as a significant source of male BWF1 disease resistance 
[137]. 
Androgens are protective in humans as well as in mice. Women with active SLE 
had decreased levels of androgens, including testosterone, androstenedione, and 
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dehydroepiandrosterone [115,138]. Interestingly, the same has been found for female 
SLE patients without active disease, suggesting that the low levels are not caused by 
active disease activity [139,140]. Androgen levels are also lower in male SLE patients 
[141-144], and a subset of them exhibit hypogonadism [143,145]. Both males and 
females with SLE have been found to exhibit excessive estradiol hydroxylation, which 
depletes testosterone and produces estrogens [144]. Similarly, men with Klinefelter 
syndrome, who naturally have lower androgen levels and higher estrogen levels than XY 
males, have a higher risk for SLE [146,147]. Since disease in men and women correlates 
with higher estrogens, female SLE patients were treated with tamoxifen, a drug which 
competes with estrogens for the estrogen receptor, but the treatment failed to alleviate 
disease severity [148]. On the other hand, multiple studies have found that treatment with 
androgens can ameliorate disease activity and lower anti-dsDNA antibody production 
[149-152]. Clearly, androgens can have a major impact on lupus progression. 
 
Efficacy of current androgen-based treatments and other therapeutics  
While androgens are known to inhibit lupus progression, translating these 
successes in the laboratory into effective clinical treatments has been challenging. 
Treatment with the testosterone-like anabolic steroid, nandrolone resulted in some 
patients improving but others saw no benefits [153-155]. Similarly, 
dehydroepiandrosterone, a weak androgenic steroid, has been shown to have mild 
benefits in premenopausal patients with non-severe disease, but it has been less beneficial 
in postmenopausal patients [149,156-162]. While these androgens can alleviate some 
symptoms of disease, the lack of consistency in benefits and the masculinizing side 
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effects make these androgens non-viable as frontline treatments [163]. Nevertheless, 
while directly treating with weak androgens has had little success, understanding 
androgen’s mechanisms of action for immunosuppression may lead to the discovery of 
targets for treating SLE [164]. 
In the past few years, therapies that deplete specific cell lineages or block certain 
cell-cell interactions have been developed. One such therapeutic, Anifrolumab, blocks the 
IFN-α cell signaling that can drive lupus progression. It has been found to benefit some 
patients if used early in the course of the disease before active renal involvement, but 
over half the patients tested did not respond to the treatment [165,166]. Another, 
Rituximab, is an anti-CD20 antibody that depleted mature B cells, but it was not found to 
be more effective than standard treatment [167,168]. Belimumab is an antibody that binds 
the cytokine B-cell activating factor (BAFF) and prevents it from binding to B cells and 
promoting their maturation. It has been found to be beneficial for patients with severe 
disease that is not responding to standard treatments, but not for patients with mild to 
moderate disease [169-171]. Atacicept, a recombinant protein that binds two B-cell 
maturation-promoting cytokines, B-lymphocyte stimulator (BLyS) and A proliferation-
inducing ligand (APRIL), has recently been developed and clinical trials testing its ability 
to treat SLE are underway. Initial results are promising, as it has been shown to decrease 
lupus flares [172]. However, atacicept was only effective in a subset of lupus patients, as 
40% of patients treated showed no benefit [173,174]. 
SLE has proved a challenging disease to treat. Between the 1950s and 1990s, the 
10-year survival rate for adults increased dramatically from 50% up to 90% [175-177]. In 
recent decades, though, progress has plateaued. Both survival rates [177,178] and the risk 
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of end-stage renal disease resulting from lupus nephritis [179] are little different now 
than they were in the 1990s. The current standard treatments are limited by high rates of 
failure and toxicity. Corticosteroid therapy, a current first-line treatment, may actually 
contribute to kidney damage over the long term [178]. Clearly, recent advances in 
treatment have not succeeded in improving the condition of SLE patients, and there is a 
dire need for new paradigms of SLE management. 
Autoimmunity and the gut microbiota 
In recent years, a new paradigm has emerged as we have learned more about the 
interactions between the microbiota and the immune system. The immune system is 
designed to detect and respond to foreign entities. The presence of a few thousand 
bacteria in the blood or peripheral tissues would result in recognition by innate immune 
cells followed by a strongly inflammatory immune response that would drive a 
subsequent adaptive immune response [180]. In dramatic contrast, the trillions of bacteria 
normally present in a healthy human intestine rarely trigger spontaneous pathological 
inflammatory immune responses or systemic immune responses [181-183]. These 
commensal bacteria are collectively termed the gut microbiota, and a complex system of 
interactions with the host immune system is needed to maintain a state of mutualism and 
homeostasis [181-184]. The past two decades have seen a dramatic increase in our 
understanding of the importance of the microbiota in health and disease, including how 
interactions between the host immune system and the gut microbiome are essential for 
proper immune system development and function [184-187]. 
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 Because colonization by commensal organisms begins after birth [188], it is 
possible to use cesarean sections in a germ-free environment to derive mice that lack any 
commensal bacteria [189,190]. Experiments comparing these germ-free (GF) mice to 
genetically identical mice born with a microbiota (“conventional” mice) have greatly 
enhanced our understanding of how the microbiome affects the host [186]. These studies 
with germ-free animals have long shown that the absence of gut microbiota leads to 
serious defects in the development of the spleen, thymus, lymph nodes, and other 
lymphoid tissue [191,192]. Structures of gut-associated lymphoid tissue (GALTs) are 
most affected. GF mice have lower frequencies of isolated lymphoid follicles as well as 
smaller Peyer’s patches and mesenteric lymph nodes (mLN) [193-195]. In addition to 
deficient lymphoid tissue structures, the lack of microbiota in GF mice also causes 
significant and detrimental changes to immune cell populations. The numbers of αβ and 
γδ intra-epithelial lymphocytes are considerably lower in GF mice than conventionally 
colonized animals [196]. The balance between Th1 and Th2 T cells is also affected by the 
lack of a microbiota [197]. The small intestine lamina propria normally contains a 
considerable number of IL-17 producing T helper cells. These cells are critical for 
defense against bacterial and fungal pathogens but are absent in GF mice [198,199]. 
Similarly, the microbiota also influences the development and V(D)J recombination of 
lamina propria B cells [200]. These differences in B cell development may contribute to 
the lower production of IgA antibodies, the primary antibody in protective mucosal 
immunity, in GF mice [201].  
 Germ-free pups that have never been directly exposed to bacteria are still 
affected by the microbiota of their mother. A recent study showed that germ-free pups 
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whose mothers had been transiently colonized by E. coli during pregnancy had increased 
intestinal group 3 innate lymphoid cells and F4/80+CD11c+ monocytes as well as higher 
production of epithelial antibacterial peptides. This effect was dependent on maternal 
antibodies, and the study found that maternal IgG facilitated transfer of microbiota-
derived compounds to the fetus. It further showed that these changes had functional 
consequences, as the pups whose mothers were transiently colonized had improved 
intestinal barrier integrity that was better able to block bacterial translocation [202]. 
It is important to note that while many immune deficiencies of GF mice can be 
corrected by colonization with commensals at a later age [197,199,201,203], some 
defects are the result of the absence of microbiota during a crucial period of development 
in early life [184,186]. This was demonstrated in a study that compared the intestinal 
transcriptome profiles of mice born with a microbiota and mice that were born germ-free 
but colonized with commensals as adults. The transcriptional profiles of jejunal and 
colonic epithelial cells were significantly different between these two groups, with 
dramatic differences in genes related to inflammatory responses, immune cell trafficking, 
and other biological processes [204]. A more recent study identified an age-dependent 
immune response to bacteria that affects the composition of the microbiota into 
adulthood. It found that the neonatal mouse gut epithelium expresses the flagellin-sensing 
Toll-like receptor 5 (TLR5). This expression is age-dependent and transitory. While it is 
expressed, TLR5-mediated signaling drives a Reg3g c-type lectin-dependent immune 
response that selects against flagellated bacteria. This resulted in a long-term reduction of 
the presence of flagellated bacteria. Experiments with GF mice showed that the potential 
for an anti-flagellated bacteria immune response was only present for a short period after 
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birth, demonstrating that early life represents a crucial time for the establishment of the 
microbiota and development of the immune system [205]. 
Multiple studies have shown that changes in the immune system brought about 
by early-life exposure to microbes have considerable health ramifications. GF mice 
accumulate higher numbers of invariant natural killer T (iNKT) cells in the lung and 
colon. This made the mice more vulnerable to oxazolone-induced colitis and ovalbumin-
driven allergic asthma. These vulnerabilities could be eliminated if the GF mice were 
colonized with a conventional microbiota as neonates, but colonization of adult GF mice 
failed to protect them against disease [206]. GF mice also have abnormally high serum 
levels of IgE [207]. This makes them more susceptible to severe allergic reactions and 
systemic anaphylaxis. Colonizing GF mice with a conventional microbiota up to a week 
after weaning prevents the development of high IgE and protects against allergic 
reactions, but colonizing adult GF mice does not have the same therapeutic effect [208]. 
These effects can be seen even in mice that are not completely germ-free. Treating mice 
with vancomycin, a widely-used antibiotic, can decrease microbiota diversity and cause 
significant shifts in microbial populations. However, the effect of these changes on health 
depends on the timing of the treatment. Mice that are treated with vancomycin as 
neonates and as adults are more susceptible to experimental allergic asthma than mice 
that only received the antibiotic as adults [209]. 
These findings in mice parallel findings in humans, as there is a plethora of 
evidence that immune system interactions with the microbiota at an early age affect the 
chances of developing immune-mediated diseases later in life. As an infant grows, the 
diversity of the microbiota increases gradually, but the composition can shift abruptly in 
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response to health or dietary changes [210,211]. One of the things that can cause a drastic 
shift is if the child is treated with antibiotics. While the development of antibiotics has 
been an incredible boon to the fight against infectious diseases, increasing evidence 
suggests that their use during childhood increases the risk of developing asthma and other 
autoimmune diseases [184]. Multiple studies have found children that are treated with 
antibiotics during the first year of life are considerably more likely to develop asthma 
[212-214]. Another study found that treating pre-school children with macrolide 
antibiotics resulted in a long-lasting shift in the microbiota, with lower levels of 
Actinobacteria and higher levels of Bacteroidetes and Proteobacteria. These changes 
correlated with increased risk of asthma and antibiotic-associated weight gain [215] 
Similarly, children receiving antibiotic treatment before one year of age are 5 times more 
likely to develop inflammatory bowel disease [216,217]. Clearly, the long-term adverse 
effects of antibiotics on the microbiota can increase the chances of immune-mediated 
diseases. Understanding the mechanisms by which the microbiota affects the immune 
system will be key to mitigating the long-term side effects of these crucial medicines.  
 By inhibiting the growth of bacteria, antibiotics cause a change in the bacterial 
composition of the microbiome. This can potentially lead to an imbalance and/or a loss of 
diversity that results in the microbiota promoting disease. Bacteria that promote health 
may be lost or suppressed, and bacteria that promote inflammatory and harmful effects 
may be gained or expand. A microbiome in this state is said to be in dysbiosis. While 
childhood treatment with antibiotics offers a dramatic view of the effects of dysbiosis, 
adults can develop a dysbiotic microbiota as well [184,218,219]. Also, while antibiotics 
are a common cause of dysbiosis, it can also result from other environmental factors such 
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as the side effects of other medications, dietary deficiencies, and infectious diseases. 
Since the 1950s, there has been a significant increase in the prevalence of autoimmune 
diseases and allergies, and there is considerable evidence this is partly due to changes in 
microbial exposure [220-222]. Increases in antibiotic treatments, reductions in the 
frequency of infections, and other environmental changes have led to alterations in the 
microbiota which in turn have affected the functions of the immune system [222]. 
Consistent with this hypothesis, dysbiosis has been linked to multiple autoimmune 
diseases [184,218,219]. Considerable effort has been put into understanding how 
dysbiosis and autoimmune disease are linked [184]. Understanding the mechanisms that 
connect dysbiotic microbiota and autoimmune disease could potentially lead to therapies 
that treat or prevent autoimmune disease by altering the microbiota into a more beneficial 
state. 
One disease with considerable evidence linking it to the microbiota is 
inflammatory bowel disease (IBD) [223,224]. IBD, which includes Crohn’s disease and 
ulcerative colitis, is characterized by chronic and relapsing immune-mediated intestinal 
inflammation that causes abdominal pain, diarrhea and bloody stools [223,224]. The 
correlation between IBD and dysbiosis is well established [225-235], and treatment with 
antibiotics can alleviate disease symptoms, indicating that the bacteria do play a causative 
role in the disease [236-240]. While all of these studies found dysbiosis in IBD patients, 
the specific alterations in bacterial taxa varied widely [223,225-235]. The most 
consistently found alteration was an increase in Enterobacteriaceae in IBD patient stools 
relative to healthy individuals, but even this finding was not universal [223,241-245]. 
Adherent-invasive strains of the Enterobacteriaceae member, E. coli have been found in 
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the ileal mucosa of Crohn’s patients, but no clear cause-and-effect relationship has been 
established [246]. Multiple studies found lower levels of the Firmicutes member 
Faecalibacterium prausnitzii in the stools of IBD patients [230-235], though studies of 
mucosal biopsies from IBD patients have not consistently replicated that finding 
[247,248]. This lack of consistency is likely due to the heterogeneous nature of both the 
disease and the human microbiota [223,224]. Differences in environment and genetics 
result in the human microbiota varying widely from person to person and from region to 
region [223,224]. The more controlled settings of mouse models have shed light on the 
mechanisms of microbiota-immune system interactions that can drive or suppress IBD. 
Some bacterial species, including Bacteroides fragilis, and assorted Clostridia strains, 
can suppress disease in mice by promoting the development of immunosuppressive 
regulatory T cells (Tregs) in the intestine. Other bacterial species have been shown to 
promote disease. Some IBD models induce disease by injecting mice with exogenous 
inflammatory Th17 cells, which drive inflammation and tissue damage in an interferon 
gamma (IFNγ) dependent manner [249]. However, these cells will not cause disease in 
the absence of a microbiota [250,251]. Helicobacter muridarum, Helicobacter 
hepaticus, and segmented filamentous bacteria have been identified as being able to 
stimulate colitis-promoting activities in adoptively transferred Th17 cells [250-252]. 
These studies show that differences in microbiota composition can affect autoimmune 
disease progression. 
Just as interactions with the microbiota shape the immune system, the actions of 
the immune system affect the composition of the microbiota. The immune system can 
produce pathogen specific IgA antibodies to coat and neutralize problematic bacteria in 
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the intestine. Studies have found that known colitis-promoting pathobionts such as 
Prevotellaceae, Helicobacter, and SFB are more likely to be coated in IgA. Transferring 
IgA-coated bacteria from IBD patients into mice rendered the recipient mice significantly 
more susceptible to severe DSS-induced colitis [253-255]. Additionally, IgA deficiency 
is associated with increased risk for ulcerative colitis and Crohn’s disease [253] This 
highlights the complexity of the interactions between the microbiota and the immune 
system, as a deficiency in the immune system can alter the composition of the microbiota, 
which in turn can affect the immune system and promote responses that result in disease. 
Consequently, attempting to determine whether dysbiosis or inflammation was the initial 
cause of the disease is not an easy task. 
 The microbiota can also affect the development of autoimmune diseases in tissues 
outside the intestine. Rheumatoid arthritis (RA) has also been linked to dysbiosis. RA is a 
chronic autoimmune disease characterized by the production of autoantibodies against 
collagen and mediate synovial inflammation resulting in destruction of bone cartilage in 
affected joints. In addition to genetic and environmental factors, the microbiome is 
believed to influence the pathogenesis of RA [184,256,257]. This systemic disease is 
associated with periodontitis, a severe infection of the gums, and treatment of 
periodontitis ameliorates RA disease activity [258-260]. Studies investigating this link 
have shown that infection with one of the major periodontal pathogens, Porphyromonas 
gingivalis, can drive RA progression. One of the characteristics of RA is the production 
of antibodies against cyclic citrullinated proteins (CCP), self-antigens present in cartilage. 
Infection with P. gingivalis correlates with increased production of anti-CCP antibodies, 
because P. gingivalis produces an enzyme that citrullinates proteins. Antibodies against 
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these proteins also bind the self-antigen CCP and thus the immune response against P. 
gingivalis promotes the autoimmune response that causes RA [261-264]. In addition to 
promoting autoantibody production via molecular mimicry, P. gingivalis infection also 
induces a Th17 response via TLR2 stimulation that further drives RA disease activity 
[265]. Recently, other periodontitis-causing bacteria, including Anaerglobus geminatus 
and Aggregatibacter actinomycetemcomitans, have also been found to promote RA 
progression via an anti-CCP antibody-dependent mechanism [266,267]. In addition to the 
oral microbiome, the intestinal microbiome has also been implicated in the pathogenesis 
of RA. Both individuals at high risk for RA [268] and new-onset RA patients who have 
not begun treatment [269,270] have increased abundance of intestinal Prevotella copri. A 
recent study used the SKG mouse model of RA to investigate whether P. copri could play 
a causative role. The SKG mouse model of RA contains a point mutation in ZAP-70 that 
decreases T cell receptor (TCR) signaling, allowing auto-reactive T cells to escape 
negative selection. This renders SKG mice susceptible to arthritis induction by activation 
of innate immunity. When treated with innate-immune activating compounds such as the 
fungal-derived zymosan, SKG mice develop arthritis similar to human RA. However, 
because disease induction depends on innate immunity, it is affected by the microbiota, 
and arthritis cannot be induced in germ-free mice that contain no commensals [271,272]. 
To test whether the presence of P. copri would affect the course of disease, microbiota 
from high-Prevotella-abundance RA patients or from healthy controls was transferred 
into germ-free SKG mice and the mice were treated with Zymosan to induce arthritis. 
The mice that received the high-Prevotella microbiota developed significantly more 
severe arthritis with higher IL-17 responses [270]. A recent study found T cells activated 
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by Prevotella epitopes cross-reacted with the self-antigens GNS and FLNA, suggesting 
that P. copri could potentially drive RA progression by activating autoreactive T cells 
[273]. However, a study of gut commensal compositions of people from Africa and 
tropical Asia found that healthy people had a large abundance of Prevotella species, 
including P. copri, in their intestines [274]. Similarly, another recent study found 
Prevotella histicola isolated from the intestine of healthy humans decreased disease 
severity in a collagen-induced mouse model of RA [275]. These seeming contradictions 
emphasize the challenges of identifying what bacterial species in the human microbiota 
can promote disease. The context of the microbiota and the other species that it contains 
will affect the effect of a given species, and even in very similar contexts, closely related 
species can have opposite effects.  
 Like rheumatoid arthritis, systemic lupus erythematosus (SLE) is a systemic 
disease characterized by autoantibody production, and SLE patients also exhibit 
dysbiosis. Numerous recent studies have found the microbiota of SLE patients differ 
significantly from those of healthy controls [276-283]. However, while all of these 
studies found dysbiosis, the differences in specific taxa were significantly less consistent. 
The only finding that was replicated across multiple studies was an increase in the 
Bacteroidetes phylum and a decrease in Firmicutes phylum in SLE patients [277-
280,284]. Another recent study confirmed the lower ratio of Firmicutes/Bacteroidetes in 
SLE patients and found that treatment with glucocorticoids increased the 
Firmicutes/Bacteroidetes ratio and correlated with lower serum levels of inflammatory 
cytokines [285]. Overall richness, as measured by α-diversity is generally decreased in 
SLE patients in comparison to healthy controls [276,280,282]. Despite this lack of 
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consistency, investigations of the microbiota in SLE patients as well as in mouse models 
of lupus yielded several interesting discoveries that have increased our understanding of 
how the gut microbiota can affect disease progression. 
One study identified Ruminococcus gnavus as a potential pathobiont that could 
contribute to lupus progression. SLE patients have 5-fold greater abundance of R. gnavus, 
and many had antibodies against one or more strains of R. gnavus. The level of anti R. 
gnavus antibodies correlated positively with overall autoantibody levels and active 
nephritis, which could suggest that immune responses against R. gnavus may increase 
disease severity [276]. 
Another study found that the pathobiont Enterococcus gallinarum might drive 
lupus both in human SLE patients, and the NZWxBXSB F1 (NxB F1) mouse model of 
lupus. NxB F1 male mice develop lupus due to having a duplicate TLR7 gene, and the 
study found male mice with disease had E. gallinarum in their livers. Liver biopsies from 
patients with SLE or other autoimmune diseases were more likely to contain E. 
gallinarum than biopsies from healthy patients. This could be due to impaired gut barrier 
function, which is common in SLE patients and mouse models of lupus. Germ-free B6 
mice monocolonized with E. gallinarum developed impaired barrier function, E. 
gallinarum translocation to the liver, and the production of antinuclear autoantibodies and 
pro-inflammatory cytokines. However, E. gallinarum did not translocate or induce 
autoimmunity in conventional B6 mice. When NxB F1 male mice were vaccinated 
against E. gallinarum, serum levels of autoantibodies were reduced and survival was 
increased, showing that eliminating a specific bacterial species could suppress 
autoimmunity without suppressing the entire immune system. Among SLE patients, the 
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presence of E. gallinarum in the liver correlated with higher levels of autoantibodies, 
suggesting that the pathobiont could play a similar role in humans as it does in the NxB 
F1 mouse model [286]. 
Another recent study suggested commensal bacteria may promote lupus by 
expressing an ortholog of the human protein Ro60. Ro60 is a nuclear antigen, and anti-
Ro60 antibodies are often among the first to develop in SLE patients [287,288]. There is 
significant cross-reactivity between human Ro60 and the bacterial Ro60 ortholog. The 
bacterial Ro60 ortholog is recognized by T cells and B cells from SLE patients that have 
anti-Ro60 autoantibodies. Some people have commensals that express the Ro60 ortholog 
in their gut microbiota, suggesting a possible link. Additionally, GF mice monocolonized 
with a Ro60 ortholog-expressing bacteria developed an anti-Ro60 autoantibody response 
that led to glomerular deposition of immune complexes. This suggests that an immune 
response against the bacterial Ro60 ortholog could potentially contribute to the 
development of lupus. However, almost all of the SLE patients and healthy subjects in 
the study had Ro60 ortholog-expressing bacteria in their microbiomes. This indicates that 
the presence of the Ro60 bacteria is not enough to stimulate autoimmunity on its own. 
Also, Ro60 ortholog-expressing bacteria were found at equal frequency in SLE patients 
that were positive for anti-Ro60 autoantibodies and SLE patients that were negative for 
anti-Ro60, showing that even in patients with active autoimmune disease the presence of 
Ro60 ortholog-expressing bacteria in the gut is not enough to stimulate an anti-Ro60 
antibody response. Analysis at the family level did not reveal any significant differences 
in the composition of the microbiota between the anti-Ro60 positive and negative SLE 
26 
 
patients [277]. Thus, while the possibility of microbiota Ro60 cross-reactivity stimulating 
lupus development is possible, the events that would lead to this are still undetermined.  
 
Gut microbiota and mouse models of lupus 
 A recent study found a link between microbiota tryptophan metabolism and lupus 
in the BWF1-derived triple congenic B6.Sle1.Sle2.Sle3 (S123) mouse strain. Compared 
to healthy control female B6, S123 microbiota is enriched for Prevotellaceae, 
Paraprevotella, and Lactobacillus. When adult female S123 microbiota was transferred 
to GF B6 mice, the B6 mice developed lupus-like symptoms including elevated 
autoantibodies and mild glomerulonephritis. Fecal metabolite analysis found evidence 
that microbiota tryptophan metabolism was altered in female S123 mice to favor 
kynurenine production over serotonin production. Changing the tryptophan content of the 
diet altered the S123 microbiota composition and impacted disease development; a low 
tryptophan diet protected against disease, and a high tryptophan diet exacerbated disease. 
A high tryptophan diet increased the ability of female S123 microbiota to cause 
autoimmune phenomena in GF female B6 mice. Microbiota from mice fed a low 
tryptophan diet did not induce autoimmune phenotypes in the GF B6 mice. Altering 
female S123 microbiota by cohousing with female B6 mice reduced autoantibody 
production, but glomerulonephritis was unchanged [289]. This study showed that changes 
in the microbiota caused by changes in diet affected whether the microbiota suppresses or 
promotes lupus-like disease progression. It also showed that the microbiota in the lupus-
prone female S123 mice have altered tryptophan metabolism and that they promote the 
development of lupus-like symptoms. However, it did not determine whether female 
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S123 microbiota affected the immune system and disease progression via altered 
production of tryptophan metabolites. Bacterial associated tryptophan metabolites have 
been found to have immunomodulatory properties [290-292], and the high kynurenine 
and low serotonin in the mouse feces matches findings in SLE patient sera [293]. 
Inhibiting kynurenine production did not protect against disease, so the paper did show 
higher kynurenine production is not responsible for disease, but additional research into 
the role the other tryptophan metabolites play could be illuminating. 
Diet can also affect the composition of the microbiota in the SNF1 mouse model 
of lupus. Giving lupus-prone female SNF1 mice acidified water suppressed disease. It 
delayed the onset of nephritis and decreased the level of antinuclear autoantibodies 
compared to SNF1 mice on neutral pH water. The composition of the microbiota was 
significantly changed by the acidified water, and the most significant change was in the 
Rikenellaceae family, which was greatly increased in the SNF1 mice receiving acidified 
water. Additionally, the level of Firmicutes was increased and the level of Bacteroidetes 
was decreased in the acidified water group [294]. This mimics findings from human 
studies that have found healthy controls to have higher Firmicutes and lower 
Bacteroidetes levels than SLE patients [277-280,284]. In the SNF1, the changes 
correlated with increased intestinal levels of Th17 cells which promote lupus progression, 
suggesting that the alterations to the microbiota might decrease its Th17-stimulating 
characteristics [294]. 
It has been shown that treating MRL/lpr mice with antibiotics after disease onset 
ameliorates disease, indicating a connection between microbiota and disease [295]. A 
study from the lab of Xin M. Luo investigated this connection and found lupus-prone 
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MRL/lpr mice have significantly lower levels of bacteria from the family 
Lactobacillaceae relative to healthy control MRL mice [296]. A later study from the 
same lab followed up on this finding, and showed Cecal transfers from MRL mice into 
MRL/lpr mice decreased anti-dsDNA autoantibody production. Weekly gavages with a 
mixture of strains from the Lactobacillaceae genus Lactobacillus not only decreased anti-
dsDNA production, they also slowed nephritis onset and increased survival in the 
MRL/lpr mice. In both Lactobacillus gavaged and non-gavaged MRL/lpr mice, 
Lactobacillus reuteri and an unknown strain were by far the most common bacteria. 
Treatment with the Lactobacillus bacteria corrected the “leaky” gut that Mrl/lpr mice 
normally exhibit. In addition, intestinal IL-10 production was increased and IL-6 was 
decreased, promoting an anti-inflammatory environment. This resulted in decreased 
deposition of IgG2a in the kidney and in changing the Treg/Th17 balance in the kidney to 
skew more towards Tregs [297]. Together, these findings suggest an immunoregulatory 
role for Lactobacillus bacteria in the MRL/lpr mouse model. This was suggestion is 
strengthened by another recent paper that found treating MRL/lpr mice with antibiotics 
before disease onset resulted in dysbiosis characterized by lower levels of Lactobacillus 
and Bifidobacterium. These dysbiotic MRL/lpr mice developed more severe disease 
compared to untreated controls [298]. 
A later paper from the Luo lab, however, found that the opposite was true for the 
BWF1 mouse model of lupus. It found that in disease-prone female BWF1 mice, the gut 
microbiota composition changed significantly between the pre-disease and lupus disease 
stages. However, unlike in the studies of MRL/lpr mice, higher Lactobacillus abundance 
in female BWF1 mice was associated with increased loss of renal function and higher 
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levels of autoantibodies [282]. This suggests that the effect of lactobacillus may depend 
other factors such as the genetics of the host and the overall composition of the 
microbiota. 
 A study from a different lab raised even more questions about the role of L. 
reuteri in lupus. This study found greater abundance of L. reuteri in a subset of SLE 
patients compared to healthy controls. L. reuteri was also enriched in the feces of a 
TLR7-dependent models of lupus, the TLR7.1 transgenic (Tg) mouse strain. Like the 
BXSB/Yaa strain, male TLR7.1 Tg mice spontaneously develop lupus-like disease due to 
having an extra copy of the TLR7 gene on the Y chromosome. This was also true for 
their TLR7 agonist-induced model, where C57BL/6 (B6) mice are regularly treated with 
the TLR7 agonist imiquimod (IMQ) to induce a lupus-like disease. Gavaging imiquimod-
treated B6 germ-free or conventional mice with cecal contents from lupus-prone TLR7.1 
Tg mice significantly increased the severity of glomerulonephritis, splenomegaly, and 
other lupus symptoms. Additionally, gavaging TLR 7.1 Tg mice with L. reuteri 
exacerbated the spontaneous lupus-like disease. In direct contrast to what was found in 
the MRL/lpr model, L. reuteri gavage worsened gut permeability in the IMQ-induced B6 
model. L reuteri also translocated. The ‘leakiness’ induced by L. reuteri allowed it to 
translocate across the intestinal barrier to the mesenteric lymph nodes, spleen, and liver, 
suggesting this may be involved in its increasing of disease severity [299].  
 These differences in Lactobacillus findings underscore the importance of 
biological context when investigating the microbiota. While the MRL/lpr, BWF1, and 
TLR7.1 Tg mouse strains all model the same disease, the genetic differences that make 
them lupus prone are quite different. Given their diversity, it is unsurprising that the 
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effect of a bacterial taxon would differ between them. This is especially important to 
consider when considering how microbiota findings in animal models could be applied to 
human patients. The diversity of human lifestyles translates to significant heterogeneity 
in microbiota. Obviously, it is not possible to replicate the diversity of human diet and 
environmental exposures in lab animals, however, sex and sex hormones have a 
significant effect on the microbiota and yet are often overlooked or ignored in studies. 
Sex differences in the gut microbiota and the effect on autoimmune diseases 
Of course, one of the major sources of microbiota heterogeneity are the effects of 
sex and sex hormones. Many studies have found differences in the microbiota between 
men and women, though the taxa that differ vary and often conflict from study to study 
[182,300-303]. For example, one study found a higher level of Bacteroides/Prevotella in 
men than women [304], while another found that Bacteroides abundance was lower in 
men than women [300]. While taxa may differ, women do tend to have a higher level of 
richness and α-diversity than men [305,306]. Not only does host sex affect the microbiota 
directly, it also affects how other environmental factors affect it. A recent study found 
that the microbiota in men and women responded differently to dietary changes [301]. 
Combined with the increasing evidence that the microbiota can impact lupus progression, 
these differences in microbiota between men and women raise the question of whether 
sex differences in microbiota might contribute to sex bias in SLE. 
There is evidence that the sex of the host changes how the gut microbiota interacts 
with and influences the immune system. When microbiota from male or female 
conventional mice is transferred into germ-free mice, the sex of the donor affects how the 
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immune system of the recipient changes after the transfer. Recipients of female 
microbiota had higher levels of thymic double-negative T cell precursors than recipients 
of male microbiota. Male recipients of male microbiota had higher levels of mesenteric 
RORγt+Foxp3+ T cells and IgA production than males who received female microbiota 
[307]. The effect of these differences has not been explored, but it does show that 
microbiota has sex-specific immunoregulatory characteristics that can be transferred by 
microbiota transplantation. 
Like many differences between males and females, sex differences in microbiota 
can be mediated by differences in sex hormones levels. In longitudinal human studies, the 
changes in hormone production during puberty are associated with significant changes in 
the composition of the microbiota [308] Changes in female hormones due to oral 
contraceptive use or bilateral ovariectomy have been found to alter the composition of the 
gut microbiota in women [305]. Additionally, in males and postmenopausal women, 
urinary estrogen levels positively correlate with microbiome richness and α-diversity as 
well as higher abundance of Clostridia [309,310]. Serum estrogen levels also correlate 
with a more diverse microbiota, as women with higher serum levels of estradiol had a 
more diverse gut microbial composition. Hormonal effects are not limited to estrogen 
either, as men with higher serum levels of testosterone also exhibit greater richness and 
α-diversity [311]. Mouse studies have further demonstrated the microbiota interacts with 
and is affected by these hormones. Orchiectomy and ovariectomy both affect the 
microbiota composition. Supplementing orchiectomized male mice with testosterone 
suppressed the effect of castration on microbiota [312,313]. Clearly, sex hormones 
influence the microbiota. 
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Some of the effects of sex hormones are likely indirect. As described above, sex 
hormones have a considerable effect on the immune system, and the immune system 
exerts a great deal of influence over the composition of the microbiota. However, sex 
hormones can also interact directly with the microbiota. Estrogens and estrogen-like 
compounds have been found to promote the proliferation and growth of certain kinds of 
bacteria [314]. Androgens like testosterone can also influence the metabolism and growth 
of gut bacteria [315]. In fact, the direct interaction between hormones and microbiota 
goes both ways, as there is evidence that commensal bacterial metabolic activities can 
affect the levels of sex hormones of the host. Gut commensals can metabolize estrogen-
like dietary compounds into active forms [316,317]. Some commensal bacteria have β-
glucuronidase activity that could potentially increase reabsorption of estrogens and 
androgens in the intestine by converting them from the less active glucuronidated form to 
the more active and absorbable non-glucuronidated form [309]. Some gut bacteria can 
also convert testosterone to the more potent dihydrotestosterone [318]. A study 
comparing germ-free mice that lack a microbiome to conventional mice found that in 
both male and female mice, GF mice had lower intestinal levels of non-glucuronidated 
androgens and lower levels of the potent androgen dihydrotestosterone compared to 
conventionalized mice [319]. This suggests that the gut microbiota may play a 
physiologically relevant role in the maintenance of androgen signaling. This has been 
supported by the findings of other studies. Treating mice with a strain of Lactobacillus 
reuteri isolated from human milk increased serum levels of testosterone, reduced age-
associated testicular atrophy, and increased spermatogenesis [320,321]. When 
conventional and GF male mice were compared, it was found that GF mice had delayed 
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testis development and lower intratesticular testosterone levels, suggesting that the 
microbiota may influence the development of an organ key to androgen production in 
males [322]. This indicates that microbiota may also affect the immune system by 
altering the levels of immunomodulatory sex hormones. 
The crosstalk between male sex hormones and the microbiota can impact the 
progression of autoimmune disease. Unlike most autoimmune diseases, Type 1 Diabetes 
(T1D) does not exhibit a sex bias in humans. However, this is not the case in the Non-
obese diabetic (NOD) model of T1D; female NOD mice and castrated male NOD mice 
have a much higher incidence of disease than intact male NOD mice. GF NOD mice, 
conversely, lack a sex bias as both male and female GF NOD mice have high incidence 
of T1D. The microbiota composition differs significantly between male and female NOD 
mice. Bacterial strains that were more abundant in male NOD mice were cultured and 
transferred into GF NOD mice. One of them, an Enterobacteriaceae strain (EntS), was 
able to suppress disease when transferred into GF male NOD mice, but none tested were 
able to suppress disease in GF female NOD mice. Conventional male NOD mice 
normally have higher serum levels of testosterone than GF male NOD mice, but 
colonizing GF male NOD mice with EntS rescued serum testosterone levels. These 
increased testosterone levels correlated strongly with disease protection and were not 
seen in GF female NOD mice colonized with EntS [323]. Taken together these findings 
suggest that both hormones and microbiota act to suppress disease in male mice and that 
the microbiota-hormone interactions reinforce this disease-suppressing phenotype. This 
conclusion was reinforced by another study using the NOD model. It found that 
transferring in the whole gut microbiota from adult male NOD mice into young female 
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NOD mice suppressed islet inflammation, reduced autoantibody titers, and increased 
serum testosterone levels. This protection from disease was testosterone-dependent [324]. 
This raises the possibility of treating autoimmune diseases by correcting intestinal 
dysbiosis via microbiota transplantation.  
Not all sex differences are mediated by hormones. A study of SNF1 mice found 
that the lupus-prone female mice had significantly higher numbers of proinflammatory 
molecules and immune cells than the less-lupus-prone male mice before puberty or 
disease onset [25]. This indicates that the immune responses that shape the microbiota in 
these lupus-prone mice are also different even in the absence of differences in sex 
hormone levels.  
 A recent study of SNF1 mice found that female SNF1 mice, which are more 
susceptible to lupus than males, have a different microbiota composition than the male 
SNF1 mice. When antibiotics were used to deplete the microbiota, glomerulonephritis 
and autoantibody production were suppressed in female SNF1 mice, but antibiotic 
depletion had no effect in male SNF1 mice. This certainly suggests that female 
microbiota could be promoting disease progression. However, transferring female SNF1 
microbiota into male SFN1 mice or vice versa failed to significantly affect disease 
progression, which lessens the overall impact of their findings [325]. A follow-up study 
by the same lab found that female SNF1 mice have higher levels of B cells producing 
anti-nuclear antigen reactive IgA in the gut mucosa and higher fecal levels of nuclear 
autoantigen reactive IgA than male SNF1 mice or healthy controls. Antibiotic depletion 
of SNF1 female microbiota correlated with a decrease in the levels of those B cells and 
fecal IgA levels, suggesting a mechanism for the antibiotic-mediated reduction in disease 
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severity [326]. All of these studies illustrate that the microbiota can have a significant 
impact on the progression of autoimmune disease, and the fact that female S123 anti-
dsDNA titers could be lowered by cohousing with female B6 illustrates the possibility 
that disease progression could be suppressed by transferring microbiota from healthy 
individuals into sick individuals of microbiome research [289]. 
Gut microbiota and immunomodulatory metabolite production 
One intriguing area of microbiota studies focuses not on identifying what bacteria 
species are associated with disease and good health, but what bacterial functions are. 
Identifying the microbial activities that drive the immune system in beneficial or harmful 
ways could lead to the development of therapies that seek to mimic or to block those 
mechanisms. One of the major ways that microbiota can affect the immune system is 
through the production of immunomodulatory metabolites. In recent years, numerous 
metabolites have been shown to alter immune activities [327]. 
Perhaps the most studied class of immunomodulatory metabolites is the short 
chain fatty acids (SCFAs). This category, which includes acetate, butyrate, and 
propionate, have potent anti-inflammatory effects. By engaging G protein-coupled 
receptors and inhibiting histone deacetylases, they promote Treg induction [328], 
suppress inflammasome activation [329,330], and promote anti-inflammatory activities in 
macrophages and neutrophils [331,332]. Multiple autoimmune diseases including IBD, 
Crohn’s disease, and spondyloarthritis have been found to be associated with decreased 
levels of SCFAs and SCFA-producing bacteria [333-336]. Additionally, treatments with 
SCFAs alleviate symptoms in mouse models of these diseases [334,337-339]. 
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Like the microbiota composition, metabolite production can be altered by changes 
in diet. The clinical relevance of the diet’s effect on metabolites was demonstrated in a 
recent study that examined the changes in the fecal metabolite profiles of children with 
Crohn’s disease (CD) after they started a prescribed diet that has been shown to alleviate 
disease. It found that the diet resulted in higher intestinal production of anti-inflammatory 
SCFAs, and that this correlated strongly with a positive clinical response to the treatment. 
Unfortunately, this beneficial effect was seen only in children with small/bowel colonic 
CD and not in those with perianal engagement. Since different areas of the intestine have 
different microbial populations, this could indicate that the success of the CD treatment 
depends on which population of microbiota is dysbiotic [340]. 
Autoimmune diseases of the central nervous system (CNS) can also be affected 
by intestinal metabolites. One recent study found decreased levels of SCFAs in the serum 
of long-term multiple sclerosis (MS) patients and that SCFA treatment increased anti-
inflammatory IL-10-producing T cells and suppressed disease in a mouse model of 
experimental autoimmune encephalitis (EAE). However, it also found that depending on 
the immunological context, SCFAs could also induce inflammatory CD4 T cells that 
promoted disease [336]. Another recent study of CNS autoimmunity and metabolites 
emphasized that alterations in metabolite production can significantly affect disease. In a 
mouse model of EAE, SCFA treatment resulted in increased induction of regulatory T 
cells in the lamina propria that suppressed disease and reduce nerve damage. However, 
treatment with long-chain fatty acids not only boosted the expansion of inflammatory 
Th1 and Th17 cells and accelerated disease, they also decreased the levels of anti-
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inflammatory SCFAs [341]. These findings show that alterations in microbiota 
metabolite production can affect immune cells well outside the intestine. 
Another class of immunoregulatory metabolites are tryptophan metabolites. 
Tryptophan conversion into other compounds primarily happens via one of three 
pathways, the kynurenine, serotonin, and indole pathways [342]. Microbial metabolism 
contributes to all three of these pathways, especially the indole pathway, and disruptions 
of the balance between the pathways have been associated with autoimmune diseases 
[327]. Indole derivatives activate the Aryl hydrocarbon receptor (AhR),  which can 
inhibit Th17 differentiation and protect against colitis [343,344], and colitis patients have 
decreased intestinal AhR levels, indicating a possible connection between decreased 
microbial indole production and disease [345]. A recent study found that the commensal 
bacteria P. russelli, could increase production of an AhR-activating indole derivative that 
increased goblet cell differentiation and decreased inflammatory signals. This resulted in 
reduced susceptibility to DSS-induced colitis in mice [346]. Another autoimmune disease 
that correlates with altered tryptophan metabolism is rheumatoid arthritis, as patients 
have been found to have decreased indole levels [347]. SLE has also been linked to 
altered tryptophan metabolism. SLE patients have increased serum levels of kynurenine 
[348], which can promote the increased cellular metabolism that is characteristic of 
lymphocytes in lupus [293]. Other studies have found tryptophan itself is decreased in 
SLE patient serum, indicating that the disease is associated with an altered tryptophan 
metabolite profile [349,350]. Also, as described above, tryptophan metabolism is altered 
in the microbiota of lupus-prone female S123 mice, and the microbiota promotes lupus-
like disease when transferred into GF B6 mice. The study did not establish whether this 
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lupus-promoting ability was connected to the differential production of tryptophan 
metabolites, though [348]. 
Recent studies have identified histamine as another intestinal metabolite that 
could potentially affect autoimmune diseases. It has been shown that probiotic and 
endogenous bacterial species can produce histamine and affect intestinal immune 
responses [351-353]. Histamine is an effector molecule that can mediate either 
inflammatory or regulatory responses depending on the type of histamine receptor 
expressed by the target cell (i.e., H1R, H2R, H3R, H4R). While histamine is classically 
associated with allergic reactions, microbe-produced histamine has been shown to 
directly inhibit inflammatory factors in the gut [354-356]. Chronic low-grade intestinal 
inflammation and defective intestinal barrier function are associated with lupus and a 
number of autoimmune diseases [297,357], so inhibition of gut inflammation in lupus-
prone mice (or humans) via microbe-produced histamine could affect autoimmune 
disease development and/or progression. 
Many anti-inflammatory metabolites have been identified, but some metabolites 
have pro-inflammatory effects. Trimethylamine (TMA), a choline metabolite, is 
synthesized exclusively by the microbiota. It is transported into the liver where it is 
converted to trimethylamine N-oxide (TMAO). TMAO is an inflammatory metabolite 
that activates the NLRP3 inflammasome [358,359], and higher serum TMAO levels have 
been linked to several human autoimmune diseases, including primary sclerosing 
cholangitis [360], psoriatic arthritis [361], and RA [362]. 
Another class of microbial metabolites are secondary bile acid metabolites. 
These are synthesized from primary bile metabolites by the microbiota, and they have 
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been shown to have anti-inflammatory effects. Many secondary bile acids activate the 
farnesoid X receptor (FXR) [363], which reduces secretion of the pro-inflammatory 
cytokines IL-17, IFNγ, and TNFα [364]. FXR is also crucial for the development of 
colonic RORγ+ regulatory T cells in mice [365]. Increased FXR stimulation has been 
found to alleviate dextran sodium sulfate-induced colitis in mice [364], Higher primary 
bile acid levels and lower secondary bile acid levels have been found in patients with 
IBD [342]. This suggests that the microbiota’s ability to convert primary bile acids into 
secondary bile acids can affect inflammatory intestinal diseases. Further supporting that 
conclusion is the finding that microbiota bile acid processing can increase FXR 
stimulation not only by producing FXR agonists, but also by reducing the levels of a 
primary bile acid, taurine-conjugated β-muricholic acid (TβMCA) which a natural 
antagonist of FXR [366]. Together these data show that alterations in the metabolism of 
primary bile acids by intestinal microbes can significantly affect disease processes. 
Furthermore, the effects of secondary bile acid production are not limited to the intestine. 
About 95% of bile acids are reabsorbed by the epithelium of the intestine and carried into 
the liver through the portal vein system [367]. There they interact with innate immune 
cells, including liver-resident macrophages via the FXR and G protein-coupled bile acid 
receptor 1 (GBAR1). Activation of these receptors on innate immune cells contributes to 
the maintenance of a tolerogenic phenotype and the prevention of disease [363]. 
Disruption of bile acid homeostasis can lead to inflammation and contributes to the 
development of nonalcoholic fatty liver disease, cholestatic liver injury, and other 
diseases [368]. It is not fully understood what alterations in cell populations and functions 
lead to disease. However, it is clear that alterations in the generation of secondary bile 
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acid metabolites by the microbiota can affect macrophages and other immune cells in an 
organ outside the intestine in ways that affect disease progression [363,369]. Like the 
findings on SCFAs and CNS diseases described above, this finding emphasizes that 
immune processes outside the intestine can be affected by altered microbiota metabolite 
production. This raises the question of whether the sex bias of disease in BWF1 mice 
could be due to sex-based differences in the microbiota’s production of 
immunomodulatory metabolites. 
 
Macrophage efferocytosis and systemic lupus erythematosus 
 The immune system has numerous mechanisms designed to prevent 
autoimmune reactions. One of these is efferocytosis, which is the clearance of apoptotic 
cells by phagocytes in an anti-inflammatory manner [370]. Cell turnover results in the 
constant generation of apoptotic cells, and these cells contain self-antigens that could 
potentially stimulate autoimmune responses [371]. To prevent this, apoptotic cells are 
bound and ingested by phagocytes, primarily macrophages. This prevents the apoptotic 
cells from interacting with and activating other immune cells. The ingestion of apoptotic 
cells promotes macrophage production of anti-inflammatory cytokines that dampen any 
inflammatory responses against the apoptotic debris [370-372]. Because apoptotic cells 
are normally non-inflammatory, as long as they are swiftly cleared, they are unlikely to 
provoke an immune response. However, if efferocytosis is impaired or defective, 
apoptotic cells will accumulate and can undergo secondary necrosis. In this case, the 
apoptotic cells undergo swelling and lysis, which results in the release of damage-
associated molecular patterns. These can act as alarm signals that activate nearby immune 
41 
cells and promote immune responses against the self-antigens they contain [373,374]. 
Defects in efferocytosis are thought to significantly increase susceptibility to 
SLE and to promote disease progression. SLE patients exhibit accumulation of apoptotic 
cells in the lymph-node germinal centers, bone marrow, and epidermis [375-377]. This 
results in immune cells being exposed to nuclear self-antigens in the inflammatory 
context of cells undergoing secondary necrosis. This stimulates an immune response 
characterized by production of anti-nuclear autoantibodies (ANAs) against dsDNA, 
ssDNA, snRNPs, and other nuclear antigens. Since apoptotic cells are constantly 
generated by cell turnover, additional self-antigens are constantly being generated and 
promoting disease progression [378]. Additionally, the accumulated apoptotic cells 
provide ample fodder for the formation of nuclear antigen-ANA immune complexes. 
These complexes lodge in the kidneys and other organs, leading to the inflammation and 
kidney damage that is the primary cause of lupus morbidity and mortality [3,379]. This is 
likely why disease severity in SLE patients is strongly correlated with deficient 
efferocytosis [375,380]. Things that increase the number of apoptotic cells can also 
trigger lupus flares. For example, excessive sun exposure can cause lupus flares, as 
dermal cells undergo apoptosis in response to the damage caused by UV radiation [377]. 
In mouse models, it has been shown that deficiencies in components important for 
efferocytosis or signaling proteins that promote efferocytosis lead to the mice developing 
lupus-like disease spontaneously [381-385]. Clearly, there is a substantial amount of 
evidence connecting efferocytosis deficiencies and lupus. 
Macrophages isolated from patients with SLE are deficient in apoptotic cell 
phagocytosis, indicating that they have an intrinsic defect in efferocytic activity [386]. As 
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macrophages are the cell type primarily responsible for efferocytosis, this defect is likely 
a major contributor to the accumulation of apoptotic cells [387-390]. Like SLE patients, 
peritoneal macrophages from lupus-prone female BWF1 mice also have deficient 
efferocytic activity compared to healthy female controls [391]. Also, in comparison to 
healthy female controls, female BWF1 macrophages are also deficient in their ability to 
produce anti-inflammatory cytokines in response to apoptotic cell exposure [392]. These 
parallels in deficient macrophage function between SLE patients and female BWF1 
female mice make the BWF1 mouse model of lupus a good choice for investigating the 
factors affecting defective macrophage efferocytosis. Also, while female BWF1 mice 
have deficient macrophage efferocytosis compared to female mice of other strains, no 
one has investigated whether disease resistant male BWF1 mice share this defect. 
Previous studies of non-disease-prone rats and mice have found female macrophages had 
higher phagocytic activity than those from males [74,75]. Determining whether the same 
sex-based difference exists in BWF1 mice or if macrophages from disease-resistant male 
BWF1 have higher efferocytic activity could advance our understanding of the source of 
the lupus sex bias in BWF1 mice. 
The clear links between deficient macrophage efferocytosis and lupus 
progression makes improving macrophage efferocytosis a promising therapeutic target. 
There are many pathways and genes involved in efferocytosis regulation, providing many 
possible ways of stimulating efferocytic activity. Three of the major pathways 
responsible for promoting efferocytosis are the LXR, PPARγ and PPARδ pathways 
[381,393-400]. 
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PPARδ knockout (KO) mice develop lupus-like autoimmune kidney disease and 
their macrophages have decreased efferocytic activity. Conversely, PPARδ agonists 
improve macrophage efferocytosis. This is due to the decreased production of opsonins 
like C1qb, a component of the C1q trimeric complex that binds phosphatidylserine on 
apoptotic cells and the C1q receptor on macrophages, bridging the two and facilitating 
macrophage uptake of the apoptotic cell [400]. In humans, C1q deficiency drastically 
increases lupus susceptibility; over 90% of C1q-deficient people develop lupus [401-
403]. 
PPARγ signaling can also increase expression of C1qb, as well as C1qa and 
C1qc [404]. As with PPARδ, PPARγ insufficient mice develop SLE-like disease due to 
increased Th17 polarization that drives autoantibody production and lymphoproliferation 
[383]. Treating macrophages with a PPARγ agonist increases their ability to phagocytose 
apoptotic cells [395]. Another pro-efferocytic opsonin upregulated by PPARγ is milk fat 
globule-EGF factor 8 (MFG-zE8). Like C1q, MFG-E8 binds phosphatidylserine and a 
macrophage surface receptor to promote apoptotic cell ingestion [404], and decreased 
MFG-E8 expression inhibits efferocytosis [405]. In addition to opsonins, PPARγ 
signaling also upregulates expression of the receptors AXL, MERTK, and CD36 
[393,406]. AXL and MERTK bind phosphatidylserine-targeting opsonins Protein S or 
GAS6, and knocking down either of them decreases macrophage efferocytic activity 
[378,379]. CD36 binds calreticulin, an eat-me signal that can either be displayed by an 
apoptotic cell or secreted by macrophages to bind asialoglycans on the apoptotic cell 
membrane [407]. Blocking PPARγ leads to downregulation of CD36 in macrophages and 
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decreased efferocytosis [393]. Conversely, increased CD36 expression correlates with 
increased efferocytosis [408]. 
Like PPARγ, LXR signaling promotes the expression of many pro-efferocytic 
genes, including the receptors MERTK and CD36 [381,409,410]. Also, like PPARγ 
knockout mice, LXR knockout mice develop ANAs and glomerulonephritis, and 
macrophage efferocytic activity can be increased by an LXR agonist [381,399]. In 
addition to MERTK and CD36, LXR stimulation can also upregulate TIMD4 [411,412]. 
Unlike MERTK or CD36, TIMD4 can bind phosphatidylserine directly and promote 
apoptotic cell phagocytosis without an opsonin [385,412,413]. Knocking out TIMD4 
leads to decreased efferocytosis and promotes autoimmunity [385]. Not all efferocytosis 
genes are directly involved in binding and ingesting apoptotic cells. The phagocytosing 
of apoptotic cells means ingesting a large amount of cholesterol. Excess free cholesterol 
could potentially damage the cell membrane, but the LXR-regulated cholesterol pump 
ABCA1 flushes out the excess cholesterol allowing the efferocytic macrophage to remain 
functional [414,415]. 
All three of these pathways have one thing in common. LXR, PPARγ, and PPARδ all 
form a permissive heterodimer with RXR. This means that an RXR agonist would 
activate all three of these pathways [416]. Unsurprisingly macrophage lineage-specific 
deletion of RXR resulted in defective macrophage clearance of apoptotic cells and lupus-
like autoimmune kidney disease, while treatment with an RXR agonist significantly 
increased macrophage efferocytic activity [394]. Clearly, differences in the stimulation of 
any one of these pathways could potentially contribute to the deficient macrophage 
efferocytosis seen in lupus-prone female mice.
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MATERIALS AND METHODS 
Animals and surgeries
Six-week-old female New Zealand Black (NZB) and male New Zealand White 
(NZW) mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). The 
NZB and NZW mice were bred in our animal facility to produce the NZBxNZW F1 
(BWF1) mice. Sixteen-week-old female BALB/c mice were purchased from the Jackson 
Laboratory, and used in the RNA sequencing (RNA-seq) study. C57/BL mice were bred 
in our own facility. Mice were maintained under specific pathogen-free conditions in our 
animal facilities following the guidelines stipulated by the University of Louisville 
Institutional Animal Care and Use Committee. 
For castration, pre-pubertal (24-day-old) male BWF1 mice were anesthetized with 
isoflurane, the scrotum was incised, the vas deferens and spermatic vessels were ligated, 
the testes and epididymis were removed, and the skin was sutured. Sham castration was 
done on age-matched males by incising the scrotum and then suturing the skin. Analgesic 
(ketoprofen) was administered during the procedure and 24 hours after the procedure. 
For flutamide pellet treatment, pre-pubertal (24-day-old) male BWF1 mice were 
anesthetized and a time-release pellet containing vehicle or the androgen receptor blocker 
flutamide was implanted subcutaneously in their upper back. (Innovative Research of 
America, Sarasota, FL; #NA-152). The flutamide-containing pellet released 1.5 g of 
flutamide over 90 days (16.7 mg dose/day). 
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Reagent descriptions 
Super complete media (SCM) is RPMI 1640 (Sigma, Burlington, MA; #R7509) 
supplemented with 1000 U/mL penicillin/streptomycin, 2 mM L-glutamine (Corning, 
Corning, NY; #25-005-CI), 1% Non-essential amino acids (Thermo Fisher, Waltham, 
MA; #11150-060), 1 mM Sodium Pyruvate (Thermo-Fisher, #SH30239.01), 10 mM 
HEPES (Corning #25-060-CI), and 10% fetal calf serum (FCS) (R&D Systems, 
Minneapolis, MN; #S11150). 
Clostridium histolyticum Collagenase type VIII and DNase were purchased from 
Sigma C2139, d4527) 
The monoclonal antibodies anti-CD16/32, anti-CD11b-PE, anti-F4/80-APC, anti-
CD11b-BV421, anti-F4/80-APC, anti-CD36-PECy7, anti-TIMD4-PE, anti-Thy1-
APC/Cy7 were purchased from Biolegend (San Diego, CA; #101301, 101208, 123115, 
101251, 102615, 130005, 105328). The monoclonal antibodies anti-rabbit IgG-PE, anti-
MERTK-PE/Cy7 were purchased from Thermo Fisher (#12-4739-81, 25-5751-82). The 
monoclonal antibody anti-LRP1 was purchased from Abcam (Cambridge, UK; 
#Ab92544). The monoclonal antibody anti-CD36 was purchased from BD Biosciences 
(Franklin Lakes, NJ; #552544) 
Cell-trace VioletTM was purchased from Thermo Fisher (#C34557) 
The RXR inhibitor HX531, the PPARγ inhibitor GW9662, the LXR inhibitor, 
GSK2033, and the PPARδ inhibitor GSK0660 were purchased from Sigma (#SML2170, 
M6191, SML1617, G5797). 
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Microbiota composition analysis 
Bacterial DNA was extracted from fecal samples using QIAamp PowerFecal DNA 
Kits (Qiagen 12830-50). Extracted DNA was sent to the Genome Technology Access 
Center at Washington University. There they sequenced 9 hypervariable regions of the 16S 
rRNA gene and the multi-amplicon data was used to create species-level taxonomic 
profiles of the microbiota [417]. In our lab, we used QIIME2 to calculate Bray-Curtis 
dissimilarity matrices for the species-level microbiota compositions and to perform 
Principal Coordinate Analysis (PCoA). The intra- and inter-group Bray-Curtis beta 
diversity distances were compared using Permutational multivariate analysis of variance 
(PERMANOVA) pairwise comparisons [418]. PCoAs were visualized using EMPeror 
[419]. The inter-group differences in the abundances of specific taxa were analyzed with 
two-way ANOVAs with corrections for multiple comparisons. 
Metabolomic composition analysis 
Three different sets of fecal samples were sent to our collaborators in the 
Biochemistry department (Metabolomic Experiments #1,2,3). Our collaborators extracted 
polar metabolites and analyzed them using a variety of methods. For Metabolomic 
Experiment #1, the samples were derivatized with N-methyl-N-
trimethylsilytrifluoroacetamide (MSTFA) and then two-dimensional gas chromatography 
mass spectrometry (GC×GC-MS) was used to analyze metabolite composition and 
abundance. For Metabolomic Experiment #2, the samples were analyzed with both 
GC×GC-MS with MSTFA derivatization and parallel two-dimensional liquid 
chromatography mass spectrometry (2DLC-MS/MS) in both negative and positive 
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ionization modes. For Metabolomic Experiment #3, the most recent and comprehensive 
analysis, samples were analyzed also analyzed by GC×GC-MS with N-tert-
Butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) derivatization as well as the 
methods used in Metabolomic Experiment #2 [420]. We used partial least squares-
discriminant analysis was performed to compare the metabolomic profile differences 
between the groups. Pairwise two-tailed t-tests were used to compare metabolite 
abundances between the groups. Quantitative pathway enrichment analysis was performed 
using Metaboanalyst (version 4.0). Intensities of metabolites identified with significant 
difference between intact male and female mice or between intact male and castrated male 
mice were analyzed by the program. The data were auto-scaled and matched against the 
KEGG pathway library for Mus musculus. The “GlobalTest” and “Betweenness centrality” 
algorithms were used for pathway enrichment and topology, respectively [421].  
 
Phytanic acid microsphere production and feeding 
Poly(lactic-co-glycolic acid) microspheres were made by our collaborators at 
TherapyX Inc (Buffalo, NY). Phytanic acid was encapsulated by using a modification of 
the solvent evaporation technique at 10 mg phytanic acid per 1 g of microspheres 
[422,423]. Vehicle microspheres were not loaded with any compound. In vitro validation 
of phytanic acid release was done by suspending 100 mg of microspheres (containing a 
predicted 1 mg of phytanic acid) in 1 mL of phosphate-buffered saline (PBS). At 24, 48, 
and 72 hours the microspheres were spun down and the supernatant was collected and 
replaced. Subsequent analysis of the collected supernatants via high pressure liquid 
chromatography (HPLC) confirmed that the microspheres were releasing phytanic acid 
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and continued to do so for at least 72 hours (Fig. 1). For each feeding, microspheres were 
resuspended via mechanical agitation with a miniature pestle, and the resulting solution 
was delivered via oral gavage using a blunt ended 22 gauge feeding needle. Each dose 
consisted of 80 μg phytanic acid loaded in 2 mg of microspheres suspended in 250 μL of 
PBS. 
For the experiment determining the effect of oral administration of phytanic acid 
on splenic macrophage efferocytic activity, female BWF1 mice received 3 doses of 
phytanic acid-containing microspheres a week starting at 12 weeks of age and the spleens 
were harvested at 16 weeks of age. For the experiment determining the effect of oral 
administration of phytanic acid on splenic macrophage CD36 expression, female mice 
were fed vehicle or phytanic acid-containing microspheres at the doses described above. 
The mice were fed every other day for two weeks, then spleens were harvested and 
splenic macrophage CD36 expression was measured by flow cytometry as described 
below. 
Cecal microbiota transfer 
The cecal contents of a 16-week-old male or female BWF1 mice were harvested and 
suspended in 12.5 mL of 0.03% L-cysteine in PBS. The suspension was vortexed to 
suspend cecal contents and then loaded into a syringe. Mice were fed 250 μL of 
suspension via oral gavage using a blunt ended 22 gauge feeding needle. Cecal feedings 
were performed at 4 weeks of age, 5 weeks of age, and every 4 weeks thereafter. 
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Preparation of adherent and sorted spleen cells 
For all experiments, splenic macrophages were isolated and processed in the 
following manner. Spleens were harvested from adult mice (12-16 weeks old) and placed 
in petri dishes, and mechanically diced. The diced spleens were placed in a 10 mL 
solution of 2 mg/mL Clostridium histolyticum Collagenase type VIII (Sigma #C2139), 10 
KU/mL DNase (Sigma #d4527), and 10% FCS in HBSS. Spleens were digested in this 
solution for 30 minutes at 37OC. EDTA was added (final concentration 0.2 mM) and the 
solution was incubated at room temperature for 5 minutes to stop the digestion. The 
spleen fragments were placed in a 70-micron mesh boat, mechanically pressed, and 
rinsed to create a single cell suspension. The cells were washed twice with FACS buffer 
(2% FCS in HBSS), and then resuspended in 5 mL RBC lysis buffer (Biolegend 
#420301). After 3 minutes in the lysis buffer, the cells were washed 2 times with FACS 
buffer. 
For sorting macrophages, splenocytes that were disassociated as described above 
were suspended in FACS buffer (2% FCS in HBSS) at 50x106 cells/100 μL in 1.5 mL 
siliconized Eppendorf tubes. Nonspecific binding to FcγRs was blocked by incubating the 
splenocytes with anti-CD16/32 antibody (Biolegend #101301) at room temperature for 5 
minutes. They were then labeled with anti-CD11b-PE and anti-F4/80-APC (Biolegend 
#101208, 123115) for 20 minutes at 4OC. The splenocytes were washed twice and then 
resuspended in FACS buffer at 40x106 cells / 1 mL. A BD FACS Aria III cell sorter was 
used to sort CD11b+F4/80+ splenocytes that were then used in the experiments described 
below. 
For the adherent macrophage experiments, splenocytes were prepared as 
described above, then the cells were counted, and resuspended in super complete media 
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(SCM) and 40x106 splenocytes in 3mL of SCM were placed in a 60 mm cell culture dish 
and incubated at 37 OC in a 5% CO2 incubator for 2 hours to select for adherent 
splenocytes. After 2 hours the dishes were gently but thoroughly washed 3 times with 
room temperature HBSS to remove the nonadherent cells, taking care that the cells did 
not become dry at any point. Two mL of SCM were added and these adherent 
splenocytes were then used for the experiments described below. 
 
RNA sequencing and transcriptome analysis 
Individual spleens from 16-week-old female BALB/c, male BWF1, and female 
BWF1 mice (n=3) were digested and prepared as described above. Splenocytes were 
counted, and 5x106 cells were lysed and RNA was extracted using an RNeasy Plus Mini 
Kit (Qiagen, Hilden, Germany; #74134). The rRNA was depleted with the NEBNext 
rRNA Depletion Kit (New England Biolabs, Ipswich, MA; #E6350). Libraries were 
prepared using the NEBNext Ultra II RNA Library Prep Kit (NEB #E7775) and the 
NEBNext Multiplex Oligos for Illumina Index primers sets 1 & 2 (NEB #E7335, E7500) 
according to the manufacturer’s directions. Size, purity, and semi-quantitation was done 
using an Agilent BioanalyzerTM (Santa Clara, CA) and the Agilent DNA HS Kit. Samples 
were diluted to 10 nM aliquots in 10mM TrisHCl, pH 8.5 supplemented with 0.1% 
Tween20 buffer. The wide range of concentrations amongst samples resulted in total 
volume of diluted samples varying from 10-50 µL. A pooled 10 nM library was made by 
taking 3 µL of each sample and combining them in a new LowBind 1.5 mL micro 
centrifuge tube for a total volume of 27 µL. The library was then diluted to 4 nM and 
denatured by mixing with diluted NaOH and incubating at room temperature for 5 
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minutes before neutralizing with 200 mM Tris-HCl, pH 7. The reaction mixture was 
diluted to 1.8 pM using the pre-chilled HT1 Buffer. Next, 13 µL of denatured 1.8 pM 
PhiX control was added to 1287 µL of denatured 1.8 pM library to a total volume of 1.3 
mL. The library was loaded onto the reagent cartridge, and the library was sequenced was 
done on an Illumina NextSeq 500TM using the NextSeq 500/550 75 Cycle High Output 
Kit v2.5 (Illumina, San Diego, CA #20024906). Quality control, adapter trimming, and 
aligning to the Mus musculus genome were done using FastQC, Trimmomatic, and STAR 
(version 2.6), respectively by the KBRIN Bioinformatics Core at the University of 
Louisville. Reads were normalized using the Relative Log Expression method and 
filtered to exclude genes with fewer than 20 counts among samples. Differential 
expression analysis was done with DESeq2 using a P-value cutoff ≤ 0.05, a q-value 
cutoff ≤ 0.05, and log2Fold Change > 0 [424]. 
To identify pathways enriched in healthy controls, genes upregulated in female BALB/c 
or male BWF1 mice compared to female BWF1 mice were functionally classified using 
the Gene Ontology:Biological Processes (GO:BP) database [425,426]. PANTHER 
(version 14) was then used to identify biological processes (q-value cutoff < 0.05 and 
fold enrichment cutoff ≥ 2) that were significantly enriched in the healthy controls 
relative to the lupus-prone female BWF1 mice [427-430]. The list of differentially 
regulated genes was also analyzed using Metacore from Clarivate Analytics to perform a 
transcription factor enrichment analysis, identifying transcription factors whose target 
genes were enriched in our set of differentially expressed genes. Statistical comparisons 
were done using Fisher’s exact test with an FDR multiple comparison correction of 0.05. 
Clustvis software was used for both Principal component analysis (PCA) and cluster 
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analysis with heatmaps [431]. PCA of the transcriptomes was performed using singular 
value decomposition with imputation method. The normalized read counts of all genes 
differently expressed between at least two of the three groups were analyzed using 
hierarchical clustering and heatmap analysis. Column and row clustering distances were 
calculated as the Pearson correlation subtracted from one, and the linkage method used 
was average distance of all possible pairs.  
 
Measurement of transcript levels by qPCR 
Macrophages were sorted as described above, and RNA was extracted using an 
RNeasy Micro Kit (Qiagen #74004). Reverse transcription was done using a High-
Capacity cDNA Reverse Transcription Kit (Thermo Fisher #4368814). PowerUp ™ 
SYBR™ Green Master Mix (Thermo Fisher #A25742) and IDT PrimeTime qPCR 
primers were used to assay gene expression of murine LRP1 (Mm.PT.58.45834660 IDT), 
AXL (Mm.PT.58.11506780), C1QA (Mm.PT.58.5375735), and Mfge8 
(Mm.PT.58.9107639) using ACTB (Mm.PT.39a.22214843.g) as the reference gene. The 
ΔCT for each gene was calculated using the reference gene, and Student’s t-tests were 
used to assess statistical differences between experimental groups. The ΔΔCT was 
calculated for each gene relative to the average ΔCT of the control group and the fold 






Analysis of surface marker expression in splenic macrophages by flow cytometry 
Splenocytes from individual mice were prepared as described above. Nonspecific 
binding to FcγRs was blocked as described above for the sorting protocol and then the 
samples were labeled with one of two panels consisting of different combinations of 
antibodies. For panel 1, anti-LRP1 (rabbit IgG, Abcam Ab92544), anti-CD11b-BV421, 
anti-F4/80-APC, and anti-CD36-PECy7 (Biolegend 101251, 123115, and 102615) for 20 
minutes at 4OC. The samples were washed twice and then incubated with anti-rabbit IgG-
PE (Thermo Fisher 12-4739-81) for 30 minutes at 4OC. For panel 2, anti-TIMD4-PE 
(Biolegend 130005) and anti-MERTK-PE/Cy7 (Biolegend 130005) were used instead of 
anti-LRP1 and anti-CD36 and the second labeling step was skipped. The samples were 
washed twice and then resuspended in 300 μL FACS buffer and analyzed on a BD 
FortessaTM for geometric mean fluorescence intensity (MFI) of LRP1, CD36, MERTK, 
and TIMD4 on splenic macrophages, (CD11b+F4/80+). Fluorescence-minus-one (FMO) 
controls were used. Analysis of all flow cytometry data in this paper was done using 
FlowJoTM software and statistical comparisons were done using Student’s t-tests.  
Assay for phagocytosis of apoptotic thymocytes (efferocytosis) 
For adherent macrophage efferocytosis assays, spleens from individual mice were 
processed and plates of adherent splenocytes were prepared as described above. Next, 
16x106 Cell-trace Violet
TM (CTV)-labeled apoptotic thymocytes, prepared as described 
below, were suspended in 1 mL of SCM and added to the adherent macrophage plates. 
For each experiment, an extra adherent macrophage dish was made. No thymocytes were 
added to that dish and it served as a negative control. The dishes were gently swirled to 
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mix the cells and then were placed in a 37OC, 5% CO2
 incubator for 1 hour. After 1 hour, 
the dishes were gently but thoroughly washed 3 times with room temperature HBSS to 
remove nonadherent thymocytes. Next, they were put on ice for 10 minutes to loosen the 
adherent cells, and then scraped and rinsed to harvest the adherent cells, which were 
transferred to 1.5 mL siliconized Eppendorf tubes. The samples were spun down at 3200 
RPM for 3 minutes and then resuspended in 100 μL of FACS buffer. Nonspecific binding 
to FcγRs was blocked with anti-CD16/32 antibody (Biolegend 101301) as described 
above. The samples were then labeled with anti-CD11b-PE, anti-F4/80-APC, and anti-
Thy1-APC/Cy7 (Biolegend 101208, 123115, and 105328) for 20 minutes at 4OC. The 
samples were washed twice and then resuspended in 300 μL FACS buffer and analyzed 
on a BD FortessaTM for the percentage of splenic macrophages, (F4/80+CD11b+) that 
were positive for the CTV label, indicating that they were in the process of phagocytosis 
apoptotic thymocytes. The well that received no thymocytes served as a negative control. 
CTV-labeled apoptotic thymocytes were prepared in the following manner. 
Thymi were harvested from 4 to 8-week-old C57/BL mice, placed in a 70-micron mesh 
boat, mechanically pressed, and rinsed with FACS buffer to create a single cell 
suspension. This was spun down at 1500 RPM for 5 minutes, then resuspended in 3 mL 
RBC lysis buffer (Biolegend 420301). After 3 minutes, the suspension was washed 2 
times with FACS buffer and counted, then resuspended in SCM+β-ME (SCM with 0.1% 
β-mercapto-ethanol (Sigma #M3148)) at 20x106 cells/mL. An equal volume of 2 μM 
dexamethasone (Sigma #D4902) in SCM was prepared and added to the thymocyte 
suspension, placed in a petri dish, and then placed in a 37OC, 5% CO2
 incubator for 16 
hours. After 16 hours, the suspension was washed 2 times with PBS and then 
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resuspended in room-temperature PBS to 40x10^6 cells/mL in a 15 mL conical, and the 
cells were labeled with Cell-trace VioletTM (Thermo Fisher #C34557). A 2 μM solution 
of CTV in room-temperature PBS solution was prepared by adding 0.4 µL of 5 mM stock 
per 1 mL of room temperature PBS and mixing thoroughly. Immediately after making the 
CTV solution, an equivalent volume was added to the thymocyte suspension for a final 
concentration of 1 μM and the mixture was vortexed thoroughly, then incubated at room 
temperature in the dark for 20 minutes. The cells were washed 3 times with FACs buffer, 
counted, and resuspended in SCM at 8x106 cells/mL. To verify the thymocytes were 
apoptotic and CTV-labeled, a 100 μL aliquot was taken, 5 μL of AnnexinV-FITC 
(Biolegend 640945), and 5 μL of 7-AAD (BD Biosciences 559925) was added and the 
aliquot was incubated at room temperature in the dark for 15 minutes. The aliquot was 
then diluted to 300 μL with FACS buffer and analyzed in a BD FortessaTM for apoptosis 
(AnnexinV and 7-AAD) and CTV label. 
For assays of sorted splenic macrophage efferocytic activity, spleens from 
individual mice were digested and macrophages were sorted as described above and 
resuspended in SCM. For each sample, 200,000 (0.5 mL) of the sorted macrophages were 
put in a separate well of a 24 well plate. CTV-labeled apoptotic thymocytes were 
prepared as described above and to each experimental well, 2x106 CTV-labeled apoptotic 
thymocytes in 0.25 mL of SCM were added. An additional control well had macrophages 
but no thymocytes. The plate was gently swirled to mix the cells and then was placed in a 
37OC, 5% CO2
 incubator for 1 hour. The plate was then placed on ice for 5 minutes, and 
the wells were scraped and rinsed to harvest the cells, which were transferred to 1.5 mL 
siliconized Eppendorf tubes. Samples were then labeled for F4/80, CD11b, and Thy1 and 
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analyzed for the percentage of splenic macrophages (F4/80+CD11b+) that were positive 
for the CTV label, as described above. 
Assays of the effect of phytanic acid treatment on splenic macrophages 
For analysis of the effect of phytanic acid treatment on splenic macrophage 
marker expression, spleens from individual mice were digested and processed as 
described above, and suspended in super complete media (SCM). SCM is RPMI 1640 
(Sigma E#7509) supplemented with 1000 U/mL penicillin/streptomycin, 2 mM L-
glutamine (Corning #25-005-CI), 1% Non-essential amino acids (Gibco #11150-060), 1 
mM Sodium Pyruvate (HyClone #SH30239.01), 10 mM HEPES (Corning #25-060-CI), 
and 10% FCS. Two 5x106 cell aliquots from each sample were put in the wells of a 24-
well plate, and either phytanic acid (final concentration = 50 μM) or vehicle (ethanol, 
final concentration = 0.06% v/v) was added. The plates were placed in a 37OC, 5% CO2 
incubator for 24 hours. Next, the plates were placed on ice for 5 minutes, and then the 
wells were scraped and rinsed to harvest the cells. Staining for macrophage markers and 
analysis was done as described above. 
For the experiments examining the effect of phytanic acid on adherent female 
BWF1 macrophage efferocytosis, the adherent macrophages were prepared as described 
before, with the exception that spleens were pooled, and after the 2-hour incubation and 
removal of non-adherent cells, SCM containing 50 μM phytanic acid was added to the 
dish, and the cells were placed back in the incubator for an additional 24 hours. After 24 
hours, the phagocytosis assay proceeded as described above. 
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For the experiments examining the effect of phytanic acid on sorted BWF1 
macrophage efferocytosis, spleens were pooled and digested and macrophages were 
sorted as described above. Sorted macrophages were then resuspended in SCM 
containing, vehicle (ethanol, final concentration = 0.06% v/v), 50 μM phytanic acid 
(Cayman 90360), a nuclear receptor inhibitor. Macrophages were divided into 200,000 
cells/0.5 mL aliquots and placed in a 24 well plate and incubated at 37OC at 5% CO2
 for 
48 hours. After 48 hours, the phagocytosis assay proceeded as described above. 
Assays for effect of nuclear receptor inhibition on efferocytic activity 
Spleens from adult female BWF1 mice were pooled and digested as described 
above. Macrophages were sorted, split into two groups, and resuspended in SCM 
containing, vehicle (ethanol, final concentration = 0.06% v/v), 50 μM phytanic acid 
(Cayman 90360), a nuclear receptor inhibitor. Macrophages were divided into 200,000 
cells/0.5 mL aliquots and placed in a 24 well plate and incubated at 37OC at 5% CO2
 for 
48 hours. After 48 hours, the phagocytosis assay proceeded as described above. The 
following concentrations of nuclear receptor inhibitors were used:  The RXR inhibitor, 
HX531 (Sigma SML2170), was used at a concentration of 10 μM. The PPARγ inhibitor, 
GW9662 (Sigma M6191), was used at a concentration of 10 μM. The LXR inhibitor, 
GSK2033 (Sigma SML1617), was used at a concentration of 5 μM. The PPARδ 
inhibitor, GSK0660 (Sigma G5797), was used at a concentration of 10 μM. 
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Assays for the effect of CD36 inhibition on macrophage efferocytic activity 
The CD36 neutralizing antibody was validated with a titration experiment where 
macrophages were sorted as described above and treated with 0.5, 1, or 2 μg/mL of anti-
CD36 for 30 minutes (Clone CRF D-2712, BD Biosciences #552544) [372]. 
Macrophages were then cultured with CTV-labeled apoptotic thymocytes for one hour 
and the efferocytosis assay proceeded as described above. A dose-dependent reduction in 
efferocytosis after anti-CD36 treatment was observed (Fig. 2) 
For the phytanic acid and anti-CD36 co-treatment experiment, sorted 
macrophages were treated for 48 hours with 50 μM phytanic acid. Macrophages were 
then treated with 2 μg/mL of anti-CD36 for 30 minutes. CTV-labeled apoptotic 
thymocytes were then added for one hour and the efferocytosis assay proceeded as 
described above. 
Statistical analyses 
Statistical analysis of disease scores was performed using two-way ANOVA and 
two-tailed Student’s t-tests. Statistical analyses of incidence and survival curves were 
performed using the Log rank (Mantel-Cox) test. For Intra- and inter-group microbiota 
Bray-Curtis beta diversity distances were compared using PERMANOVA statistical 
analyses [418]. The inter-group differences in the abundances of specific taxa were 
analyzed with two-way ANOVAs with corrections for multiple comparisons. For 
comparisons of metabolite abundance, metabolites were filtered for those that had an 
abundance change of over 20% between two groups and were present in more than 75% 
of the samples for at least one group. Student’s t-tests with sample permutation were used 
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to determine if the abundance change was significant. Grubbs’ test was used to detect and 
remove outliers. For comparisons of gene expression as measured by flow cytometry or 
qPCR, Student’s t-tests were used. For comparisons of efferocytic activity as measured 
by fold change %CTV+ macrophages, statistical comparisons between groups were 
performed using Student’s t-tests if only two groups were compared. If three or more 
groups were compared, then one-way ANOVAs with multiple comparisons were 
performed, using the Tukey post-analysis method to correct for multiple comparisons. 
For comparing expression of genes by qPCR or flow cytometry, Student’s t-tests were 
used to assess statistical differences between experimental groups.  
 GraphPad Prism 9 (Sand Diego, CA) was used for all statistical analysis unless 
stated otherwise. All error bars shown are +/- standard error of the mean. A cutoff of 0.05 
was used for significance for analyses, and significance was indicated as follows: 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001    
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Figure 1. Validation of Phytanic acid release by microspheres. Phytanic acid was 
encapsulated in poly(lactic-co-glycolic acid) microspheres at 10 mg phytanic acid per 1 g 
of microspheres. Release of phytanic acid was assayed by suspending 100 mg of 
microspheres in 1 mL of PBS and incubated at 37 OC. At 24, 48, and 72 hours the 
microspheres were spun down and the supernatant was collected and replaced. Phytanic 
acid levels in the supernatants were measured by HPLC (n=3). 
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Figure 2 Blocking CD36 with a neutralizing antibody decreases splenic macrophage 
phagocytosis in a dose-dependent manner. Splenocytes from 16-week-old female 
BWF1 mice were collected and sorted for CD11b+F4/80+ cells by FACS. Sorted cells 
were cultured without (Ctl) or with varying concentrations of blocking anti-CD36 
antibody for 30 mins then phagocytosis of apoptotic cells was assayed by culture with 
CellTraceTM Violet (CTV)-labeled apoptotic thymocytes for one hour followed by 
analysis of percentages of CD11b+F4/80+ cells that were CTV+. Data are reported as fold 
change (FC) in %CTV+ cells (n=2). 
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SPECIFIC AIM 1 
Sex-based differences in gut microbiota composition associated 
with protection from lupus 
Introduction
Like many autoimmune diseases, systemic lupus erythematosus (SLE) has a 
significant sex bias, with women comprising over 90% of SLE patients with autoimmune 
diseases [1,2]. This sex bias is also present in the NZBxNZWF1 (BWF1) mouse model of 
lupus. Female mice develop severe disease early in life, often having elevated 
autoantibodies at 16 weeks of age and beginning to develop glomerulonephritis between 
20 to 25 weeks of age; virtually all female mice die of this disease by 50 weeks of age. 
Male BWF1 mice on the other hand only rarely develop a mild form of disease late in life 
[16]. Male resistance to disease is androgen dependent, as males who undergo androgen 
depletion by castration develop more severe disease at a younger age [17]. This is also 
similar to what is seen in humans, as female and male SLE patients have decreased levels 
of androgens, and treatment with androgens can suppress disease activity [115,138,141-
144,149-152]. The BWF1 mouse strain is an excellent model of lupus particularly for the 
study of mechanisms underlying the sex bias in lupus. 
Sex differences in the commensal bacteria in the intestine could potentially 
contribute to the sex bias of lupus in humans and in lupus-prone mice. A complex 
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network of interactions exists between these bacteria, called the gut microbiota, and the 
immune system. These interactions shape both microbiota composition and immune 
responses and they are vital for the proper development and function of the immune 
system [181-187]. When the microbiota is disrupted or imbalanced, it is said to be in 
dysbiosis. A dysbiotic microbiota can have a pro-inflammatory effect on the immune 
system and promote the development of autoimmune diseases [184,218,219]. 
Many autoimmune diseases have been linked to dysbiotic microbiota. Patients 
with inflammatory bowel disease (IBD) have been found to have dysbiotic microbiota 
[225-235]. No clear causal links between alterations in bacterial taxa and disease have 
been established in human IBD, but mouse models have shed some light on possible 
mechanisms. Bacteroides fragilis and some Clostridia strains have been shown to 
suppress IBD in mice by promoting Treg induction [433-435]. On the other hand, 
Helicobacter muridarum, Helicobacter hepaticus, and segmented filamentous bacteria 
can exacerbate disease by promoting pro-inflammatory activity in Th17 cells [250-252]. 
Non-intestinal autoimmune diseases such as rheumatoid arthritis can also be 
affected by the microbiota [184,256,257]. SLE is a systemic disease that has been linked 
to dysbiotic microbiota. The microbiota of SLE patients differ significantly from healthy 
controls [276-283]. While the specific taxa altered in SLE patients vary from study to 
study, their findings have still increased our understanding of how the gut microbiota can 
affect disease progression. For example, Ruminococcus gnavus abundance was five times 
higher in SLE patients, and higher levels of antibodies against R. gnavus correlated with 
overall antibody levels and kidney damage [276]. This suggests that R. gnavus may 
stimulate immune responses that increase SLE activity. Another study found SLE 
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patients with Enterococcus gallinarum in the liver had higher levels of autoantibodies. In 
further experiments using the lupus-prone NxB F1 mouse strain, E. gallinarum 
stimulated disease by translocating across the intestinal barrier to the liver and 
stimulating pro-inflammatory cytokine production [286]. Lupus-prone B6.Sle1.Sle2.Sle3 
mice were also found to exhibit dysbiosis, with higher levels of Prevotellaceae, 
Paraprevotella, and Lactobacillus compared to healthy controls. Cohousing the 
B6.Sle1.Sle2.Sle3 mice with the healthy control mice reduced autoantibody production, 
suggesting that the differences in microbiota could affect processes involved in disease 
[293]. A study of the MRL/lpr lupus mouse model had a similar finding, as cecal 
transfers from healthy control MRL mice decreased autoantibody production [297]. The 
MRL/lpr study found that Lactobacillus, which was enriched in healthy controls, 
protected against disease, but studies in SLE patients and BWF1 mice found that higher 
Lactobacillus was associated with more severe lupus [282,297,299]. This demonstrates 
that the effect of a given taxa of microbiota is highly dependent on the overall context of 
the microbiota.  
Sex and sex hormone levels also significantly affect the microbiota, suggesting 
that sex-based differences in microbiota function could potentially contribute to the sex 
bias of lupus [182,300-303,315]. Recently, two studies found evidence to support this 
theory. In the NOD mouse model of type 1 diabetes (T1D), female mice are more 
susceptible and male mice are more resistant to disease. However, the studies found that 
male mice possessed a distinct microbiota that conferred this protection in an androgen-
dependent manner [323,324]. Also, a recently published paper on the SWRxNZB F1 
(SNF1) mouse model of lupus found differences in microbiota composition between 
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intact male, androgen-depleted male, and female mice. Kidney disease wasn’t affected by 
these sex-based microbiota changes, but it also wasn’t affected by androgen depletion 
(i.e., castration), suggesting that their model may not have been effective at investigating 
sex differences [325]. Nevertheless, these studies suggest that sex-based differences in 
microbiota could influence immune functions associated with lupus progression. 
Previous studies have found microbiota from healthy control female mice can 
suppress disease in lupus-prone female mice, but none have shown the same effect 
between male and female mice of a lupus-prone strain. The goal of the present study was 
to investigate differences in the gut microbiota composition in female and male BWF1 
mice and their impact on disease. We have shown that transferring microbiota from 
disease-resistant BWF1 mice into female BWF1 mice delays disease onset and improves 
survival. However, changes in mouse facilities resulted in a period of time where the 
transfer of male microbiota was no longer protective. The protective phenotype was 
eventually restored, and we have used this opportunity to compare the sex differences in 
the microbiota between periods when male microbiota was protective and periods when it 
was not, with the goal of identifying what male-enriched species are associated with 
protection against lupus. 
Results 
Disease susceptibility and microbiota composition in the BWF1 mouse model of 
lupus 
The findings of recent studies suggested sex differences in the microbiota might 
contribute to the lupus sex bias in BWF1 mice [16,323,324]. To investigate this, our lab 
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first examined microbiota composition in female and male BWF1 mice as well as 
confirmed that disease incidence and progression in our colony is accelerated and more 
severe in female than male BWF1 mice as has been previously reported [16,17]. As 
expected, the incidence and level of glomerulonephritis severity were significantly higher 
in females, and survival was significantly decreased (Fig. 3A-C). We analyzed the 
bacterial composition of feces from female and male BWF1 mice to compare the 
intestinal microbiota. We used Bray-Curtis analysis of beta-diversity to analyze how 
different the microbiota composition of each sample was from the other samples. The 
principal coordinate analysis (PCoA) visualization of this analysis showed that the 
microbiota profiles formed two distinct groups based on sex (Fig. 4A). Permutational 
multivariate analysis of variance (PERMANOVA) of the beta-diversity values confirmed 
the female and male BWF1 gut microbiota profiles were significantly different (Fig. 4B). 
This showed that in addition sex-based differences in disease, there were also sex-based 
differences in the microbiota in BWF1 mice. As with human SLE patients, androgens 
suppress disease in BWF1 mice, and depleting androgens in male BWF1 mice makes 
them more susceptible to disease [133,134]. Castrated male BWF1 mice have 
significantly increased incidence and severity of glomerulonephritis and a dramatic 
decrease in survival (Fig. 5; [420]). Comparison of intact and castrated male BWF1 
microbiota showed that androgen depletion caused a major shift in the microbiota profile 
(Fig. 6). These results showed that lupus-susceptible female and castrated male BWF1 
mice have divergent microbiota profiles from lupus-resistant intact male BWF1 mice.  
In order to investigate whether the sex-based differences in the microbiota could 
affect lupus progression, our laboratory carried out microbiota transfer experiments, 
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where BWF1 mice were fed cecal contents from female or male BWF1 mice (Fig. 7A). 
Since dysbiotic microbiomes have been linked to autoimmune diseases [184,218,219], 
our lab tested whether the female BWF1 microbiota could promote lupus progression in 
male recipients. Transfer of cecal contents from female BWF1 mice did not increase 
disease in male BWF1 mice (data not shown). Interestingly, when the opposite 
experiment was performed, and male microbiota was transferred via cecal contents to 
female BWF1 recipients, the transfer of male microbiota significantly delayed disease 
onset and improved survival in female BWF1 mice (Fig. 7B-D). Our lab has also found 
that this protective effect is androgen dependent, as shown in experiments where 
microbiota from castrated male mice transferred into female mice had no protective effect 
on disease incidence or progression, or survival (data not shown). Taken together, these 
data indicate that female and male gut microbiota differ in composition and the male 
microbiota may contain bacterial populations that can protect against lupus. 
Alterations in mouse facilities/animal husbandry procedures resulted in changes in 
the ability of male BWF1 microbiota to suppress lupus progression in female BWF1 
mice and in microbiota composition. 
The disease progression, and initial microbiota analysis and transfer experiments 
in BWF1 mice described above were performed in our animal facility in the A Tower 
building on the University of Louisville campus from 2014 through late 2016. However, 
in January 2017, due to circumstances beyond our control, our mouse colony was moved 
to the barrier animal facility in the Center for Translational Research Building (CTRB). 
We first monitored disease in female and male BWF1 mice produced in the CTRB 
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facility, and found no differences in disease kinetics, severity, or incidence, or mortality 
in either sex compared to our colony in the A Tower facility, i.e., female BWF1 mice 
exhibited accelerated and severe glomerulonephritis and increased mortality by 
comparison to male BWF1 mice (data not shown). We also conducted experiments to 
confirm that male microbiota transferred into female BWF1 mice delayed disease, and 
decreased severity and mortality in CTRB as we had found in the A Tower. We 
conducted three microbiota transfer experiments between January 2017 and Fall 2018 
(designated the "CTRB Early" period), but were unable to replicate the protective 
phenotype that we had seen in the A Tower. We found no difference in the onset and 
progression of glomerulonephritis between female BWF1 mice receiving male 
microbiota and those receiving female microbiota (Fig. 8A,B). Survival was also not 
different between these two groups of recipients (Fig. 8C). A Bray-Curtis analysis 
comparing microbiota compositions in feces collected from female and male BWF1 mice 
from the A Tower and the CTRB Early period showed that the microbiota compositions 
differed between the A Tower and the CTRB Early mouse colonies (Fig. 9A). Analysis 
of Bray-Curtis beta-diversity distances between female and male profiles from the CTRB 
Early colony found that they were only slightly statistically different (Fig. 9B; p=0.043) 
by comparison to the differences found between female and male microbiota composition 
found in the A Tower (Fig. 4; p=0.001). This suggests that not only did the microbiota 
profiles differ between the A Tower and the CTRB Early period, but also that the CTRB 
Early female and male microbiota compositions are less different from each other than 
female and male compositions were in the A Tower facility. 
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To attempt to recover our protective transfer phenotype, several changes were 
made in Fall 2018 to the animal husbandry of our mice in the CTRB facility that included 
a change in animal room (we did not actually have a choice in this, since we were moved 
out of the room that eventually became part of the new germ-free facility), a change in 
disinfecting protocols used by our animal care technician, and a change in water source, 
from either autoclaved tap water or water purified by sterile filtration to water purified by 
reverse osmosis (RO) then autoclaved directly in the water bottles. Although we cannot 
conclude with any certainty which if any of these changes had an effect, we have found 
that since these changes were implemented, transfers of male microbiota again 
consistently suppress disease in female BWF1 recipients. In microbiota transfer 
experiments performed during this more recent time period in the CTRB (designated 
"CTRB Recent" and covering the period of 2019 to present), disease onset is significantly 
delayed and incidence is decreased, and survival is increased in female BWF1 recipients 
of male microbiota compared to recipients of female microbiota (Fig. 10). Additionally, 
Bray-Curtis analysis of beta-diversity shows that the female and male microbiota profiles 
form distinct groups based on sex (Fig. 11A), and are again highly significantly different 
(Fig. 11B; p=0.001). Taken together, our preliminary analysis strongly suggests that the 
microbiota populations were altered after the move from the A Tower (A Tower - 2014-
2016) to the CTRB (CTRB Early - 2017-2018) and then again after the modification of 
the animal husbandry practices in the CTRB (CTRB Recent - 2019-present) and these 
changes correlated with changes in the protective phenotype we observed in our male 
microbiota transfer experiments. These observations presented us with the opportunity to 
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explore whether and which sex-based differences in commensal abundance at the 
genus/species level are associated with protection from disease.  
 
The change in mouse facilities/animal husbandry procedures resulted in genus and 
species level changes in the male and female BWF1 microbiota 
We first analyzed female and male BWF1 microbiota down to the genus and 
species levels in feces collected shortly before the move from the A Tower (2016) and in 
the months following the move to the CTRB (CTRB Early - 2017-2018). Our findings 
showed that the change in facilities had a dramatic and destabilizing impact on the 
composition of the microbiota. In the A Tower, Bacteroides abundance, in general, was 
high (~20-30%) and significantly higher in adult male BWF1 mice than in adult female 
BWF1 mice (Fig. 12A). However, this was not the case in the CTRB Early experiments. 
In three of the CTRB Early experiments, Bacteroides levels were almost undetectable in 
both female and male BWF1 mice (Fig. 13A,C,E). Moreover, the levels of Clostridium 
abundance in the CTRB Early experiments (~40-60%) were three to four times greater 
than was seen in the A Tower (~15-20%; Fig. 12A; 13A,C,E). In a fourth CTRB Early 
experiment, Bacteroides was present, but was actually higher in female than male BWF1 
mice, and Clostridium was still considerably higher than had been seen in the A Tower 
(Fig. 12A; 14A). This experiment (CTRB Early Exp 4) took place four months after the 
first CTRB Early experiment (Exp 1) and two months after CTRB Early Experiments 2 
and 3, so the wildly disparate levels of Bacteroides abundance between CTRB Early 
Experiments 1-3 and CTRB Early Experiment 4 could indicate that the microbiota 
composition of the mice was still in flux, although it should be noted that the Clostridium 
72 
levels remained very high in all four CTRB Early experiments. The microbiota analysis 
also identified another genus, Alistipes (Alistipes putredinis and Alistipes timonensis), 
that was present in A Tower, but was undetectable in the CTRB Early experiments (Fig. 
12-14). Species analysis of the microbiota showed that Bacteroides acidifaciens and 
Clostridium leptum were the predominant Bacteroides and Clostridium species, 
respectively. These species, when present, exhibited the same patterns as their genera in 
both the A Tower and CTRB Early experiments (Fig. 12B; 13B,D,F; 14B). Clearly the 
change in facilities and the loss of the ability of male microbiota to suppress lupus 
coincided with significant alterations, both decreases and increases, in the relative 
abundances of bacteria in the female and male mice. 
Mice microbiota compositions are affected by how their drinking water is sterilized. 
During the CTRB Early period, experiments were conducted to evaluate the effect 
of different drinking water sources on the microbiota. Female and male BWF1 mice 
received either tap water autoclaved in bottles (Autoclaved Tap H2O; this was the same 
water that was provided to mice in the A Tower) or sterile filtered (but not de-ionized) 
water (Filtered H2O) from birth through the end of the experiment. Feces were collected 
and mice were monitored for disease incidence and severity, and survival. There were no 
differences in disease or mortality for either the female or male mice compared to the A 
Tower (data not shown). A side-by-side comparison shows there were subtle differences 
in genus/species abundance that were dependent on the water source. This experiment 
showed that changes in environmental (e.g., water source) and genetic factors (e.g., sex) 
affect different bacterial taxa differently. Lachnoanaerobaculum abundance (primarily, 
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the L. umeaense species) was affected by the water source, but less so by sex. 
Conversely, Lactobacillus abundance (primarily the L. gasseri and johnsonii species) was 
affected by the sex of the mice but not the water source. Clostridium abundance was 
affected by the water source and by the sex at the genus level (Fig. 15A), but the 
predominant species, C. leptum, was only affected by the water source (Fig. 15B). These 
data highlight the complexities and challenges of studying the gut microbiota and how 
changes in mouse facility conditions can alter microbiota compositions.  
 
During the CTRB Recent period, Bacteroides and Clostridium abundances returned 
to levels similar to the A Tower 
As described above, we had found that the loss of the protective phenotype of the 
male microbiota during the CTRB Early period (2017-2018) corresponded to decreases 
or absence of both Bacteroides and Alistipes abundances and/or an increased abundance 
of Clostridium, in general, by comparison to the A Tower. We next turned to the in-depth 
analysis of the microbiota in the feces collected from mice during the CTRB Recent 
period (2019-2020) when the protective transfer phenotype was re-established in the 
CTRB (Fig. 10). We found that the CTRB Recent period coincided with another shift of 
the microbiota composition to one that more resembled that seen in the A Tower. In two 
experiments (CTRB Recent Experiments 1 & 2) conducted during the CTRB Recent time 
period, Bacteroides (Fig. 16A,C), particularly the Bacteroides acidifaciens species (Fig. 
16B,D), is once again present and at high levels, and was found at consistently greater 
abundance in male compared to female BWF1 mice. Also, the levels of Clostridium (Fig. 
16A,C), again particularly C. leptum (Fig. 16B,D), are back down to levels at or even 
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below (~5-10%) those seen in the A Tower in both female and male BWF1 mice 
compared to the considerably elevated levels (40-60%) found during the CTRB Early 
period. Additionally, Alistipes, which had been present in the A Tower, but undetectable 
in the CTRB Early experiments (Fig. 12; 13; 14), was detected in all of the CTRB Recent 
experiments (Fig. 16). The same species of Alistipes that were predominant in the A 
Tower, A. putredinis and A. timonensis, were also predominant in the CTRB Recent 
experiments. (Fig. 12B; 16B,D). 
Interestingly, the high levels of Bacteroides (and also the B. acidifaciens species) 
found in male BWF1 mice appeared to be androgen-dependent. In experiments also 
conducted during the CTRB Recent period, we found that when androgen was depleted 
by castration, the abundance of Bacteroides was significantly decreased, although still 
present at detectable levels. In addition, as was found in the experiments comparing 
microbiota composition in female and male BWF1 mice described above, both castrated 
and intact male mice had relatively low Clostridium levels in comparison to the CTRB 
Early period and also had detectable levels of Alistipes. (Fig. 17). 
 In summary, Bacteroides was consistently present and levels of Bacteroides 
abundance were consistently higher in males compared to females during both the A 
Tower and CTRB Recent periods (when the protective transfer experiments were 
working) and this was mostly due to differences in the B. acidifaciens species. 
Conversely, during the CTRB early period (when the protective transfer experiments 
were not working), Bacteroides levels were either barely detectable in female and male 
BWF1 mice or significantly lower in females compared to males. Furthermore, 
Clostridium (primarily C. leptum) levels were much higher during the CTRB Early 
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period than either the A Tower and CTRB Recent periods. While the same Alistipes 
species, A. timonensis and A. putredinis were predominant in mice during the A Tower 
and CTRB Recent periods, no members of the genus Alistipes were detectable in mice 
during the CTRB Early period. The shift in microbiota profiles that coincided with the 
change in our mouse facility from the A Tower to the CTRB had reverted during the 
CTRB recent period to be more similar to the profiles seen in the A Tower. 
Protection from disease by male to female microbiota transfer correlates with 
elevated levels of Bacteroides in the recipients 
The fact that male BWF1 microbiota can be protective suggests that the bacteria 
that are more abundant in male BWF1 mice may be acting to suppress disease. The only 
taxa consistently enriched in male BWF1 mice during the A Tower and CTRB Recent 
periods, periods during which the male microbiota protected against disease (Fig. 7; 10), 
were the genus Bacteroides and in particular, the species Bacteroides acidifaciens (Fig. 
12; 16). This makes Bacteroides a possible candidate for a mediator of male microbiota 
disease suppression. However, if increased Bacteroides does promote protection against 
disease, then suppression of disease in female recipients of male microbiota should 
correlate with the presence of high levels of Bacteroides (received via transfer of cecal 
contents). To evaluate this possibility, we performed an in-depth analysis of microbiota 
data from microbiota transfer experiments conducted during the CTRB Early period 
(when transfer was not protective) and the CTRB Recent period (when transfer mediated 
protection was reestablished). We saw several of the same differences in microbiota 
abundances between the CTRB Early and Recent microbiota transfer experiments that we 
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saw between the CTRB Early and Recent experiments comparing female and male 
BWF1 mice. In the CTRB Early cecal transfer experiment, where male microbiota failed 
to protect (Fig. 8), Bacteroides levels (which were predominantly the Bacteroides 
acidifaciens species) were actually high in all of the groups, but they were lower in 
female recipients of male microbiota compared to recipients of female microbiota (Fig. 
18). However, similar to the microbiota profiles female and male mice in the four CTRB 
Early experiments described above (Fig. 13; 14), all of the groups had very high levels of 
Clostridium (30-40%), and undetectable levels of Alistipes (Fig. 18). In contrast, analysis 
of a microbiota transfer experiment from the CTRB Recent period found that recipients 
of male microbiota had significantly higher Bacteroides abundances compared to the 
female BWF1 recipients of female microbiota (Fig. 19A). The levels of Clostridium were 
considerably lower for all groups (10-20%) in comparison to the levels found in CTRB 
Early transfer experiment (30-40%) (Fig. 18A; 19A). Furthermore, unlike the CTRB 
Early period when Alistipes was completely absent (Fig. 13; 14), Alistipes was detected 
in all recipients during the CTRB Recent period and the same species were predominant 
as in the A Tower female and male mice (A. timonensis and A. putredinis). (Fig. 19B). 
This microbiota profile in the CTRB Recent cecal transfer experiment was highly stable, 
as we tested the microbiota composition again 4 weeks later and found the same higher 
levels of Bacteroides in the recipients of male microbiota as well as lower levels of 
Clostridium and detectable Alistipes in all groups (Fig. 19C). Taken together, these data 
show that higher Bacteroides and lower Clostridium levels consistently correlated with 
delay and decrease in severity of disease and increase in survival. Additionally, species-
level analysis of the CTRB Early and CTRB Recent transfer experiments showed that as 
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in the other experiments, Bacteroides acidifaciens and Clostridium leptum comprised 
almost all of the Bacteroides and Clostridium present, respectively (Fig. 19B,D). 
In conclusion, during periods when transfers of male microbiota were shown to 
suppress lupus in female recipients (A Tower and CTRB Recent), Bacteroides was 
consistently present and more abundant in male than female BWF1 mice (Figs. 16; 20A). 
Bacteroides also correlated with protection in the microbiota transfer experiments, as 
female recipients of male microbiota that were protected from disease (CTRB Recent) 
had elevated levels of Bacteroides compared to female recipients of female microbiota 
(Figs. 19; 21). This suggests that Bacteroides may play a role in suppressing lupus 
progression. Failure to protect also correlated with high abundance of Clostridium in both 
female and male mice and in the microbiota transfer recipients during the CTRB Early 
period (Figs. 13; 14; 18) compared to the A Tower (Fig. 12) and CTRB Recent 
Experiments (Figs. 16; 19; 20; 21). The fact that higher levels of Clostridium correlate 
with a failure of the male microbiota to protect against disease raises the possibility that 
an overabundance of Clostridium might interfere with the disease-suppressing activities 
of other bacteria, and that the ratio of Bacteroides to Clostridium may be critical. We 
calculated the Bacteroides/Clostridium ratio, and found that during periods when the 
male microbiota was protective the Bacteroides/Clostridium ratio was higher in male 
than female BWF1 mice. (Fig. 22A). Additionally, when we compared the CTRB Early 
and Recent transfer experiments, the Bacteroides/Clostridium ratio differed little in the 
female recipients of female microbiota, but for recipients of male microbiota, the 
Bacteroides/Clostridium ratio was much higher in the CTRB Recent transfer experiment 
(Fig. 22B). In addition, Alistipes was present in BWF1 mouse microbiota during periods 
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(i.e., A Tower and CTRB Recent) when the male microbiota protected against disease 
when transferred into female recipient, and absent during the period when the male 
microbiota failed to protect (i.e., CTRB Early). Taken together, these data suggest that 
there might be some type of cooperation or collaboration occurring between several 
bacterial species in the gut community that confer protection that can only occur when 
other species are in low abundance.  
 
Discussion 
One new paradigm in autoimmune disease that has emerged in recent years is the 
ability of the microbiota to significantly affect immune functions. The intestinal 
microbiota is significantly affected by immune activities and it can significantly affect the 
immune system via a variety of mechanisms [218,436]. When a microbiome has been 
disrupted, it is said to be in dysbiosis, and patients with autoimmune diseases have been 
found to exhibit dysbiotic microbiomes [184,256,257,276-280,282,283] as well as altered 
metabolite production [333-336,348,360-362]. This includes SLE, as many studies have 
found the intestinal microbiota of SLE patients differs significantly from those of healthy 
controls [276-283,437]. The microbiota of lupus prone mouse strains like 
B6.Sle1.Sle2.Sle3 and BWF1 has also been found to differ from sex-matched healthy 
control strains [282,289]. However, despite the fact that BWF1 mice exhibit a similar sex 
bias as human SLE patients [16], the microbiota of female and male BWF1 mice had not 
been compared until our lab found that lupus-susceptible female BWF1 mice and lupus- 
resistant male BWF1 mice had divergent microbiota compositions (manuscript in 
preparation). Our lab has also found that transferring adult male BWF1 microbiota into 
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female BWF1 mice suppressed the progression of lupus (manuscript in preparation). Our 
lab has repeated the finding that transfer of male microbiota suppresses disease in several 
experiments, and we have since performed new microbiota analysis experiments 
confirming that female and male BWF1 microbiota composition differs. The initial 
experiments were performed during the period of 2014 to 2016, while our mouse colony 
was located in the A Tower. At the end of 2016, however, we moved our mouse colony 
to a different facility on the University of Louisville campus, the barrier facility located 
in the CTR Building (CTRB), and we observed that, in experiments begun after that 
point, transferring male microbiota to female BWF1 mice no longer suppressed disease. 
This period, which we have termed the CTRB Early period, lasted from early 2017 to 
2018. When we compared female and male BWF1 microbiota from the A Tower period 
(2014-2016) and the CTRB Early period (2017-2018), we saw a clear difference between 
the two periods. Additionally, while the female and male BWF1 microbiota from the 
CTRB Early period were still significantly different, the degree of significance was 
considerably less than had been seen in the A Tower. Later, following changes in mouse 
facilities and animal husbandry procedures in the CTRB facility, the protective ability of 
male microbiota was restored. During this later period, termed the CTRB Recent period 
(2019-present), the male and female microbiota profiles were again highly significantly 
different. Figure 23 provides a timeline of microbiota composition, microbiota transfer 
results and animal facility/husbandry changes. Comparison of CTRB Early Experiments 
2 and 3, which were contemporaneous but received water that had been purified using 
different methods, showed that sterilization using filtering or autoclaving techniques had 
some effect on the abundance of microbiota taxa illustrating the sensitivity of the 
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microbiota to environmental changes. In the time between the CTRB Early and CTRB 
Recent periods, one of the changes we made was a switch to water that was purified by 
reverse osmosis (RO) and also autoclaved. This and other changes that were made to the 
animal housing and husbandry in the CTRB very likely have had a significant impact on 
the microbiota composition, including making it more stable. 
Our first aim centered around investigating what changes in microbiota 
composition correlated with the loss of the protective ability of the male microbiota to 
suppress disease in female recipients. During the A tower period, Bacteroides 
(predominantly B. acidifaciens) abundance was significantly higher in male than female 
BWF1 mice. This is similar to what has been found in patients with autoimmune 
rheumatoid arthritis. Multiple studies have shown that healthy controls have significantly 
higher abundance of Bacteroides than rheumatoid arthritis patients [269,438]. However, 
in the CTRB Early experiments, male BWF1 mice did not have higher Bacteroides 
abundance, and in fact, in CTRB Early Experiments 1, 2, and 3, Bacteroides levels were 
almost undetectable, although in CTRB Early Experiment 4, Bacteroides was higher in 
female than male BWF1 mice. The samples from CTRB Early Experiment 1 were 
collected 2 months before the samples for CTRB Early Experiments 2 and 3 were 
collected and 4 months before the samples from CTRB Early Experiment 4. For the 
levels of Bacteroides to change so drastically in mice from the same colony in such a 
short span of time suggests that the microbiota profiles were in a state of flux. Together 
with the differences found between the A Tower and CTRB Early microbiota profiles, the 
data indicate that moving the mouse colony and setting up at the new facility resulted in 
significant changes to the microbiota. Another change that highlighted the differences 
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between the A Tower and CTRB Early mice was the disappearance of the entire Alistipes 
genus. Whereas in the A Tower the Alistipes abundance was ~10-20%, it was completely 
undetectable in the microbiota of all CTRB Early experiments. Additionally, in the 
CTRB Early Experiments, 30-40% of all bacteria were from the Clostridium genus 
(predominantly C. leptum), which was 2 to 3 times higher than in the A Tower mice. This 
suggests a possible explanation for why high Bacteroides in female mice in CTRB Early 
Experiment 4 did not correlate with protection against disease. It is possible that high 
levels of Clostridium may promote lupus progression and/or block any beneficial effect 
of high Bacteroides. There is some evidence in the literature supporting this possibility. 
A longitudinal analysis of SLE patient gut microbiota found that C. leptum was enriched 
in SLE patient gut microbiota compared to healthy controls, and that after treatment that 
successfully reduced disease activity, C. leptum abundance was decreased [439]. 
Furthermore, in a recent study, bacteria from the class Clostridia, which includes 
Clostridium, were able to suppress retinoic acid synthesis in the intestine [440]. Retinoic 
acid is important for the induction of tolerance-promoting T regulatory cells (Tregs) 
[441], and SLE is associated with lower levels of Tregs [442]. This suggests that an 
overabundance of Clostridia could potentially increase susceptibility to lupus by 
suppressing retinoic acid-dependent Treg induction. Further study will be required to 
determine if Clostridium is playing a similar role in the BWF1 mice. 
Analysis of the female and male microbiota compositions in the CTRB Recent 
period (when the male microbiota was again able to suppress disease in female 
recipients) strengthened the association of high Bacteroides and low Clostridium with 
protection from disease. In both CTRB Recent female vs male experiments, Bacteroides 
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is higher in male than female BWF1 mice, and Clostridium abundance is very low (~5-
10%). The two genera have the same predominant species, B. acidifaciens and C. leptum, 
as the A Tower, further supporting the similarities between the CTRB Recent and A 
Tower microbiota profiles. Additionally, analysis of a CTRB Recent intact vs castrated 
male experiment found lupus-resistant intact male BWF1 mice had higher Bacteroides, 
and specifically B. acidifaciens, abundance than the lupus-susceptible castrated male 
BWF1 mice, which further supports the connection between higher Bacteroides and 
disease resistance. The finding that B. acidifaciens is the predominant Bacteroides 
species is interesting, as B. acidifaciens has been associated with anti-inflammatory 
phenotypes. A previous study found that in the non-obese diabetic (NOD) mouse model, 
a therapeutic diet increased both the survival rate and B. acidifaciens abundance. The 
increase in B. acidifaciens correlated with changes in multiple changes in immune 
parameters that shifted systemic immunity towards a more anti-inflammatory profile 
[443]. Similarly, in a study examining the colitis-suppressing activities of a Lactobacillus 
probiotic, it was found that treatment with the Lactobacillus resulted in a massive 
increase in B. acidifaciens abundance, and this correlated with suppression of colitic 
inflammation and restoration of gut homeostasis [444]. This supports the theory that 
increased abundance of B. acidifaciens could suppress the inflammatory immune 
responses seen in lupus. 
 Alistipes, which had been absent in CTRB Early experiments, was present in all 
of CTRB Recent experiments, and the same species (A. putredinis and A. timonensis) 
were predominant as in the A Tower. This further supports the conclusion that the return 
of the protective effect of male to female microbiota transfers coincides with a shift of the 
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microbiota taxa abundances to become more similar to that seen in the A Tower. It also 
suggests that the presence of Alistipes could potentially be required for the protective 
effect of the male microbiota. 
It is also worth noting that the samples from CTRB Recent Experiments 1 and 2 
were collected about 2 months apart, similar to the length of time separating CTRB Early 
Experiments 2 and 3 from CTRB Early Experiment 4. However, while Bacteroides went 
from being undetectable in CTRB Early Experiments 2 and 3 to up to 30-40% abundance 
in CTRB Early Experiment 4, the Bacteroides abundances of CTRB Recent Experiments 
1 and 2 varied far less. This suggests that the Bacteroides population during the CTRB 
Recent time period is more stable than it was during the CTRB Early time period. 
Further evidence of the correlation of high Bacteroides and low Clostridium with 
protection from disease was found when the microbiota profiles of CTRB Early and 
CTRB Recent cecal transfer experiments were compared. In the CTRB Recent transfer 
experiment, the female and male BWF1 recipients of male BWF1 microbiota had higher 
Bacteroides abundance compared to female recipients of female microbiota, and this 
higher level of Bacteroides corresponded with suppression of disease. This fits with 
previous studies that have found adoptive transfer of Bacteroides suppresses 
inflammatory diseases. One study showed that transferring Bacteroides vulgatas into IL-
2 knockout mice protected them against Escherichia coli-triggered colitis [445]. In 
another study, Bacteroides fragilis transfer conferred resistance to EAE [446]. More 
recently, a study found that administering B. acidifaciens to mice fed a high fat diet 
protected them against obesity and the development of obesity-derived inflammation 
[447]. Taken together with our findings, these data suggest species within the Bacteroides 
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genus can suppress inflammatory diseases. 
However, female recipients of female microbiota in the CTRB Early transfer 
experiment were not protected from disease, despite having higher Bacteroides 
abundance than recipients of male microbiota. This could potentially be because, as with 
the female vs male experiments, the CTRB Early transfer experiment had substantially 
higher levels of Clostridium than the CTRB Recent transfer experiments. A comparison 
of the Bacteroides/Clostridium ratios suggested that the combination of high Bacteroides 
with low Clostridium may be key to the protective effect of male microbiota. Also, like 
the male vs female experiments, Alistipes was absent in the CTRB Early and present in 
the CTRB Recent cecal transfer experiments supporting the idea that Alistipes and 
Bacteroides could potentially be acting in concert. Findings like this not only could 
potentially lead to the development of new lupus therapies, but could also inform the use 
of current treatments. For example, the current frontline treatment for lupus is 
corticosteroids, but a recent study comparing SLE patients who had and had not 
undergone glucocorticoid treatment found glucocorticoid treatment was associated with 
decreased Bacteroides abundance [285]. If further research showed that higher 
Bacteroides abundance was beneficial for human SLE patients, the effects of a therapy on 
the microbiota might need be considered when designing a treatment plan.  
 Taken together, our results emphasize that no single taxon can be considered in 
isolation, and that examination of the entire microbiological profile is essential for studies 
of the microbiota. For our data, male microbiota suppression of disease does not track 
with any one taxon, but with a combination of high Bacteroides, low Clostridium and the 
presence of Alistipes.   
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Figure 3. Female, but not male, NZBxNZWF1 (BWF1) mice develop severe 
glomerulonephritis spontaneously. Female and male BWF1 mice were monitored for 
kidney disease (glomerulonephritis) bi-weekly by measuring proteinuria in the urine. 
Proteinuria was scored on a scale of 1-5 with a score of 5 indicating death (n=5). (A) 
Kidney disease score (B) Incidence of kidney disease (% mice with a proteinuria score of 
≥3 for two consecutive biweekly readings). (C) Survival curve. Kidney disease scores 
were compared with two-way ANOVAs, and incidence and survival curves were 




Figure 4. Adult female and male BWF1 mice have significantly different microbiota 
compositions. Feces were collected from 16-week-old female (F) and male (M) BWF1 
mice during the A Tower period (2014-16) and bacterial DNA was extracted. The 9 
hypervariable regions of the 16S rRNA gene were sequenced and used to determine 
microbiota taxonomic composition. (A) Principal coordinate analysis (PCoA) plot of 
female and male BWF1 microbiota beta diversity using the Bray-Curtis dissimilarity 
metric. Each symbol represents one fecal sample. (B) Female and male microbiota beta 
diversity distances were compared with the permutational multivariate analysis of 






PC2 (19.5%) (A) 
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Figure 5. Androgen depletion increases incidence and time of onset of kidney disease 
and decreases survival in male BWF1 mice. Female, intact male, and castrated (at ~ 
24-days of age) male BWF1 mice were monitored for kidney disease 
(glomerulonephritis) bi-weekly by measuring proteinuria in the urine. Proteinuria was 
scored on a scale of 1-5 with a score of 5 indicating death (n=8) [420]. (A) Kidney 
disease score. (B) Incidence of kidney disease (% mice with a proteinuria score of ≥3 for 
two consecutive biweekly readings). (C) Survival curve. Kidney disease scores were 
compared with two-way ANOVAs, and incidence and survival curves were compared 
using the Log rank (Mantel-Cox) test [420]. *p<0.05, **p<0.01, ***p<0.001 
(C) 
(A) 
Kidney Disease Incidence 
(B) 
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Figure 6. Adult intact and castrated male BWF1 mice have significantly different 
microbiota compositions. Feces were collected from 16-week-old intact (Intact M) and 
castrated (at ~24 days of age; Cast M) BWF1 mice and bacterial DNA was extracted. The 
9 hypervariable regions of the 16S rRNA gene were sequenced and used to determine 
microbiota taxonomic composition. (A) Principal coordinate analysis (PCoA) plot of 
intact and castrated male BWF1 microbiota beta diversity using the Bray-Curtis 
dissimilarity metric. (B) Intact and castrated male microbiota beta diversity distances 
were compared with the permutational multivariate analysis of variance (PERMANOVA) 








Figure 7. Transfer of male microbiota significantly suppresses kidney disease and 
enhances survival in female BWF1 mice. Female BWF1 mice were fed cecal contents 
(i.e., microbiota) via gavage from 16-week-old female or male BWF1 mice. Female-to-
female (F-F, n=6) and male-to-female (M-F, n=5) cecal transfer recipients were 
monitored for kidney disease (glomerulonephritis) bi-weekly by measuring proteinuria in 
the urine. Proteinuria was scored on a scale of 1-5 with a score of 5 indicating death. 
Experiments were conducted during the A Tower period (2014-16). (A) Cecal transfer 
regimen. (B) Kidney disease score. (C) Incidence of kidney disease (% mice with a 
proteinuria score of ≥3 for two consecutive biweekly readings). (D) Survival curve. 
Kidney disease scores were compared with two-way ANOVAs, and incidence and 
survival curves were compared using the Log rank (Mantel-Cox) test. **p<0.01 
Autoantibody production Pre-disease 
Cecal transfers 





Figure 8. Transfer of male microbiota did not suppress kidney disease or enhance 
survival in female BWF1 mice during the CRTB Early period. Female BWF1 mice 
were fed cecal contents (i.e., microbiota) via gavage from 16-week-old female or male 
BWF1 mice. Female-to-female (F-F) and male-to-female (M-F) cecal transfer recipients 
were monitored for kidney disease (glomerulonephritis) bi-weekly by measuring 
proteinuria in the urine. Proteinuria was scored on a scale of 1-5 with a score of 5 
indicating death (n=6). Experiments were conducted during the CTRB Early period 
(2017-18). (A) Kidney disease score. (B) Incidence of kidney disease (% mice with a 
proteinuria score of ≥3 for two consecutive biweekly readings). (C) Survival curve. 
Kidney disease scores were compared with two-way ANOVAs, and incidence and 




Figure 9. Female and male microbiota compositions differ between the A Tower and 
CTRB Early periods. Feces were collected from 16-week-old female and male BWF1 
mice during either the A Tower (2014-16; n=6) or the CTRB Early (2017-18; n=7) 
periods, and bacterial DNA was extracted. The 9 hypervariable regions of the 16S rRNA 
gene were sequenced and used to determine microbiota taxonomic composition. (A) 
Principal coordinate analysis (PCoA) plot of female and male BWF1 microbiota beta 
diversity using the Bray-Curtis dissimilarity metric. Each symbol represents one fecal 
sample. (B) Female and male microbiota beta diversity distances for samples collected 
during the CTRB Early period were compared with the permutational multivariate 
analysis of variance (PERMANOVA) pairwise statistical test (p = 0.043). 
Female - A Tower 
Male - A Tower Male - CTRB Early 
Female - CTRB Early (A) 





Figure 10. Transfer of male microbiota suppressed kidney disease and enhanced 
survival in female BWF1 mice in during the CRTB Recent period. Female and male 
BWF1 mice were fed cecal contents (i.e., microbiota) via gavage from 16-week-old 
female or male BWF1 mice. Female BWF1 mice were fed cecal contents from adult male 
or female BWF1 mice. Female-to-female (F-F), male-to-female (M-F), and male-to-male 
(M-M) cecal transfer recipients were monitored for kidney disease bi-weekly by 
measuring proteinuria in the urine on a scale of 1-5 with a score of 5 indicating death 
(n=6). Experiments were conducted during the CTRB Recent period (2019-present). (A) 
Kidney disease score. (B) Incidence of kidney disease (% mice with a proteinuria score 
of ≥3 for two consecutive biweekly readings). (C) Survival curve. Kidney disease scores 
were compared with two-way ANOVAs, and incidence and survival curves were 




Figure 11. Female and male BWF1 mice have highly significantly different 
microbiota compositions during the CTRB Recent period. Feces were collected from 
16-week-old female and male BWF1 mice during the CTRB Early (2019-present) period 
and bacterial DNA was extracted. The 9 hypervariable regions of the 16S rRNA gene 
were sequenced and used to determine microbiota taxonomic composition (n=7). (A) 
Principal coordinate analysis (PCoA) plot of adult male and female BWF1 fecal 
microbiota beta diversity using the Bray-Curtis dissimilarity metric. (B) Female and male 
microbiota beta diversity distances were compared with the permutational multivariate 
analysis of variance (PERMANOVA) pairwise statistical test. Outliers are indicated as 
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Figure 12. Abundance of Bacteroides was higher in adult male than female BWF1 
mice during the A Tower period. Feces were collected from 16-week-old female and 
male BWF1 mice during the A Tower period (2016) and bacterial DNA was extracted. 
The 9 hypervariable regions of the 16S rRNA gene were sequenced and used to 
determine microbiota taxonomic composition (n=7). Abundances were compared with 
One-way ANOVAs. (A) Genus level microbiota from the A Tower – Female vs Male 
experiment genus (n=6). (B) Species level microbiota from the A Tower – Female vs 
Male experiment species (n=6). *p<0.05, **p<0.01, ***p<0.001 
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Figure 13. Bacteroides is virtually absent and abundance of Clostridium is very high 
in both females and males in most CTRB Early Experiments. Feces were collected 
from 16-week-old female and male BWF1 mice during the CTRB Early (2017-18) period 
and bacterial DNA was extracted. The 9 hypervariable regions of the 16S rRNA gene 
were sequenced and used to determine microbiota taxonomic composition. Abundances 
were compared with One-way ANOVAs. (A) Genus level microbiota from Experiment 1 
(n=8). (B) Species level microbiota from Experiment 1 (n=8). (C) Genus level microbiota 
from Experiment 2 (n=7). (D) Species level microbiota from Experiment 2 (n=7). (E) 
Genus level microbiota from Experiment 3; (n=7). (F) Species level microbiota from 
Experiment 3 (n=7). *p<0.05, **p<0.01, ***p<0.001 
100 
CTRB Early – Experiment 4 – Genus (A) 
(B) 
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Figure 14. In the final CTRB Early, Experiment 4, unlike in other CTRB early 
experiments, abundance of Bacteroides was high, while abundance of Clostridium 
also continued to be high in both female and male adult BWF1 mice. Feces were 
collected from 16-week-old female and male BWF1 mice during the CTRB Early (2017-
18) period and bacterial DNA was extracted. The 9 hypervariable regions of the 16S
rRNA gene were sequenced and used to determine microbiota taxonomic composition 
(n=6). Abundances were compared with One-way ANOVAs. (A) Genus level microbiota 






Figure 15. Both sex and drinking water source affect microbiota compositions. Feces 
were collected from 16-week-old female and male BWF1 mice during the CTRB Early 
(2017-18) period and bacterial DNA was extracted. The 9 hypervariable regions of the 
16S rRNA gene were sequenced and used to determine microbiota taxonomic 
composition (n=7). Mice received either autoclaved tap H2O (also see Experiment 2 in 
Figure 13C,D) or filtered H2O (also see Experiment 3 in Figure 13E,F) drinking water 
for the entire period of the experiment. Abundances were compared with One-way 
ANOVAs. (A) Genus level microbiota; (B) Species level microbiota. *p<0.05, **p<0.01, 
***p<0.001 
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Figure 16. Abundance of Bacteroides was considerably higher in adult male than 
female BWF1 mice, and abundance of Clostridium levels was low in CTRB Recent 
experiments. Feces were collected from 16-week-old female and male BWF1 mice 
during the CTRB Recent (2019-present) period and bacterial DNA was extracted. The 9 
hypervariable regions of the 16S rRNA gene were sequenced and used to determine 
microbiota taxonomic composition. Abundances were compared with One-way 
ANOVAs. (A) Genus level microbiota from Experiment 1 (n=7). (B) Species level 
microbiota from Experiment 1 (n=7). (C) Genus level microbiota from Experiment 2 
(n=6). (D) Species level microbiota from Experiment 2 (n=6). **p<0.01, ***p<0.001 
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Figure 17. Androgen depletion through castration reduces Bacteroides abundance. 
Feces were collected from 16-week-old intact and castrated (at ~24 days of age) BWF1 
mice during the CTRB Recent period and bacterial DNA was extracted. The 9 
hypervariable regions of the 16S rRNA gene were sequenced and used to determine 
microbiota taxonomic composition (n=8). Abundances were compared with One-way 
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Figure 18. In CTRB Early microbiota transfer experiments, Bacteroides was present 
but abundance was lower in the Male to Female transfers and Clostridium was high 
in all experimental groups. During the CTRB Early (2017-18) period, female BWF1 
mice were fed cecal contents (i.e., microbiota) from 16-week-old female (Female-to-
Female) or male (Male-to-Female) BWF1 mice via gavage. Feces were collected from 
16-week-old cecal transfer recipients (4 weeks after cecal transfer), and bacterial DNA 
was extracted. The 9 hypervariable regions of the 16S rRNA gene were sequenced and 
used to determine microbiota taxonomic composition. Abundances were compared with 
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Figure 19. In CTRB Recent microbiota transfer experiments, abundance of 
Bacteroides was higher in the recipients of male microbiota, and abundance of 
Clostridium was low at two different time-points. During the CTRB Recent (2019 - 
present) period, female BWF1 mice were fed cecal contents (i.e., microbiota) from 16-
week-old female (Female-to-Female) or male (Male-to-Female) BWF1 mice via gavage. 
Male mice (Male to Male) were fed male cecal contents as a control. Feces were 
collected from 16-week-old cecal transfer recipients and bacterial DNA was extracted. 
The 9 hypervariable regions of the 16S rRNA gene were sequenced and used to 
determine microbiota taxonomic composition. Abundances were compared with One-way 
ANOVAs (n=6). (A) Genus level microbiota in feces collected at 15 weeks of age (4 
weeks after cecal transfer); (B) Species level microbiota in feces collected at 15 weeks of 
age (4 weeks after cecal transfer); (C) Genus level microbiota in feces collected at 19 
weeks of age (4 weeks after cecal transfer); (D) Species level microbiota in feces 






Figure 20. Comparison of Bacteroides and Clostridium abundance data in female 
and male BWF1 mice from experiments conducted during the A Tower, CTRB 
Early, and CTRB Recent periods. Feces were collected from female and male BWF1 
mice during the A Tower (2014-16), CTRB Early (2017-2018), and CTRB Recent (2019-
present) periods and bacterial DNA was extracted. The 9 hypervariable regions of the 16S 
rRNA gene were sequenced and used to determine microbiota taxonomic composition. 
Abundances were compared with One-way ANOVAs. Data were compiled from 
experiments shown in Figures 12, 13, 14 and 16. (A) Compilation of data for Bacteroides 
abundances in females and males; (B) Compilation of data for Clostridium abundances in 





Figure 21. Comparison of Bacteroides and Clostridium abundance data in cecal 
transfer experiments conducted during the CTRB Early and CTRB Recent periods. 
During the CTRB Early (2017-2018) and CTRB Recent (2019-present) periods, female 
BWF1 mice were fed cecal contents (i.e., microbiota) from 16-week-old female (Female-
to-Female) or male (Male-to-Female) BWF1 mice via gavage. Feces were collected from 
16-week-old cecal transfer recipients (4 weeks after cecal transfer), and bacterial DNA 
was extracted. The 9 hypervariable regions of the 16S rRNA gene were sequenced and 
used to determine microbiota taxonomic composition. Abundances were compared with 
One-way ANOVAs. Data were compiled from experiments shown in Figures 18 and 19. 
(A) Compilation of data for Bacteroides abundances in cecal recipients; (B) Compilation 





Figure 22. Ratios between Bacteroides and Clostridium abundance in female vs 
male and cecal transfer experiments. Fecal samples from (A) female and male 
collected during the A Tower, CTRB Early (2017-2018) and CTRB Recent (2019-
present) periods and (B) cecal transfer recipients collected during the CTRB Early (2017-
2018) and CTRB Recent (2019-present) periods and bacterial DNA was extracted. The 9 
hypervariable regions of the 16S rRNA gene were sequenced and used to determine 
microbiota taxonomic composition. The Bacteroides/Clostridium ratios were calculated 
from the data shown in Figure 20 for the female and male comparisons and Figure 21 
for the cecal transfer comparisons by dividing average Bacteroides abundance by average 
Clostridium abundance. (A) Bacteroides/Clostridium ratios for the female to male 












Comparison of metabolomic profiles in lupus-prone versus lupus-
resistant BWF1 mice 
Introduction 
Lupus exhibits a considerable sex bias with women having a much higher 
incidence [1,2], and sex hormone levels can significantly affect lupus progression 
[115,138,141-144,149-152]. Additionally, lupus has been linked to dysbiotic 
microbiomes in both human SLE patients and in mouse models of lupus [276-
283,286,293,297,299]. Alterations in the microbiome have been shown to affect lupus 
progression [282,297,299], and microbiome composition can be affected by sex and sex 
hormones [182,300-303,315]. Consequently, sex-based differences in the microbiota 
have been proposed as a potential contributor to the sex bias of lupus. This is supported 
by recent studies showing that sex-based microbiota differences contributed to the sex 
bias in the NOD mouse model of type 1 diabetes [323,324]. As described above, we have 
found differences in microbiota composition between female and male BWF1 mice and 
between intact and castrated male BWF1 mice (Fig. 4; 6). Furthermore, we have found 
that transfer of male microbiota to female recipients protects them from disease (Fig. 7; 
10). The mechanisms underlying this protection are currently not known. 
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One way that the gut microbiota can affect immune response is by producing 
immunomodulatory metabolites. These come in many different classes and have been 
shown to be able to affect the progression of autoimmune diseases [327]. Short chain 
fatty acids (SCFAs) including acetate, butyrate, and propionate, are one class that have 
been repeatedly shown to promote anti-inflammatory immune activities in dendritic cells, 
macrophages, and neutrophils [328-332]. Low levels of SCFAs and SCFA-producing 
bacteria are associated with multiple auto-inflammatory diseases including IBD, Crohn’s 
disease, and spondyloarthritis [333-336], and SCFAs can ameliorate symptoms in mouse 
models of auto-inflammatory diseases [334,337-339]. SFCAs can also affect diseases 
outside the intestine. Multiple sclerosis patients have lower levels of SCFAs in their 
serum [448] and treating a mouse model of experimental autoimmune encephalomyelitis 
(EAE) with SCFAs reduces disease severity [341]. 
Not all gut metabolites have anti-inflammatory effects. Trimethylamine (TMA) is 
a choline metabolite synthesized exclusively by the microbiota. It is transported into the 
liver where it is converted to trimethylamine N-oxide (TMAO). Unlike SCFAs, TMAO 
promotes inflammatory responses. It activates the NLRP3 inflammasome [358,359], and 
higher serum TMAO levels have been linked to several human autoimmune diseases, 
including primary sclerosing cholangitis [360], psoriatic arthritis [361], and RA [362]. 
Another category of gut metabolites are secondary bile acid metabolites which 
are synthesized from primary bile metabolites by the microbiota. Like SCFAs, they have 
been shown to have anti-inflammatory effects. Disruption of secondary bile acid 
production can contribute to the development of IBD, nonalcoholic fatty liver disease, 
cholestatic liver injury, and other diseases [342,363,368]. As with the studies on SCFAs 
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and described above, these studies emphasize that immune processes both inside and 
outside the intestine can be affected by altered microbiota metabolite production.  
In the current study, we have found that the fecal metabolomic profiles of female 
and male BWF1 mice differ. Androgen depletion via castration also causes a shift in 
metabolite composition. In three separate experiments, we found phytol, a gut metabolite 
with RXR and PPARγ agonist activities, to be more abundant in male than female BWF1 
feces. In the most recent and comprehensive analysis, phytol was also elevated in intact 
vs castrated male BWF1 feces [420], and phytol’s derivative, phytanic acid which is a 
very potent RXR and PPARγ agonist [449-453], was detected in intact male BWF1 feces, 
but not female or castrated male BWF1 feces. This indicates that lupus-resistant male 
BWF1 mice and lupus-susceptible female and castrated male BWF1 mice have 
differences in intestinal metabolites that may be linked to the differences in microbiota 




Lupus-prone female and castrated male BWF1 mice have significantly different gut 
metabolite profiles from lupus-resistant male BWF1 mice 
 Differences in microbiota composition between female and male, and between 
intact and castrated male mice such as we have found could lead to differential 
production of gut metabolites that could have an impact on the immune response and/or 
disease. To evaluate this possibility, we compared the intestinal metabolomic profiles of 
adult lupus-prone female and lupus-resistant male BWF1 mice by analyzing fecal 
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metabolite compositions. Metabolites were extracted from the feces, derivatized with N-
methyl-N-trimethylsilytrifluoroacetamide (MSTFA), and analyzed using two-
dimensional gas chromatography mass spectrometry (GC×GC-MS). Retention time and 
mass spectra of compounds detected were compared to those of known metabolites to 
determine the composition and abundance of gut metabolites (Fig. 24A; Table 1). Partial 
least squares-discriminant analysis (PLS-DA) was performed to visualize the differences 
between female and male metabolite profiles. We observed a clear sex-based difference 
in metabolite profiles (Fig. 24B). In the time since that initial experiment (Metabolomic 
Experiment #1), our collaborators have upgraded their metabolite detection platforms, 
and this experiment was repeated. In the second experiment, (Metabolomic Experiment 
#2), in addition to the analysis using GC×GC-MS with MSFTA derivatization, metabolite 
composition was analyzed using two-dimensional liquid chromatography mass 
spectrometry (2DLC-MS/MS) with either negative or positive ionization. This expanded 
the range of metabolites that could be detected, since 2DLC-MS/MS is more efficient at 
detecting less polar metabolites. Combined with improvements to the GC×GC-MS 
reference database, Experiment #2 identified 76 metabolites significantly different 
between female and male BWF1 mice (Table 2), compared with 16 in Experiment #1 
(Table 1). The ionization mode, which is the charge metabolites are given before 
entering the detector, also influences which metabolites can be detected. Positive 
ionization allows the detection of a greater range of compounds, but negative ionization 
lowers background noise and is useful for detecting low-abundance metabolites [454]. In 
a third experiment (Metabolomic Experiment #3), we compared the metabolomic profiles 
of lupus-resistant intact male BWF1 mice not only to lupus-prone female mice, but also 
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to lupus-prone castrated male BWF1 mice. In Metabolomic Experiment #3, the samples 
were analyzed via four different methods: GC×GC-MS with either MSTFA or N-tert-
Butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) derivatization, and two-
dimensional liquid chromatography mass spectrometry (2DLC-MS/MS) with either 
negative or positive ionization (Tables 3-5). The use of multiple derivatization reagents 
further increased the range of metabolites that could be detected. The derivatization 
reagent MSTFA is more efficient at facilitating detection of larger metabolites, while 
MTBSTFA is more efficient at facilitating detection of smaller metabolites [455]. Using 
multiple methods therefore increases the number and types of metabolites detected. For 
all four of the methodologies, PLS-DA analysis indicated that there were differences 
between the intact male, castrated male, and female BWF1 metabolomic profiles (Fig. 
25), strongly suggesting that both sex and sex hormone levels affect the composition of 
intestinal metabolites. In addition, there was considerable overlap between the 
metabolites that differed between the female and intact male BWF1 mice and the 
metabolites that differed significantly between the castrated and intact male BWF1 mice. 
Side-by-side comparison of the fold changes in these sets of metabolites showed that not 
only did they overlap, but the direction of the fold change compared to the male mice was 
often the same (Fig. 26). These data suggest that the male sex hormones, androgens, have 
a significant impact on metabolomic profiles. In addition, quantitative pathway 
enrichment analysis of the two sets of significantly different metabolites showed several 
pathways were significantly altered in intact male BWF1 mice compared to both female 
and castrated male BWF1 mice (Fig. 27). This suggests that lupus-resistant intact male 
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BWF1 may have functional metabolic differences from lupus-susceptible female and 
castrated male BWF1 mice.  
 
Specific immunomodulatory metabolites are increased in lupus-resistant intact male 
BWF1 mice compared to lupus-susceptible female and castrated male BWF1 mice.  
 Differences in the production of microbial metabolites with immunomodulatory 
properties are known to affect the progression of autoimmune diseases [327]. We studied 
the known properties of the metabolites that were significantly different between female 
and male BWF1 mice to determine whether any could potentially affect the development 
and/or progression of disease. Pathway analysis of Metabolomic Experiment #3 
identified histidine metabolism as being significantly altered both between the female and 
male BWF1 mice, and the intact and castrated male BWF1 mice (Fig. 27). In this 
pathway, histidine is converted into histamine, a molecule with potent effector activities. 
2DLC-MS/MS with positive ionization (2DLC-MS/MS (+)) showed that compared to 
female and castrated male BWF1 mice, intact males had lower levels of the histamine 
precursor, histidine (Fig. 28A), and higher levels of histamine (Fig. 28B), and the 
histamine breakdown product, methylimidazoleacetic acid (Fig. 28C). This suggests that 
intestinal histamine production may be higher in intact male than female or castrated 
male BWF1 mice. The gut microbiota is a known producer of histamine, so the higher 
production in intact males could be due to the altered microbiota profiles seen in male 
BWF1 mice [351-353]. This theory is supported by our previous results from positive 
ionization 2DLC-MS/MS (2DLC-MS/MS(+)) analysis in Experiment #2, which also 
found histamine was more abundant in male than female BWF1 mice (Fig. 28D). In this 
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prior analysis, neither histidine or methylimidazoleacetic acid were detected, but this is 
likely due to improvements in metabolite detection ability and reference databases 
between Experiments #2 and #3. 
Many findings of significant metabolite differences between female and male 
BWF1 feces in one experiment were not repeated in other experiments. For example, 
butyrate and niacin, both well-documented immunomodulators, were both found to be 
significantly higher in male than female BWF1 mice in Experiment #2 (Fig. 29A,B, 
Table 2). However, in Experiment #3, although both were detected, neither of these 
metabolites was found to be significantly different between male and female BWF1 mice 
(Fig. 29C,D). Neither butyrate nor niacin was detected in Experiment #1, but this could 
be due to the more limited detection capabilities of the platform at that time. This 
inconsistency in findings between experiments is a major obstacle in the study of 
metabolomics. 
However, there was one metabolite that was consistently higher in male than 
female BWF1 mice across all three metabolomic experiments. This metabolite, phytol, 
was more abundant in lupus-resistant male than lupus-prone female BWF1 mice in all 
three analyses (Fig. 30). Phytol is an acyclic diterpene alcohol which is produced from 
the breakdown of chlorophyll and has known RXR and PPARγ agonist activity, 
[449,450,456], and there is evidence in animal models that signaling through RXR and 
PPARγ receptors can, in general, alter immune responses in ways that could potentially 
suppress lupus [394,457-459]. This correlation between lower phytol levels and lupus 
susceptibility was also found in lupus-prone castrated male BWF1 mice which also have 
lower abundance of phytol than intact male BWF1 mice and similar levels as female 
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BWF1 mice (Fig. 31A). Phytol is produced exclusively by the gut microbiota [460-462], 
but once absorbed by the intestine, host enzymes convert it to phytanic acid, which has 
even more potent RXR and PPARγ agonist activity than phytol, and is more easily 
transported in esterified form through the circulatory system [449-453,463]. For the most 
recent experiment, Metabolite Experiment #3, improvements in detection capabilities and 
reference databases allowed us to detect phytanic acid. We found high levels of phytanic 
acid in feces from intact male mice compared to feces from female and castrated male 
BWF1 mice, and in fact, no phytanic acid was detected in female and castrated male 
feces (Fig. 31B). Taken together, the data show that both phytol and its derivative, 
phytanic acid, are more abundant and/or only present in intact male BWF1 mice. The 
known RXR and PPARγ agonist activity of these metabolites raises the question of 
whether this could contribute to the protective capability of the male microbiota and 
whether one or both of these molecules could be used as a potential therapeutic for the 
treatment of lupus. lupus. 
 
Discussion 
While our bacterial taxa findings are promising, one of the challenges in 
microbiota research is the fact that the effects of bacterial taxa are context dependent. 
What microbiota are associated with a disease can vary between mouse strains. For 
example, low abundance of Lactobacillus is associated with increased lupus symptoms in 
the MRL/lpr mouse model [297,298], but in the BWF1 mouse model of lupus, high 
abundance of Lactobacillus is associated with more severe renal disease [282]. Mouse 
models and human patients can also differ in the bacteria that are associated with disease, 
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as a study found that, unlike MRL/lpr mice, Lactobacillus was elevated in SLE patients 
compared to healthy controls. 
Due to this complexity, it is useful to use multiple approaches when studying the 
relationship between microbiota and disease. In addition to using 16S rRNA sequencing 
to determine the bacterial species that make up the BWF1 microbiota, we also used 
metabolomic analyses to identify the fecal metabolite profiles. This approach allowed us 
to investigate differences in gut metabolism between lupus-susceptible female and lupus-
resistant male BWF1 mice. The influence of the gut microbiota on the host is likely 
mediated in part via the metabolites they produce [464]. Our aim was to characterize the 
gut metabolomic profiles of disease susceptible female and disease-resistant male BWF1 
mice. To this end, we performed three metabolomic experiments (Metabolomic 
Experiments #1, 2, & 3) analyzing female and male BWF1 fecal metabolites. The 
platforms used to analyze the fecal metabolites increased from analysis to analysis, so 
each analysis was more thorough than the last. While Experiment #1 only used GC×GC-
MS with MSTFA derivatization, Experiment #2 also used 2DLC-MS/MS, which is more 
efficient at detecting less polar metabolites. In Experiment #3, GC×GC-MS with 
MTBSTFA derivatization was added, which is more effective at detecting small 
metabolites. For Experiment #3, castrated male BWF1 feces were analyzed in addition to 
the male and female BWF1 feces, and PLS-DA visualization of their metabolomic 
profiles showed that for all four platforms, the profiles of the three groups were 
divergent. This matches our findings that lupus-resistant intact male mice have 
significantly different microbiota compositions compared to both female and castrated 
male BWF1 mice. Furthermore, a side-by-side comparison of metabolites significantly 
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different between intact male compared to female or castrated male BWF1 mice, shows 
considerable overlap between the two sets, suggesting that androgens may have 
considerable influence on metabolite production. This fits with the findings of previous 
studies, which have shown that androgen levels affect the microbiota [323,324,465,466]. 
Also, androgens are known to suppress lupus progression [103,122-125], and alterations 
of production of immunomodulatory metabolites can influence autoimmune diseases 
[464]. In this context therefore, our findings suggest that androgens could potentially 
suppress lupus by altering microbiota metabolite production in addition to their direct 
effects on immune cells. 
The increased coverage of metabolites in Metabolomic Experiment #3 also 
enhanced our ability to identify differentially regulated metabolic pathways that could be 
relevant to the development and/or progression of lupus. We therefore used the 
metabolites with significant abundance difference between groups for pathway analysis. 
The metabolic pathway analysis showed that the differences in pathways between 
castrated and male mice closely resembled the differences between female and male 
mice. Of the 41 pathways differentially regulated in castrated vs intact male mice, 28 
were also differentially regulated in female vs male mice (Tables 6,7). Thus, the data 
showed that depleting androgens in castrated male mice causes shifts in intestinal 
metabolites toward a female-like phenotype that correlates with an increase in 
susceptibility of the castrated male mice to lupus. 
Androgen does not account for all biological differences between male and 
female mice. The changes in the 28 common pathways differentially regulated in both the 
castrated vs intact male analysis and the female vs male analysis of Metabolomic 
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Experiment #3 could be due to androgen depletion or due to other sources of sex 
differences (i.e., Y chromosome effects). This is evident from the fact that there were 43 
metabolites significantly different between castrated male mice and female mice (Table 
5). To narrow our pathway analysis to identify metabolic pathways that are dependent on 
androgen, we performed a pathway analysis on the set of metabolites that were 
significantly different between both castrated and intact male mice as well as between 
female and male mice, but were not significantly different between female and castrated 
male mice (i.e., metabolites present in both Tables 3 and 4 but not in Table 5). We found 
that after removing the metabolites that were significantly different between female and 
castrated male mice, 18 of the 28 common pathways remained (Table 8). These 
pathways are the most likely to be different as a result of androgen depletion.  
The significance of the pathway analysis is that it identifies potential areas of 
study for how the differences in intestinal metabolite production could affect lupus 
progression. One of the pathways differentially affected in Experiment #3 in both female 
and castrated male mice compared with intact male mice was histidine metabolism. 
Histidine is a precursor to histamine, an effector molecule that can mediate either 
inflammatory or regulatory responses depending on the target cell and type(s) of 
histamine receptor expressed. Recent studies have found that probiotic and endogenous 
bacterial species could produce histamine and affect intestinal immune responses [351-
353]. In Experiment #3, both castrated and female mice had lower levels of histamine and 
higher levels of the precursor, histidine than intact male mice. Additionally, castrated and 
female mice had lower levels of methylimidazoleacetic acid (methylimid), which is the 
end-product of histamine breakdown and is used as an indicator of histamine production 
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[467]. While histidine and methylimidazoleacetic acid were not detected in Experiment 
#2, likely due to the lower range of detection and poorer reference database, histamine 
was detected and was higher in male than female BWF1 feces. Therefore, our results 
clearly show intact male mice have a higher production of histamine in the gut that 
correlates with their lower susceptibility to lupus. However, whether altered histamine 
metabolism is simply a consequence of lupus or if it actually plays a role in the 
progression of disease has not been established. Gut-generated histamine could 
potentially affect the development or progression of lupus via local effects on the 
intestine. While histamine is classically associated with allergic reactions, microbe-
produced histamine has been shown to directly inhibit inflammatory factors in the gut 
[354-356]. Because lupus is associated with low-grade intestinal inflammation and the 
“leaky gut” that this causes [297,357], inhibition of gut inflammation in lupus-prone mice 
(or humans) via microbe-produced histamine could potentially affect the development 
and/or progression of the disease. Additionally, suppressing intestinal inflammation could 
also inhibit disease by promoting the ability of intestinal DCs to induce 
immunosuppressive Tregs in the mesenteric lymph node (mLN) since inflammatory 
impairs this ability in intestinal DCs [468-475]. Multiple studies have found links 
between lupus and decreases in regulatory T cell frequency or function in both humans 
and mouse models [476-482], so this could clearly impact the progression of lupus in 
BWF1 mice. Bacterial histamine can also directly inhibit intestinal DC production of 
TNFα [483], an inflammatory cytokine that suppresses DC induction of Tregs in the 
mLN [475,484]. In summary, the higher levels of histamine in intact male intestine could 
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affect the development and/or progression of lupus via indirect or direct effects on DCs 
that increase Treg induction by DCs in the mLN. 
However, while the finding of elevated histamine in male BWF1 mice repeated in 
Experiments #2 and #3, many metabolites did not. For example, niacin and butyrate are 
both known to induce Tregs, and therefore the finding in Experiment #2 that they were 
more abundant in male than female BWF1 feces was very interesting. However, in 
Experiment #3, both were detected but neither were significantly different between 
female and male BWF1 mice. This inconsistency between experiments has been a major 
challenge in our metabolomic studies. Therefore, it is very significant that a metabolite, 
phytol, was more abundant in male than female BWF1 mice in all three experiments and 
was higher in intact than castrated male BWF1 mice in Experiment #3. Phytol is an 
acyclic diterpene alcohol produced by the breakdown of chlorophyll by bacteria in the 
gut, and it can bind and activate the RXR and PPARγ nuclear receptors [449,450,456]. 
Once phytol is absorbed, by the host, it is broken down into phytanic acid by the liver and 
other tissues [485]. Phytanic acid has even more potent PPARγ and RXR agonist activity 
compared to its parent compound, phytol, and it is more readily transported throughout 
the body in an esterified form [449-453,463]. In Experiment #3, improvements in 
metabolite detection allowed us to test phytanic acid levels, and we found that while male 
BWF1 feces had significant levels, no phytanic acid was detected in female or castrated 
male BWF1 feces. Increased levels of phytanic acid could potentially affect lupus 
progression in a number of ways, since RXR and PPARγ stimulation promote a number 
of immune processes that could potentially suppress lupus autoimmunity 
[383,400,457,459,486]. One possibility is that phytol and or phytanic acid could enhance 
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CD103 positive dendritic cell (CD103+DC) production of retinoic acid (RA), which 
would enhance their induction of immunosuppressive Tregs. Intestinal CD103+DCs are 
important for Treg induction [487], and defects in this process can significantly impact 
systemic immune responses and inhibit tolerance induction [441,488,489]. This process 
requires CD103+DC RA production [441], and RXR agonists can promote expression of 
the enzymes that produce RA [490]. Another lupus-suppressing process that could be 
enhanced by phytol and/or phytanic acid is the phagocytosis of apoptotic cells by 
macrophages, which is called efferocytosis [371,491,492]. Apoptotic cells are a source of 
nuclear self-antigens that can stimulate production of the anti-nuclear autoantibodies 
characteristic of lupus, and deficiencies in the ability of macrophages to clear apoptotic 
cells correlate with increased disease severity in SLE patients [380,493]. Due to its strong 
ability to activate RXR and PPARγ, phytanic acid could potentially enhance macrophage 
efferocytosis through these pathways [381,393-400]. Our subsequent experiments point 
towards a strong connection between efferocytosis and phytanic acid. 
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Figure 24. The gut metabolomic profile of adult female and male BWF1 mice differ. 
For Metabolite Experiment #1 feces were collected from 16-week-old female (n=9) and 
male (n=7) BWF1 mice and metabolites extracted using 80% methanol, derivatized with 
MSTFA, and analyzed by GCxGC-MS. (A) Representative GCxGC-MS chromatogram. 
(B) Partial least squares discriminant analysis (PLS-DA) of the metabolite profiles. 
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Figure 25. Multiple metabolomic analysis techniques show the BWF1 gut 
metabolomic profile differs with both sex and androgen depletion. For Metabolite 
Experiment #3, feces were collected from 16-week-old female (n=8), intact male (Male; 
n=6), and castrated male (Castrated; n=6) BWF1 mice (castrations were done at ~24 days 
of age). Metabolites were extracted using 80% methanol [420]. Partial least squares 
discriminant analysis (PLS-DA) was performed for the metabolite profiles analyzed via:  
(A) GCxGC-MS with MSTFA derivatization. (B) GCxGC-MS with MTBSTFA 
derivatization. (C) 2DLC-MS with negative ionization. (D) 2DLC-MS with positive 
ionization. 
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Figure 26. The metabolomic profile in castrated male mice is more similar to female 
than to intact male mice. For Metabolite Experiment #3, female (n=8), intact male (n=6), 
and castrated male (n=6) feces were collected and metabolites were analyzed as described 
in Figure 25. For each analysis method, pairwise Student’s t-tests were used to identify 
metabolites that were significantly different between at least two of the groups (Tables 
3,4). The direction and fold change (FC) of metabolites significantly different between 




Figure 27. Metabolic pathways that are different in female vs intact male mice are 
also often altered in castrated vs intact male BWF1 mice. For Metabolite Experiment 
#3, female (n=8), intact male (n=6), and castrated male (n=6) feces were collected and 
metabolites were analyzed as described in Figure 25. Metabolites that were significantly 
different between intact male and female or castrated male BWF1 mice were identified 
using pairwise Student’s t-tests (Tables 3,4). Using Metaboanalyst (v4.0), quantitative 
pathway enrichment analysis was performed on the metabolites that were significantly 
different between female and intact male BWF1 mice (Table 3) and on the metabolites 
that were significantly different between intact and castrated male BWF1 mice (Table 4). 
The metabolites were matched against the KEGG database for Mus musculus and 
analyzed for pathway enrichment and topology [420]. (A) Pathway enrichment of 
metabolites that were significantly different between female and intact male BWF1 mice. 
(B) Pathway enrichment of metabolites that were significantly different between castrated 
vs intact male BWF1 mice. 
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Figure 28. Histamine is more abundant in intact male than female or castrated male 
BWF1 mice. For Metabolite Experiment #3, feces were collected from 16-week-old 
female (n=8), and intact (Intact Male; n=6) and castrated (at ~24 days of age; n=6) male 
BWF1 mice. For Metabolite Experiment #2, feces were collected from 16-week-old 
female and male (Intact Male) BWF1 mice (n=9). Metabolites were extracted using 80% 
methanol, analyzed with 2DLC-MS/MS. Significantly different metabolites were 
identified using pairwise Student’s t-tests (Tables 2,3). (A) Metabolomic Experiment #3 - 
Histidine abundance. (B) Metabolomic Experiment #3 - Histamine abundance. (C) 
Metabolomic Experiment #3 - Methylimidazoleacetic acid (Methylimid) abundance. (D) 
Metabolomic Experiment #2 - Histamine abundance. *p<0.05, **p<0.01, ***p<0.001 
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Figure 29. Niacin and butyrate were more abundant in male than female BWF1 
mice in Metabolomic Experiment #2, but not Metabolomic Experiment #3. For 
Metabolite Experiments #2 & #3, feces were collected from 16-week-old female and 
male BWF1 mice. Metabolites were extracted from feces using 80% methanol, 
derivatized with MSTFA, analyzed by GCxGC-MS. Significantly different metabolites 
were identified using pairwise Student’s t-tests (Tables 2,3). (A) Metabolomic 
Experiment #2 - Niacin abundance (n=9). (B) Metabolomic Experiment #2 - Butyrate 
abundance (n=3). (C) Metabolomic Experiment #3 - Niacin abundance (female n=8, male 
n=6). (D) Metabolomic Experiment #3 - Butyrate abundance (female n=8, male n=6). 
Outliers are indicated as triangles. ns=not significant, *p<0.05 
142 
Figure 30. Three separate metabolomic analyses of female and male BWF1 feces 
have found phytol elevated in male BWF1 mice. For Metabolite Experiments #1, #2 & 
#3, feces were collected from 16-week-old female and male BWF1 mice. Metabolites 
were extracted from feces using 80% methanol, derivatized with MSTFA, analyzed by 
GCxGC-MS. Significantly different metabolites were identified using pairwise Student’s 
t-tests (Tables 1-3). (A) Metabolomic Experiment #1 - Phytol abundance (female n=9, 
male n=8). (B) Metabolomic Experiment #2 - Phytol abundance (n=9). (C) Metabolomic 
Experiment #3 - Phytol abundance (female n=8, male n=6). **p<0.01, ***p<0.001 
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Figure 31. Phytol and the phytol derivative, phytanic acid, are both upregulated in 
intact male compared to both female and castrated male BWF1. For Metabolite 
Experiment #3, feces were collected from 16-week-old female (n=8), intact male (Male; 
n=6), and castrated (at ~24 days of age; n=6) male BWF1 mice. Metabolites were 
extracted from feces using 80% methanol, derivatized with MSTFA, analyzed by 
GCxGC-MS. Significantly different metabolites were identified using pairwise Student’s 
t-tests (Tables 3-5). (A) Metabolomic Experiment #3 - Phytol abundance [420]. (B) 
Metabolomic Experiment #3 – Phytanic Acid (PA) abundance. **p<0.01, ***p<0.001, 
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Table 1. Metabolomic Experiment #1. Metabolites with significantly different abundance 





Pentadecanoic acid 0.0027 3.23 GC×GC-MS_MSTFA 
Methyl stearate  0.0008 3.03 GC×GC-MS_MSTFA 









Paullinic acid 0.0395 1.61 GC×GC-MS_MSTFA 




Succinic acid 0.0264 1.52 GC×GC-MS_MSTFA 










3-Methylglutaconic acid 0.0156 1.32 GC×GC-MS_MSTFA 










Table 2. Metabolomic Experiment #2. Metabolites with significantly different abundance 





Nicotinic Acid 2.50E-03 12.50 2DLC-MS/MS (+) 
3-Hydroxy-3-methylglutaric 
Acid 
2.63E-03 5.26 2DLC-MS/MS (-) 
Nipecotic acid 1.10E-04 4.35 2DLC-MS/MS (+) 
11-Octadecenoic acid, methyl 
ester 
1.70E-04 4.00 GC×GC-MS_MSTFA 
2-Pyrrolidone-5-carboxylic acid  1.20E-02 2.78 GC×GC-MS_MSTFA 
4-Acetamidobenzaldehyde 2.82E-03 2.70 2DLC-MS/MS (+) 
7-Hexadecenoic acid, methyl 
ester, (Z)- 
5.53E-05 2.56 GC×GC-MS_MSTFA 
Diethylene glycol 0.00E+00 2.56 GC×GC-MS_MSTFA 
Glutamic Acid 2.83E-02 2.50 2DLC-MS/MS (+) 
Hexadecanoic acid, 15-methyl-, 
methyl ester 
6.80E-04 2.50 GC×GC-MS_MSTFA 
6-Aminocaproic Acid 2.49E-03 2.38 2DLC-MS/MS (+) 
9,12-Octadecadienoic acid 
(Z,Z)-, methyl ester 
5.31E-05 2.38 GC×GC-MS_MSTFA 
9,12,15-Octadecatrienoic acid 
(Z,Z,Z)-, methyl ester 
1.10E-03 2.27 GC×GC-MS_MSTFA 
Benzotriazole 1.04E-02 2.22 2DLC-MS/MS (+) 
Hypoxanthine 5.10E-03 2.17 GC×GC-MS_MSTFA 
N-Acetylputrescine 2.70E-03 2.13 GC×GC-MS_MSTFA 
Phytol 0.00E+00 2.04 GC×GC-MS_MSTFA 
Proline 9.64E-03 2.00 2DLC-MS/MS (-) 
cis-7-Tetradecenol 4.50E-03 1.96 GC×GC-MS_MSTFA 
DL-α-Methoxyphenylacetic 
Acid 
7.72E-03 1.92 2DLC-MS/MS (-) 
Hypoxanthine  1.39E-02 1.89 2DLC-MS/MS (-) 
5-Aminovaleric acid 4.30E-03 1.72 GC×GC-MS_MSTFA 
d-Mannose  3.90E-02 1.72 GC×GC-MS_MSTFA 
Lysine 1.28E-02 1.69 2DLC-MS/MS (-) 
Malic Acid 2.89E-02 1.69 2DLC-MS/MS (-) 
Parabanic acid 6.80E-03 1.69 GC×GC-MS_MSTFA 
Butyric Acid  2.60E-02 1.61 GC×GC-MS_MSTFA 
L-Aspartic Acid 1.71E-02 1.61 2DLC-MS/MS (-) 
Niacin 4.30E-02 1.61 GC×GC-MS_MSTFA 
Cerulenin 2.70E-03 1.59 GC×GC-MS_MSTFA 
Hydroxy-L-Proline 2.37E-02 1.59 2DLC-MS/MS (-) 
Cadaverine 4.20E-04 1.54 GC×GC-MS_MSTFA 
Serine 3.58E-05 1.54 2DLC-MS/MS (-) 
2-Aminobutyric Acid 4.15E-02 1.52 2DLC-MS/MS (+) 
Cyanuric acid 2.30E-02 1.52 GC×GC-MS_MSTFA 
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d-Galactose 5.90E-03 1.47 GC×GC-MS_MSTFA 
D-Pinitol 3.30E-03 1.47 GC×GC-MS_MSTFA 
3-tert-Butyladipic Acid 3.11E-02 1.43 2DLC-MS/MS (-) 
Histamine 1.61E-02 1.41 2DLC-MS/MS (+) 
Ribitol, 4.00E-02 1.39 GC×GC-MS_MSTFA 
Serine  2.97E-02 1.37 2DLC-MS/MS (+) 
1,3-Propanediol 1.20E-02 1.35 GC×GC-MS_MSTFA 
Tartaric Acid 2.44E-02 1.33 2DLC-MS/MS (-) 
Glycerol   2.00E-02 1.32 GC×GC-MS_MSTFA 
1-Aminocyclohexanecarboxylic 
Acid 
2.19E-02 1.30 2DLC-MS/MS (+) 
D-Ribose 3.50E-02 1.28 GC×GC-MS_MSTFA 
β-D-Talopyranose 4.30E-02 1.27 GC×GC-MS_MSTFA 
Diethylamine 1.70E-02 1.16 GC×GC-MS_MSTFA 
d-Glucose  4.00E-02 0.87 GC×GC-MS_MSTFA 
Glycerol-3-phosphate 1.20E-02 0.80 GC×GC-MS_MSTFA 
p-Coumaric acid 2.20E-02 0.71 GC×GC-MS_MSTFA 
N,N-Diisopropylethylamine  2.93E-02 0.62 2DLC-MS/MS (+) 
Adipic Acid 2.17E-02 0.60 2DLC-MS/MS (-) 
4-Guanidinobutyric Acid 1.11E-02 0.58 2DLC-MS/MS (+) 
6-Hydroxypicolinic Acid 2.97E-02 0.58 2DLC-MS/MS (-) 
Pentadecanoic acid 1.50E-02 0.58 GC×GC-MS_MSTFA 
Carnitine 1.53E-02 0.52 2DLC-MS/MS (+) 
6-Chloro-5-methyl-1H-1,2,3-
Benzotriazole 
1.21E-02 0.51 2DLC-MS/MS (-) 
6-Hydroxycaproic Acid 3.92E-02 0.50 2DLC-MS/MS (-) 
Quinic Acid 4.03E-02 0.49 2DLC-MS/MS (-) 
Creatinine 3.58E-02 0.47 2DLC-MS/MS (+) 
Taurine 4.48E-02 0.47 2DLC-MS/MS (-) 
Pyridoxine 2.04E-02 0.44 2DLC-MS/MS (+) 
Linoleic Acid 4.87E-02 0.41 2DLC-MS/MS (-) 
Deoxycholic Acid 1.02E-04 0.38 2DLC-MS/MS (-) 
2-Aminonicotinic Acid 4.62E-02 0.37 2DLC-MS/MS (+) 
L-Histidinol 2.47E-03 0.37 2DLC-MS/MS (+) 
Pyridoxal 3.81E-02 0.35 2DLC-MS/MS (+) 
Glycylproline 5.55E-03 0.34 2DLC-MS/MS (+) 
8Z,11Z,14Z-Eicosatrienoic 
Acid 
3.53E-02 0.31 2DLC-MS/MS (-) 
4-Pyridoxic Acid 6.23E-04 0.30 2DLC-MS/MS (-) 
O-Phosphoethanolamine,  1.50E-02 0.29 GC×GC-MS_MSTFA 
Triethanolamine 8.77E-05 0.29 2DLC-MS/MS (+) 
Taurine  1.05E-03 0.28 2DLC-MS/MS (+) 
Oleic Acid 3.81E-02 0.27 2DLC-MS/MS (-) 
β-Hydroxybutyric acid  1.80E-02 0.26 GC×GC-MS_MSTFA 
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Table 3. Metabolomic Experiment #3. Metabolites with significantly different abundance 





Phytanic acid 7.05E-03 Male only GC×GC-MS_MSTFA 
Phytanic acid 1.51E-03 Male only GC×GC-MS_MTBSTFA 
Benzoic acid 0.00E+00 5.26 GC×GC-MS_MTBSTFA 
Adenine 1.26E-02 4.00 2DLC-MS/MS (+) 
5-Hydroxytryptophan 9.92E-03 3.33 GC×GC-MS_MSTFA 
Ursolic acid 3.48E-03 3.03 2DLC-MS/MS (+) 
Adenine 4.74E-02 2.50 2DLC-MS/MS (-) 
Linolenic acid 1.73E-02 2.33 GC×GC-MS_MSTFA 
Palmitelaidic acid 1.41E-03 2.33 GC×GC-MS_MSTFA 
Phytol 3.58E-04 2.22 GC×GC-MS_MSTFA 
Adenosine 3.05E-02 2.17 2DLC-MS/MS (+) 
Phytol 2.95E-03 2.13 GC×GC-MS_MTBSTFA 
Xylose 1.66E-02 2.08 GC×GC-MS_MSTFA 
Aminoadipic acid 1.20E-02 2.00 2DLC-MS/MS (-) 
Methylimidazoleacetic acid 4.42E-02 2.00 2DLC-MS/MS (+) 
Valine 3.42E-04 2.00 GC×GC-MS_MTBSTFA 
2-Hydroxycaproic acid 1.08E-02 1.96 2DLC-MS/MS (-) 
Histamine 1.73E-04 1.82 2DLC-MS/MS (+) 
Myristic acid 6.48E-04 1.82 GC×GC-MS_MSTFA 
Eicosapentaenoic acid 3.13E-02 1.79 GC×GC-MS_MSTFA 
Valine 4.10E-04 1.79 GC×GC-MS_MSTFA 
Isoleucine 2.32E-03 1.75 GC×GC-MS_MTBSTFA 
Linoelaidic acid 2.82E-02 1.72 GC×GC-MS_MSTFA 
Myristic acid 3.30E-03 1.69 GC×GC-MS_MTBSTFA 
Isoleucine 1.72E-02 1.64 GC×GC-MS_MSTFA 
Leucine 3.19E-03 1.54 GC×GC-MS_MTBSTFA 
Rhamnose 4.79E-02 1.52 GC×GC-MS_MSTFA 
Nonanoic acid 3.50E-02 1.47 GC×GC-MS_MTBSTFA 
Palmitic acid 1.98E-02 1.39 GC×GC-MS_MSTFA 
Pentadecanoic acid 2.92E-02 1.37 GC×GC-MS_MSTFA 
Stearic acid 1.48E-02 1.30 GC×GC-MS_MSTFA 
Methionine 7.80E-03 0.81 GC×GC-MS_MTBSTFA 
Histidine 8.52E-03 0.76 2DLC-MS/MS (+) 
Glycerol-3-phosphate 3.47E-02 0.74 GC×GC-MS_MTBSTFA 
Dodecanoic acid 4.15E-02 0.73 GC×GC-MS_MTBSTFA 
Threonine 1.57E-02 0.72 2DLC-MS/MS (-) 
Alanine 3.37E-02 0.71 2DLC-MS/MS (+) 
Methionine 4.58E-02 0.71 2DLC-MS/MS (-) 
Alanine 2.87E-03 0.70 GC×GC-MS_MTBSTFA 
Benzyl alcohol 1.21E-02 0.69 GC×GC-MS_MTBSTFA 
Creatinine 1.08E-02 0.69 2DLC-MS/MS (+) 
N-Acetyl-histamine 1.37E-02 0.69 2DLC-MS/MS (+) 
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Alanine 2.62E-02 0.68 GC×GC-MS_MSTFA 






Benzeneacetic acid 4.53E-02 0.65 GC×GC-MS_MTBSTFA 
Choline 1.96E-02 0.65 2DLC-MS/MS (+) 
Glycine 7.13E-03 0.64 GC×GC-MS_MTBSTFA 
Threonine 4.28E-02 0.64 2DLC-MS/MS (+) 
Isobutyric acid 2.20E-02 0.63 GC×GC-MS_MTBSTFA 
Palmitoleic acid 2.32E-02 0.63 GC×GC-MS_MTBSTFA 
Tryptophan 1.07E-02 0.63 2DLC-MS/MS (+) 
beta-Hydroxypyruvic acid 1.07E-03 0.62 GC×GC-MS_MSTFA 
Azelaic acid 1.01E-02 0.61 GC×GC-MS_MTBSTFA 
Histidine 2.67E-04 0.61 2DLC-MS/MS (-) 
Proline 6.23E-03 0.61 GC×GC-MS_MSTFA 
Tryptophan 1.83E-02 0.61 2DLC-MS/MS (-) 
Lysine 1.47E-03 0.58 2DLC-MS/MS (+) 
3-Hydroxyphenylacetic acid 2.22E-02 0.57 GC×GC-MS_MTBSTFA 
Fumarate 1.80E-05 0.57 GC×GC-MS_MTBSTFA 
Proline 1.01E-02 0.56 GC×GC-MS_MTBSTFA 
4-Hydroxy-proline 5.45E-03 0.54 2DLC-MS/MS (-) 
Methionine 2.55E-02 0.52 2DLC-MS/MS (+) 
Isovaleric acid 3.17E-03 0.51 GC×GC-MS_MTBSTFA 
Lysine 6.06E-03 0.50 2DLC-MS/MS (-) 
Ornithine 4.94E-02 0.50 2DLC-MS/MS (+) 
Glucuronic acid 2.78E-02 0.47 2DLC-MS/MS (-) 
Heptadecanoic acid 2.55E-03 0.47 GC×GC-MS_MTBSTFA 
Malate 2.54E-03 0.47 GC×GC-MS_MTBSTFA 
Sucrose 1.34E-03 0.44 2DLC-MS/MS (-) 
Urea 3.29E-03 0.44 GC×GC-MS_MTBSTFA 
Vanillin 3.13E-02 0.43 GC×GC-MS_MTBSTFA 
Tyramine 8.80E-03 0.42 GC×GC-MS_MSTFA 
Lactic acid 2.93E-02 0.40 GC×GC-MS_MTBSTFA 
Malate 4.19E-02 0.38 2DLC-MS/MS (-) 
Uracil 3.26E-02 0.38 GC×GC-MS_MTBSTFA 
2-Hydroxyisocaproic acid 2.01E-05 0.19 GC×GC-MS_MTBSTFA 
Maltol 8.34E-04 0.18 GC×GC-MS_MTBSTFA 
N-Acetyl-glutamic acid 3.44E-02 0.13 2DLC-MS/MS (-) 
Deoxycholic acid 2.84E-06 0.09 2DLC-MS/MS (-) 
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Table 4. Metabolomic Experiment #3. Metabolites with significantly different abundance 





Phytanic acid 9.30E-03 Male only GC×GC-MS_MSTFA 
Phytanic acid 6.99E-03 Male only GC×GC-MS_MTBSTFA 
3-Hydroxybutyric acid 3.05E-02 12.50 2DLC-MS/MS (-) 
2-Hydroxybutyric acid 4.64E-02 11.11 2DLC-MS/MS (-) 
Benzoic acid 5.08E-06 9.09 GC×GC-MS_MTBSTFA 
Xylose 2.79E-06 9.09 GC×GC-MS_MSTFA 
N6-Acetyl-lysine 5.83E-03 5.88 2DLC-MS/MS (+) 
Phytol 6.35E-06 5.56 GC×GC-MS_MTBSTFA 
Isoleucine 6.70E-05 5.26 GC×GC-MS_MSTFA 
Leucine 3.93E-05 5.00 2DLC-MS/MS (+) 
Adenosine 6.08E-05 4.76 2DLC-MS/MS (+) 
Valine 5.22E-04 4.76 GC×GC-MS_MSTFA 
Isoleucine 8.52E-05 4.35 GC×GC-MS_MTBSTFA 
Valine 4.19E-05 4.35 GC×GC-MS_MTBSTFA 
Leucine 4.45E-05 4.17 GC×GC-MS_MTBSTFA 
Asparagine 2.21E-02 3.85 2DLC-MS/MS (+) 
Phenylalanine 4.52E-04 3.85 GC×GC-MS_MTBSTFA 
Leucine 3.10E-04 3.70 GC×GC-MS_MSTFA 
5-Hydroxytryptophan 1.93E-02 3.57 GC×GC-MS_MSTFA 
Glycerol 3.16E-04 3.45 GC×GC-MS_MTBSTFA 
Phytol 7.47E-03 3.03 GC×GC-MS_MSTFA 
Aminoadipic acid 9.58E-05 2.94 2DLC-MS/MS (-) 
Valine 4.29E-05 2.94 2DLC-MS/MS (+) 
Nonanoic acid 5.97E-05 2.78 GC×GC-MS_MTBSTFA 
Thiamine 2.08E-02 2.70 2DLC-MS/MS (-) 
3-Hydroxybutyric acid 4.81E-02 2.63 GC×GC-MS_MSTFA 






Rhamnose  8.66E-05 2.33 GC×GC-MS_MSTFA 
Tyrosine 1.02E-02 2.33 2DLC-MS/MS (-) 
Carnosine 3.32E-04 2.27 2DLC-MS/MS (-) 
Phenylalanine 2.41E-03 2.27 2DLC-MS/MS (+) 
Methionine 9.40E-03 2.13 GC×GC-MS_MSTFA 
Phloretic acid 3.44E-02 2.13 GC×GC-MS_MTBSTFA 
Cadaverine 2.88E-02 2.08 GC×GC-MS_MSTFA 
Myristic acid 8.52E-05 2.08 GC×GC-MS_MTBSTFA 
Glutamine 1.43E-02 2.04 2DLC-MS/MS (+) 
1-Methyl-histidine 7.82E-03 1.96 2DLC-MS/MS (+) 
2-Aminobutyric acid 6.75E-03 1.96 GC×GC-MS_MTBSTFA 
N-Acetyl-glucosamine 1.88E-03 1.92 2DLC-MS/MS (+) 
Pinitol  2.82E-03 1.89 GC×GC-MS_MSTFA 
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Tyrosine 2.49E-02 1.89 GC×GC-MS_MSTFA 
Histamine 2.25E-04 1.85 2DLC-MS/MS (+) 
Serine 1.67E-03 1.85 GC×GC-MS_MTBSTFA 
Glyceric acid 7.64E-03 1.82 GC×GC-MS_MTBSTFA 
Palmitelaidic acid 2.15E-02 1.82 GC×GC-MS_MSTFA 
Aceturic acid 5.80E-03 1.75 GC×GC-MS_MTBSTFA 
Carnosine 4.00E-03 1.72 2DLC-MS/MS (+) 
Ribose 1.20E-02 1.72 2DLC-MS/MS (-) 
Methionine 2.17E-02 1.64 2DLC-MS/MS (-) 
Diacetic acid 3.30E-03 1.61 GC×GC-MS_MTBSTFA 
Methionine 3.17E-03 1.61 GC×GC-MS_MTBSTFA 
Oleic acid 3.42E-02 1.61 GC×GC-MS_MSTFA 
Oxalic acid 7.86E-03 1.61 GC×GC-MS_MTBSTFA 
Methionine 3.32E-03 1.56 2DLC-MS/MS (+) 
Glutamine 6.05E-03 1.45 2DLC-MS/MS (-) 
Serine 1.47E-02 1.37 2DLC-MS/MS (-) 
Cytosine  1.00E-02 1.30 GC×GC-MS_MTBSTFA 
4-Pyridoxic acid 4.40E-02 0.80 2DLC-MS/MS (+) 
Azelaic acid 4.02E-02 0.76 GC×GC-MS_MSTFA 
Histidine 1.26E-02 0.75 2DLC-MS/MS (+) 
Azelaic acid 4.04E-02 0.72 2DLC-MS/MS (-) 
Fumarate 1.06E-02 0.72 GC×GC-MS_MTBSTFA 
Proline 1.98E-02 0.71 2DLC-MS/MS (+) 
Glutaric acid 4.34E-02 0.69 2DLC-MS/MS (-) 
Creatinine 9.66E-05 0.68 2DLC-MS/MS (+) 






Pipecolic acid 7.31E-04 0.64 GC×GC-MS_MTBSTFA 
Uracil  4.26E-02 0.64 GC×GC-MS_MSTFA 
Pipecolic acid 2.96E-03 0.63 GC×GC-MS_MSTFA 
2-Hydroxyphenylalanine 8.32E-03 0.62 2DLC-MS/MS (+) 
4-Hydroxy-Proline 2.56E-02 0.61 2DLC-MS/MS (+) 
N-Acetyl-histamine 5.29E-04 0.60 2DLC-MS/MS (+) 
Heptadecanoic acid 2.36E-03 0.59 GC×GC-MS_MTBSTFA 
Lactic acid 1.63E-03 0.59 2DLC-MS/MS (-) 






Histidine 1.53E-04 0.56 2DLC-MS/MS (-) 
4-Hydroxy-proline 3.32E-03 0.54 2DLC-MS/MS (-) 
Succinate 1.06E-02 0.54 GC×GC-MS_MSTFA 
Sucrose 3.23E-03 0.54 2DLC-MS/MS (-) 
Glutaric acid 9.92E-04 0.53 GC×GC-MS_MSTFA 
Lysine 3.08E-04 0.52 2DLC-MS/MS (+) 
Threonine 5.03E-03 0.51 2DLC-MS/MS (-) 
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Citrulline 3.41E-02 0.50 2DLC-MS/MS (-) 






Citrulline 2.67E-02 0.47 2DLC-MS/MS (+) 
Taurine 1.75E-03 0.46 GC×GC-MS_MTBSTFA 
Pyroglutamic acid 4.52E-02 0.44 GC×GC-MS_MSTFA 
Urocanic acid 4.07E-05 0.44 GC×GC-MS_MTBSTFA 
beta-Hydroxypyruvic acid 7.63E-03 0.43 GC×GC-MS_MSTFA 
Succinate 5.40E-04 0.43 2DLC-MS/MS (-) 






Maltol 1.58E-03 0.26 GC×GC-MS_MTBSTFA 
Malate 9.11E-04 0.23 GC×GC-MS_MTBSTFA 
Malate 4.44E-04 0.20 GC×GC-MS_MSTFA 
Malate 9.58E-06 0.19 2DLC-MS/MS (-) 
2-Hydroxyisocaproic acid 3.62E-04 0.18 GC×GC-MS_MTBSTFA 
N-Acetyl-glutamic acid 3.19E-06 0.06 2DLC-MS/MS (-) 
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Table 5. Metabolomic Experiment #3 (2018). Metabolites with significantly different 





Phenylalanine 4.74E-05 3.37 GC×GC-MS_MTBSTFA 
Isoleucine 1.78E-04 3.21 GC×GC-MS_MSTFA 
Methionine 2.19E-03 3.12 GC×GC-MS_MSTFA 
Phenylalanine 5.66E-05 3.03 2DLC-MS/MS (-) 
3-Aminobutyric acid 3.13E-03 2.98 GC×GC-MS_MTBSTFA 
Tyrosine 9.92E-04 2.98 2DLC-MS/MS (-) 
Phenylalanine 7.50E-06 2.86 2DLC-MS/MS (+) 
Leucine 9.65E-06 2.75 GC×GC-MS_MSTFA 
Leucine 2.43E-04 2.74 GC×GC-MS_MTBSTFA 
3-Hydroxybutyric acid 3.65E-02 2.68 GC×GC-MS_MSTFA 
Norvaline 6.79E-03 2.68 GC×GC-MS_MSTFA 
3-Hydroxybutyric acid 1.17E-02 2.56 2DLC-MS/MS (-) 
Isoleucine 1.09E-03 2.48 GC×GC-MS_MTBSTFA 
Tyrosine 1.27E-02 2.37 2DLC-MS/MS (+) 
Leucine 2.68E-03 2.36 2DLC-MS/MS (+) 
Carnosine 3.06E-06 2.31 2DLC-MS/MS (-) 
Methionine 1.68E-04 2.31 2DLC-MS/MS (-) 
Hydroxyphenyllactic acid 4.54E-03 2.29 2DLC-MS/MS (-) 
Valine 7.43E-04 2.25 2DLC-MS/MS (+) 
Valine 2.97E-03 2.15 GC×GC-MS_MTBSTFA 
Tryptophan 2.80E-04 2.02 2DLC-MS/MS (-) 
Oxalic acid 1.48E-03 2.01 GC×GC-MS_MTBSTFA 
Carnosine 1.50E-05 1.98 2DLC-MS/MS (+) 
Methionine 9.48E-05 1.98 GC×GC-MS_MTBSTFA 
4-Hydroxybenzoic acid 2.78E-02 1.92 GC×GC-MS_MTBSTFA 
Methionine 2.96E-04 1.91 2DLC-MS/MS (+) 
Nonanoic acid 6.16E-03 1.87 GC×GC-MS_MTBSTFA 
Tryptophan 3.47E-04 1.87 2DLC-MS/MS (+) 
Dodecanoic acid 3.35E-03 1.83 GC×GC-MS_MTBSTFA 
Ornithine 2.82E-02 1.82 2DLC-MS/MS (+) 
Serine 8.56E-05 1.81 GC×GC-MS_MTBSTFA 
Glycine 5.82E-03 1.79 2DLC-MS/MS (-) 
Urea 4.17E-02 1.77 GC×GC-MS_MTBSTFA 
Citrate 2.84E-02 1.74 GC×GC-MS_MTBSTFA 
Benzoic Acid 1.37E-02 1.73 GC×GC-MS_MTBSTFA 
Benzeneacetic acid 1.79E-02 1.69 GC×GC-MS_MTBSTFA 
Ribose  8.92E-04 1.68 GC×GC-MS_MSTFA 
Diacetic acid 8.22E-03 1.66 GC×GC-MS_MTBSTFA 
Tyrosine 4.36E-03 1.66 GC×GC-MS_MSTFA 
N-Acetylneuraminic acid 4.22E-02 1.65 2DLC-MS/MS (+) 
Glutamine 1.73E-03 1.60 2DLC-MS/MS (+) 
Alanine 5.86E-04 1.54 GC×GC-MS_MTBSTFA 
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Glutamine 2.52E-03 1.53 2DLC-MS/MS (-) 
Ribose  1.36E-02 1.50 2DLC-MS/MS (-) 
Phloretic acid 4.24E-02 1.49 GC×GC-MS_MTBSTFA 
Serine 9.09E-03 1.45 2DLC-MS/MS (+) 
Glycine 1.16E-02 1.44 GC×GC-MS_MTBSTFA 
5-Aminovaleric acid 1.86E-02 1.37 2DLC-MS/MS (+) 
1-Methyl-L-histidine 1.91E-04 1.36 2DLC-MS/MS (+) 
Alanine 4.18E-02 1.31 2DLC-MS/MS (+) 
Serine 2.18E-03 1.30 2DLC-MS/MS (-) 
2-Hydroxyphenylalanine 2.71E-02 0.79 2DLC-MS/MS (+) 
Azelaic acid 2.39E-02 0.79 2DLC-MS/MS (-) 
Creatinine 9.63E-05 0.74 2DLC-MS/MS (-) 
Maleic acid 2.13E-02 0.74 2DLC-MS/MS (-) 
2-Hydroxyvaleric acid 3.05E-03 0.63 2DLC-MS/MS (-) 
N-Acetylhistamine 8.31E-04 0.62 2DLC-MS/MS (+) 
Pentadecanoic acid 3.45E-03 0.55 GC×GC-MS_MSTFA 
Succinate 1.61E-04 0.55 2DLC-MS/MS (-) 
Succinate 3.49E-04 0.53 GC×GC-MS_MSTFA 
4-Hydroxybenzeneacetic 
acid 
7.24E-03 0.52 GC×GC-MS_MSTFA 
Malate 1.88E-02 0.50 2DLC-MS/MS (-) 
N-Acetyl-glutamic acid 1.73E-02 0.44 2DLC-MS/MS (-) 
alpha-Ketoglutaric acid 1.11E-02 0.37 2DLC-MS/MS (-) 
Malate 2.41E-03 0.26 GC×GC-MS_MSTFA 
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Table 6. Pathways affected by the metabolic differences between female and male 
groups (female n=8, male n=6). 
Name p-value -LOG(p) Impact 
Aminoacyl-tRNA biosynthesis 8.48E-07 13.98 0.0000 
Glyoxylate and dicarboxylate metabolism 1.10E-05 11.42 0.0645 
Tyrosine metabolism 1.66E-05 11.01 0.0269 
Alanine, aspartate and glutamate metabolism 4.42E-05 10.03 0.0032 
Citrate cycle (TCA cycle) 4.74E-05 9.96 0.0721 
Glycine, serine and threonine metabolism 4.96E-05 9.91 0.2688 
Arginine and proline metabolism 5.44E-05 9.82 0.1914 
Purine metabolism 3.75E-04 7.89 0.0057 
Fatty acid biosynthesis 6.32E-04 7.37 0.0000 
Pantothenate and CoA biosynthesis 7.11E-04 7.25 0.0000 
Histidine metabolism 8.78E-04 7.04 0.4624 
Valine, leucine and isoleucine biosynthesis 9.35E-04 6.98 1.0000 
Valine, leucine and isoleucine degradation 9.35E-04 6.98 0.0000 
Lysine biosynthesis 1.65E-03 6.41 0.0000 
Lysine degradation 1.65E-03 6.41 0.0000 
Tryptophan metabolism 2.25E-03 6.10 0.1772 
Selenoamino acid metabolism 2.52E-03 5.98 0.0000 
Nitrogen metabolism 2.72E-03 5.91 0.0000 
Pentose and glucuronate interconversions 2.98E-03 5.81 0.1333 
Galactose metabolism 3.44E-03 5.67 0.0407 
Glycerophospholipid metabolism 3.61E-03 5.62 0.0889 
Pyruvate metabolism 3.94E-03 5.54 0.0000 
Starch and sucrose metabolism 4.59E-03 5.38 0.0000 
Cysteine and methionine metabolism 7.08E-03 4.95 0.0869 
Biosynthesis of unsaturated fatty acids 8.41E-03 4.78 0.0000 
alpha-Linolenic acid metabolism 9.99E-03 4.61 1.0000 
Primary bile acid biosynthesis 1.38E-02 4.28 0.0298 
Cyanoamino acid metabolism 1.38E-02 4.28 0.0000 
Methane metabolism 1.38E-02 4.28 0.0000 
Porphyrin and chlorophyll metabolism 1.38E-02 4.28 0.0000 
Fatty acid elongation in mitochondria 1.76E-02 4.04 0.0000 
Fatty acid metabolism 1.76E-02 4.04 0.0000 
Glycerolipid metabolism 2.86E-02 3.55 0.0256 
Glutathione metabolism 2.89E-02 3.54 0.0057 
Biotin metabolism 3.01E-02 3.50 0.0000 
Ascorbate and aldarate metabolism 3.18E-02 3.45 0.4000 
Inositol phosphate metabolism 3.18E-02 3.45 0.0000 
Glycolysis or Gluconeogenesis 3.20E-02 3.44 0.0000 
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Table 7. Pathways affected by the metabolic differences between castrated and intact 




Valine, leucine and isoleucine biosynthesis 8.29E-07 14.00 0.6667 
Aminoacyl-tRNA biosynthesis 9.30E-07 13.89 0.1290 
Lysine degradation 5.19E-06 12.17 0.0000 
Valine, leucine and isoleucine degradation 1.28E-05 11.27 0.0000 
Lysine biosynthesis 3.13E-05 10.37 0.0000 
Histidine metabolism 4.66E-05 9.97 0.4624 
Glyoxylate and dicarboxylate metabolism 7.23E-05 9.54 0.1290 
Alanine, aspartate and glutamate metabolism 7.84E-05 9.45 0.3460 
Pyruvate metabolism 1.58E-04 8.75 0.0000 
Arginine and proline metabolism 1.75E-04 8.65 0.0944 
Glycine, serine and threonine metabolism 2.64E-04 8.24 0.2385 
Citrate cycle (TCA cycle) 2.92E-04 8.14 0.0977 
Phenylalanine, tyrosine and tryptophan 
biosynthesis 3.86E-04 7.86 0.5000 
Phenylalanine metabolism 3.86E-04 7.86 0.4074 
Nitrogen metabolism 4.00E-04 7.82 0.0000 
Butanoate metabolism 4.62E-04 7.68 0.1015 
Galactose metabolism 4.64E-04 7.67 0.0407 
Tyrosine metabolism 5.33E-04 7.54 0.0000 
Purine metabolism 6.17E-04 7.39 0.0010 
Tryptophan metabolism 6.96E-04 7.27 0.0000 
Propanoate metabolism 8.92E-04 7.02 0.0000 
Biotin metabolism 1.05E-03 6.86 0.0000 
Amino sugar and nucleotide sugar metabolism 1.09E-03 6.83 0.0692 
Fatty acid biosynthesis 1.16E-03 6.76 0.0000 
Taurine and hypotaurine metabolism 1.80E-03 6.32 0.4286 
Primary bile acid biosynthesis 1.80E-03 6.32 0.0298 
Cysteine and methionine metabolism 2.39E-03 6.04 0.1122 
Glycerolipid metabolism 2.65E-03 5.93 0.3857 
Methane metabolism 3.63E-03 5.62 0.4000 
Cyanoamino acid metabolism 3.63E-03 5.62 0.0000 
Sphingolipid metabolism 3.63E-03 5.62 0.0000 
beta-Alanine metabolism 5.15E-03 5.27 0.0000 
Glutathione metabolism 5.29E-03 5.24 0.0143 
Starch and sucrose metabolism 7.30E-03 4.92 0.0000 
Pyrimidine metabolism 9.26E-03 4.68 0.0000 
D-Glutamine and D-glutamate metabolism 9.26E-03 4.68 0.0000 
Pentose phosphate pathway 1.17E-02 4.45 0.0000 
Thiamine metabolism 1.39E-02 4.28 0.4000 
Synthesis and degradation of ketone bodies 1.78E-02 4.03 0.6000 
Glycolysis or Gluconeogenesis 3.34E-02 3.40 0.0000 
Vitamin B6 metabolism 3.91E-02 3.24 0.0000 
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Table 8. Pathways affected by the metabolic differences between female and castrated 
male groups (female n=8, castrated n=6). 
Name p-value -LOG(p) Impact 
Aminoacyl-tRNA biosynthesis 2.15E-08 17.66 0.1290 
Histidine metabolism 3.08E-06 12.69 0.0000 
Alanine, aspartate and glutamate metabolism 3.22E-06 12.65 0.2131 
Valine, leucine and isoleucine degradation 3.68E-06 12.51 0.0000 
Cysteine and methionine metabolism 5.71E-06 12.07 0.1122 
Arginine and proline metabolism 8.61E-06 11.66 0.1274 
Valine, leucine and isoleucine biosynthesis 1.17E-05 11.36 1.0000 
Phenylalanine metabolism 1.98E-05 10.83 0.4074 
D-Glutamine and D-glutamate metabolism 3.78E-05 10.18 0.0000 
Sphingolipid metabolism 4.12E-05 10.10 0.0000 
Phenylalanine, tyrosine and tryptophan biosynthesis 4.19E-05 10.08 1.0000 
Butanoate metabolism 4.80E-05 9.94 0.1015 
Tyrosine metabolism 5.04E-05 9.90 0.1405 
Glycine, serine and threonine metabolism 5.27E-05 9.85 0.5073 
Methane metabolism 5.27E-05 9.85 0.4000 
Cyanoamino acid metabolism 5.27E-05 9.85 0.0000 
Citrate cycle (TCA cycle) 1.21E-04 9.02 0.1924 
Synthesis and degradation of ketone bodies 1.44E-04 8.84 0.6000 
Selenoamino acid metabolism 1.45E-04 8.84 0.0000 
Purine metabolism 1.82E-04 8.61 0.0000 
Propanoate metabolism 4.87E-04 7.63 0.0000 
Pentose phosphate pathway 6.36E-04 7.36 0.0000 
Nitrogen metabolism 1.03E-03 6.87 0.0000 
Tryptophan metabolism 1.20E-03 6.73 0.1772 
Pyruvate metabolism 1.20E-03 6.73 0.0000 
Pyrimidine metabolism 1.85E-03 6.29 0.0000 
Fatty acid biosynthesis 1.97E-03 6.23 0.0000 
Glyoxylate and dicarboxylate metabolism 2.46E-03 6.01 0.2581 
Glutathione metabolism 2.81E-03 5.88 0.0057 
Pantothenate and CoA biosynthesis 3.73E-03 5.59 0.0000 
Primary bile acid biosynthesis 7.80E-03 4.85 0.0298 
Porphyrin and chlorophyll metabolism 7.80E-03 4.85 0.0000 
Ubiquinone and other terpenoid-quinone biosynthesis 8.80E-03 4.73 0.0000 
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SPECIFIC AIM 3 
Sex-based differences in splenic macrophage efferocytosis may be 
mediated by a male microbiota associated metabolite 
Introduction
Like most autoimmune diseases, the multi-organ autoimmune disease systemic 
lupus erythematosus (SLE) has a pronounced sex bias, as about 9 in every 10 people 
affected by SLE are women [1,2,4-8]. There are complex genetic and environmental 
factors that predispose individuals to SLE, and the mechanisms that play a role in its 
development are still not completely understood. Cells and molecules of both the innate 
and adaptive immune responses are clearly involved in the pathogenesis [494]. Lupus is 
characterized by the activation of autoreactive T and B cells resulting in the production of 
anti-nuclear autoantibodies that form immune complexes that are deposited in the skin, 
kidneys, and other organs. The resulting inflammation is multiorgan can manifest as 
lupus nephritis, vasculitis, pulmonary hypertension, or stroke, and over 50% of lupus 
patients eventually develop one or more of these complications, and although there are 
treatments that mitigate symptoms, there is no cure [3,5,9-13]. The NZBxNZW F1 
(BWF1) mouse strain is an excellent spontaneous model of lupus, and exhibits many of 
the features of the human disease including a definite sex bias. Female BWF1 mice 
spontaneously develop anti-dsDNA autoantibodies, glomerulonephritis, 
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lymphadenopathy, splenomegaly in a manner that resembles the progression of disease in 
humans whereas male BWF1 have much lower disease incidence and severity [16]. 
Many innate immune activities play a major role in the initiation and progression 
of lupus. Dendritic cells (DCs) present self-antigens to T cells, which then promote B cell 
maturation [495]. Deficiencies in complement proteins result in impaired clearance of the 
immune complexes that drive kidney inflammation [496], and plasmacytoid DCs produce 
IFNα in response to these immune complexes, which promotes autoantibody production 
[497]. However, all of these activities depend on the deficient macrophage phagocytosis 
of apoptotic cells [371]. This process, known as efferocytosis, sequesters nuclear antigen 
containing apoptotic debris away from other immune cells, suppressing the stimulation of 
anti-nuclear autoantibody production [370]. Macrophages isolated from SLE patients or 
lupus-prone female BWF1 mice are defective at phagocytosing apoptotic cells (i.e., 
efferocytosis) compared to healthy controls [386,391,392,498], and disease severity in 
SLE patients is strongly correlated with deficient efferocytosis [380,493]. 
Several factors are thought to play roles in the higher incidence of SLE in 
females. One is the incomplete inactivation of the X chromosome that can result in 
overexpression of X-linked genes that are involved in the immune response and promote 
autoimmunity [90-92]. Sex hormones are also thought to play a major role in both human 
and BWF1 mouse sex bias. Female sex hormones, estrogens, are generally 
immunostimulatory, and there is evidence that they promote lupus progression 
[58,102,103]. On the other hand, male sex hormones, androgens, are strongly 
immunosuppressive and anti-inflammatory and are believed to protect against lupus 
[103,122-125]. Both women and men with SLE have decreased levels of androgens 
159 
[115,138-144]. Additionally, SLE is more prevalent in men with Klinefelter syndrome, 
who naturally have lower androgen levels and higher estrogen levels than XY males 
[146,147]. Many innate and adaptive immune cells express androgen receptor, including 
macrophages, monocytes, mast cells, neutrophils, B cells, and T cells [499]. The effects 
of androgen signaling on immune cells are many and diverse. They include promoting 
neutrophil differentiation, suppressing macrophage inflammatory responses to pathogens, 
limiting T cell proliferation, promoting Treg expansion, and decreasing the numbers of 
circulating B cells [499,500]. 
Accumulating evidence indicates that the gut microbiota can have a major impact 
on immune functions systemically as well as locally. Consequently, the gut microbiota 
can affect the progression of a large variety of diseases including autoimmune diseases. 
[218,436]. Most autoimmune diseases, including SLE, are associated with dysbiosis, an 
imbalance between beneficial microbes and potential pathobionts [184,256,257,276-
280,282,283], as well as altered microbial metabolite production [333-336,348,360-362]. 
An increasing number of studies have found that the intestinal microbiota of SLE patients 
differs significantly from those of healthy controls [276-283,437]. Clearly, there is a 
strong connection between lupus and the microbiota. Furthermore, sex also significantly 
affects the microbiota, suggesting that sex-based differences in microbiota function could 
potentially contribute to the sex bias of lupus [182,300-303]. We and others have found 
sex differences in the gut microbiota in mouse models of autoimmune disease, including 
lupus (Fig. 11) [323-325]. 
One of the major ways the microbiota can affect autoimmune diseases is via the 
production of immunoregulatory metabolites [327], e.g., short chain fatty acids (SCFAs). 
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Among many other anti-inflammatory effects, SCFAs can promote regulatory T-cell 
induction and suppress inflammasome activation [328-332]. Multiple autoimmune 
diseases including multiple sclerosis, IBD, and spondyloarthritis have been found to be 
associated with decreased levels of SCFAs and SCFA-producing bacteria and 
reconstitution of these metabolites can alleviate disease in mouse models of these 
diseases [333-339]. Also, production of SCFAs and other metabolites can be affected by 
androgens [218,324,420,436,501,502]. Considering the significant effect alterations in 
immunomodulatory metabolites can have on autoimmune diseases, this suggests that sex-
based differences in metabolites could contribute to the sex bias in lupus-prone BWF1 
mice [327]. For this reason, we previously compared the fecal metabolomic profiles of 
disease-prone female and castrated male BWF1 mice and disease-resistant intact male 
BWF1 mice. The metabolomic profiles of these mice differed significantly, and we 
identified several immunomodulatory metabolites that were elevated in the intact male 
BWF1 mice compared to the female and castrated male BWF1 mice [420]. One of these 
was phytol, which is produced from the breakdown of chlorophyll and has RXR and 
PPARγ agonist activities [449,450]. Phytol is converted by host enzymes to phytanic 
acid, which was completely absent from the female and castrated male BWF1 feces but 
present in the BWF1 feces (manuscript in preparation). Phytanic acid has even more 
potent agonist activity compared to its parent compound, phytol, and it strongly activates 
the PPARγ/RXR, LXR/RXR, and PPARδ/RXR signaling complexes [449-453,463]. 
Phytanic acid could potentially affect disease progression in a number of ways, as these 




In this paper, we further investigate the functional differences in immune 
activities between female and male BWF1 mice. The splenocyte transcriptomes of 
disease-susceptible female BWF1 mice, and disease-resistant male BWF1 and female 
BALB/c mice were compared using RNA sequencing (RNA-seq), and we found disease 
resistance was associated with enrichment of phagocytosis-promoting genes. Based on 
these data, we compared efferocytic activity in splenic macrophages from female and 
male BWF1 mice and found that male macrophages were significantly more effective at 
phagocytosing apoptotic cells than macrophages from female BWF1 mice. We found 
similar differences in macrophage efferocytosis between intact and castrated male BWF1 
mice, where macrophages from intact male BWF1 mice were significantly more effective 
at phagocytosing apoptotic cells than macrophages from castrated male BWF1 mice. 
Additional analysis of the RNA-seq data suggested that increased PPARγ and LXR 
signaling might play a role in higher male efferocytic activity [393-399,503]. Our 
previous metabolomic study had found that male BWF1 mice had higher than either 
female or castrated male mice of a metabolite, phytol, which can activate those pathways 
(Fig. 31A) [420,456]. Phytol’s derivative, phytanic acid, was also elevated in intact male 
BWF1 mice and is an even more potent activator of the PPARγ and LXR pathways (Fig. 
31B) [449-453,463]. In vitro and in vivo treatments with phytanic acid increased 
macrophage efferocytosis and expression of the efferocytosis-promoting gene CD36. We 
show that this effect is dependent on both LXR/RXR and PPARγ/RXR signaling. These 
findings shed new light on how the microbiota can influence disease progression in the 




Splenic transcriptome and macrophage gene expression analysis suggests that male 
BWF1 macrophages mice may have greater efferocytic activity 
To investigate the sex differences in immune functions in BWF1 mice, we first 
compared the splenocyte gene expression profile of adult disease-prone female BWF1 
mice to disease-resistant male BWF1 and female BALB/c mice by RNA sequencing 
(RNA-seq) [16,420]. Hierarchical clustering analysis of differentially expressed genes 
revealed three prominent clusters of genes that varied between the three groups based on 
strain, sex, or disease susceptibility (Fig. 32A). The heatmap of relative gene expression 
shows that despite differing in sex and genetics, there is a significant cluster of genes 
differentially regulated in both the disease-resistant male BWF1 and female BALB/c 
mice compared to the disease-prone female BWF1 mice. This suggests that the lower 
susceptibility to lupus in male BWF1 and female BALB/c mice is associated with 
differential expression of a set of splenic genes. To investigate what specific biological 
processes differed in the disease-prone and non-disease-prone mice, we performed Gene 
ontology: Biological Process (GO:BP) analysis of the genes significantly upregulated in 
male BWF1 or female BALB/c mice compared to the female BWF1 mice (Fig. 32B). 
Functional analysis revealed similarities in some upregulated pathways between the 
disease resistant male BWF1 and BALB/c female mice relative to female BWF1 mice. 
Interestingly, both male BWF1 and female BALB/c spleens had increased levels of genes 
that positively regulate phagocytosis. This matches previous studies which have shown 
that apoptotic cell clearance by phagocytosis is deficient in SLE patients and mouse 
models of lupus. There is significant evidence that this deficiency promotes lupus onset 
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and progression [371,491,492]. Macrophages are the cells primarily responsible for 
apoptotic cell phagocytosis, referred to as efferocytosis, and macrophages isolated from 
SLE patients and lupus-prone mice have been shown to be intrinsically defective at 
efferocytosis compared to healthy controls [379,387,504,505]. We examined the 
phagocytosis-related genes that were enriched in male BWF1 mice (Table 9). One of 
them, LRP1, is known to be expressed by macrophages and directly involved in 
efferocytosis. It is a surface receptor that is specifically involved in binding apoptotic 
cells and promoting their phagocytosis [506]. The RNA-seq analysis showing that the 
expression of LRP1 is doubled in male macrophages (Fig. 32C) was confirmed using 
qPCR and flow cytometry; male BWF1 CD11b+F4/80+ splenic macrophages express 
higher levels of LRP1 than female BWF1 splenic macrophages (Fig. 32D,E; 33A; 40A). 
Androgens have been associated with protection from lupus [115,140,143], and 
we and others have found that castration dramatically accelerates and increases severity 
of disease and decreases survival of male BWF1 mice [17,133,420]. To determine if 
androgens affect LRP1 expression, male BWF1 mice were castrated and LPR1 mRNA 
and protein expression were evaluated. Androgen depletion resulted in lower levels of 
LRP1 mRNA and protein expression in castrated compared to intact male BWF1 splenic 
macrophages (Fig. 32F,G; 40B). This lower expression of LRP1 correlates with the 
greater susceptibility to lupus in castrated male BWF1 [420]. Taken together, these data 
suggest that disease resistant intact male BWF1 mice appear to have more efficient 
macrophage efferocytosis than disease-prone female and castrated male BWF1 mice. 
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Splenic macrophages from intact male BWF1 mice have higher efferocytic activity 
than macrophages from either female or androgen-depleted male BWF1 mice 
Both SLE patients and lupus-prone mice exhibit deficient macrophage clearance 
of apoptotic cells (efferocytosis), which results in accumulation of nuclear antigen-
containing debris that promotes disease progression [371,391,491,492]. The spleen is a 
major site of apoptotic cell clearance [379,387,504,505], and our analyses of splenocyte 
and splenic macrophage gene expression suggested that macrophages from lupus-prone 
female BWF1 mice might have deficient efferocytic activity compared to males (Fig. 32). 
To investigate this, we compared the ability of splenic macrophages from female and 
male BWF1 mice to phagocytose apoptotic cells. Adherent cells from digested spleens 
were incubated with CTV-labeled apoptotic thymocytes and were analyzed by flow 
cytometry to determine the percentage of F4/80+CD11b+ macrophages that had 
phagocytosed the labeled apoptotic cells. Representative figures for this flow cytometry 
assay are shown in Figure 34. As shown in Figure 35A, male BWF1 splenic 
macrophages were significantly more efficient than female macrophages as shown by the 
fold change of CTV+ macrophages. To control for the possibility of a bystander effect of 
another adherent cell type, we repeated the assay using sorted F4/80+CD11b+ cells, and 
confirmed that the male splenic macrophages had higher efferocytic activity compared to 
female splenic macrophages (Fig. 35B). 
Since we had found that androgen depletion via castration resulted in decreased 
expression of the efferocytic receptor LRP1, we tested whether castration also reduced 
macrophage efferocytosis using either adherent or sorted splenic macrophages from adult 
castrated or intact male mice. We found that androgen depletion decreases splenic 
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macrophage phagocytosis of apoptotic cells (Fig. 35C,D). Additionally, when mice were 
treated with the androgen receptor blocker, flutamide, splenic macrophage efferocytosis 
was decreased by comparison to vehicle-treated male controls (Fig. 35E). Since multiple 
studies have found that androgen signaling either has no effect or even decreases 
phagocytic activity in macrophages [507-511], the positive effect of androgen (as 
indicated by our findings that both androgen depletion and androgen receptor signaling 
blockade impair efferocytosis) on macrophage efferocytosis that we find in our studies 
may not be due to a direct effect of androgen on macrophages. One way that androgen is 
known to indirectly affect immune responses is by altering the production of 
immunomodulatory metabolites produced by gut bacteria [218,436,501,502]. 
Treatment with a male microbiota-associated metabolite increases the ability of 
female splenic macrophages to phagocytose apoptotic cells 
Having established that male BWF1 macrophages are more efficient at efferocytosis, and 
efferocytosis is impaired by androgen depletion, we next investigated the underlying 
mechanisms. Transcription factor enrichment analysis of our RNA-seq data showed the 
set of genes upregulated in male BWF1 vs female BWF1 spleens was enriched for genes 
stimulated by LXR and PPARγ signaling (Fig. 36A; Table 10,11). PPARγ and LXR 
stimulation are known to upregulate many efferocytosis-promoting genes, but this raised 
the question of what was stimulating the LXR and PPARγ genes in the male splenocytes. 
In a previous study, we found that feces from female, and intact and castrated male 
BWF1 mice exhibit different metabolite profiles. In that study, we found differences in 
the levels of a potentially immunomodulatory metabolite that could affect PPARγ and 
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LXR signaling. The acyclic diterpene alcohol, phytol can activate both the PPARγ and 
the LXR pathways [449,450,456], and was elevated in intact male BWF1 mice compared 
to female and castrated male BWF1 mice [420]. Phytol is converted by host enzymes to 
phytanic acid, which has similar but even more potent agonist activity compared to its 
parent compound phytol, and strongly activates PPARγ/RXR, LXR/RXR, and 
PPARδ/RXR signaling [449-453,463]. We have found that phytanic acid is completely 
absent from female and castrated male BWF1 feces but present in intact male BWF1 
feces (Unpublished data). Since signaling via the PPARγ/RXR, LXR/RXR or 
PPARδ/RXR pathways is known to promote efferocytosis [381,393-400], we 
hypothesized that phytanic acid could potentially increase the ability of splenic 
macrophages to phagocytose apoptotic cells. To test this, female BWF1 adherent or 
sorted splenic macrophages were pre-treated with phytanic acid then cultured with CTV-
labeled apoptotic cells. Phytanic acid (PA) significantly increased the ability of female 
BWF1 splenic macrophages to phagocytose apoptotic cells (Fig. 36B,C). Phytanic acid 
also increased efferocytosis in macrophages from castrated male BWF1 mice (Fig. 36D). 
These findings suggested that higher levels of phytanic acid and its precursor, phytol, 
found in the male gut microbiota could contribute to the higher levels of splenic 
macrophage efferocytosis found in males. If this is the case, then treating female BWF1 
mice with phytanic acid in vivo should increase splenic macrophage efferocytosis. To test 
this, female BWF1 mice were fed phytanic acid-containing microspheres that are taken 
up by the gut and slowly release their payload [422,423]. After 4 weeks of treatment, 
spleens were harvested and macrophage efferocytosis was evaluated in vitro. 
Macrophages from female BWF1 mice fed phytanic acid-containing microspheres were 
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significantly more efficient at efferocytosis than macrophages from female control mice 
fed empty microspheres (Fig. 36E). 
The intestinal production of phytanic acid’s precursor, phytol, is completely 
dependent on gut microbiota metabolism [460-462]. Therefore sex-based differences in 
the BWF1 microbiota are the most likely source of the elevated fecal levels of both 
phytol and phytanic acid in male BWF1 mice compared to female BWF1 mice [420]. If 
the male microbiota is the source of these metabolites, then transfer of male microbiota 
into female mice should also enhance macrophage-mediated efferocytosis after transfer 
into recipient female mice. To determine whether male microbiota could affect 
macrophage function in female BWF1 mice, we transferred adult male BWF1 cecal 
contents (containing the microbiota) into female BWF1 mice at regular intervals starting 
at weaning and continuing until 16 weeks of age. At that time, we harvested the spleens 
and assayed the efferocytic activity of the macrophages. We found that transfer of adult 
male, but not female (negative control), cecal contents into female BWF1 mice increased 
the ability of female splenic macrophages to phagocytose apoptotic cells to levels found 
in positive control male mice that received male cecal contents (Fig. 36F). Altogether, 
these data suggest that the male-upregulated microbiota metabolite, phytol and its 
derivative phytanic acid could play a role in the sex differences in BWF1 macrophage 
efferocytosis. 
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Phytanic acid affects macrophage efferocytosis via LXR/RXR and PPARγ/RXR 
pathways 
Phytanic acid can stimulate PPARδ/RXR, LXR/RXR, and PPARγ/RXR signaling [449-
453,463], and each of these pathways can potentially stimulate macrophage phagocytosis 
of apoptotic cells [381,393-400]. To investigate which pathways phytanic acid stimulates 
to enhance macrophage efferocytosis, splenic macrophages from female BWF1 mice 
were treated with phytanic acid along with inhibitors that block one or all of those 
signaling pathways. We found that when RXR-mediated pathways were blocked with the 
RXR antagonist HX531, phytanic acid treatment could no longer enhance macrophage 
efferocytosis, suggesting that RXR pathways are required for phytanic acid action on 
macrophages (Fig. 37A). Similarly, blocking the PPARγ/RXR heterodimer-mediated 
pathway with the PPARγ antagonist, GW9662 or the LXR/RXR heterodimer-mediated 
pathway with LXR antagonist, GSK2033 also prevented phytanic acid treatment from 
increasing macrophage efferocytosis (Fig. 37B,C). These data indicate that activation of 
both the PPARγ/RXR and LXR/RXR pathways is required for phytanic acid to increase 
macrophage ability to phagocytose apoptotic cells, and their activities are not redundant. 
However, inhibiting the PPARδ/RXR-mediated pathway with the PPARδ antagonist, 
GSK0660 did not affect the enhancement of efferocytosis by phytanic acid, indicating 
that phytanic acid does not act via the PPARδ pathway (Fig. 37D). In summary, phytanic 
acid increases macrophage efferocytosis via a PPARγ and LXR pathway dependent 
mechanism. 
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Phytanic acid may increase macrophage phagocytosis by upregulating the 
expression of the pro-efferocytic receptor CD36 
As described earlier (Fig. 32C-G), we have found that the efferocytosis-
associated receptor, LRP1, was upregulated in intact male compared to female and 
castrated male BWF1 mice. Interestingly, LRP1 has been shown to potentiate the effects 
of LXR and/or PPARγ signaling, including the upregulation of other molecules 
associated with efferocytosis in macrophages [415,512]. These data suggest that LXR 
and/or PPARγ signaling could act, possibly in concert with LRP1 that is expressed at 
higher levels in males, by upregulating surface receptors involved in efferocytosis. CD36, 
MERTK, and TIMD4 are all surface receptors that are known to be directly involved in 
efferocytosis in macrophages, and have been shown to be upregulated by LXR and/or 
PPARγ signaling [372,384,393,396,404,408-410,412,413,513-521]. To determine 
whether expression of any of these surface markers differs between female and intact and 
castrated male macrophages and, could, therefore, potentially contribute to the 
differences in efferocytosis between splenic macrophages from female and intact and 
castrated male BWF1 mice, we analyzed their expression via flow cytometry. We found 
that while MERTK and TIMD4 expression did not differ between female and male 
BWF1 macrophages, CD36 was expressed at higher levels in male BWF1 splenic 
macrophages compared to female mice (Fig. 38A; 33B; 40C-E). AXL, MFGE8, and 
C1QA are also involved in efferocytosis and upregulated by LXR and/or PPARγ, and 
defects in them are associated with lupus [375,382,393,400,405,522-533]. To evaluate 
AXL, MFGE8, and C1QA expression, we compared mRNA levels of these molecules by 
qPCR in sorted splenic macrophages from female and male BWF1 mice, but found no 
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differences in expression (Fig. 39). Additionally, CD36 was also expressed at higher 
levels in intact male compared to castrated male BWF1 mice (Fig. 38B; 40F). CD36 can 
be regulated by LXR and/or PPARγ signaling [393,409,410], and we have found that 
phytanic acid can affect efferocytosis via signaling through one or both of these pathways 
(Fig. 37A-C). For these reasons, we determined whether in vitro treatment of female or 
castrated male macrophages with phytanic acid could upregulate CD36. Treatment with 
phytanic acid in vitro induced increased CD36 expression in both female and castrated 
male BWF1 macrophages. (Fig. 38C,D; 40G,H), and feeding microspheres containing 
phytanic acid to female BWF1 mice also increased CD36 expression in splenic 
macrophages (Fig. 38E, 40I). Since CD36 is involved in phagocytosis of apoptotic cells 
and phytanic acid increases both CD36 and phagocytosis of apoptotic cells, we wondered 
whether phytanic acid could be enhancing phagocytosis of apoptotic cells by 
upregulating CD36 expression. To determine whether CD36 is required for phytanic acid 
mediated enhanced phagocytosis of apoptotic cells, we cultured female macrophages 
with phytanic acid and a CD36-blocking antibody. When CD36 was blocked, there was 
no difference in the ability to phagocytose apoptotic cells between phytanic acid and 
vehicle treated-macrophages (Fig. 38F), suggesting that CD36 is, at least, required for 
phytanic acid's effects on macrophage phagocytic activity. Taken together, these data 
suggest that a male microbiota-associated metabolite, phytanic acid, can enhance 
efferocytosis in female and castrated male BWF1 macrophages. This effect is dependent 
on LXR and PPARγ signaling and is abrogated by blocking the pro-efferocytic receptor 




The incidence of severe glomerulonephritis and kidney failure in SLE patients has 
changed little since the 1990s as progress in the development of new treatments for SLE 
has plateaued [177-179]. A more complete understanding of the factors contributing to 
lupus incidence and progression could potentially allow the development of new 
paradigms of SLE management. One area that is not fully understood is what factors 
make women and males with Klinefelter’s much more susceptible to SLE [1,4,6-8]. 
Higher dosage of X-linked immune genes due to incomplete X-inactivation has been 
proposed as a cause of this sex bias [90-92]. The higher levels of immune-promoting 
estrogen hormones and lower levels of immunosuppressive androgen hormones have also 
been shown to contribute to the higher incidence in women and men with Klinefelter’s 
syndrome [146,147,149-152]. The BWF1 mouse model of lupus as the course of disease 
closely mimics the characteristics of SLE humans. Incidence of autoantibodies and 
glomerulonephritis is much higher in female BWF1 mice, and androgens protect against 
disease [16,17,133]. However, while the sex differences in disease progression are well 
characterized, the immunological differences that make BWF1 female mice susceptible 
and male BWF1 mice resistant are largely unexplored. Here we compared the splenic 
transcriptomes of disease-prone female BWF1 mice to disease resistant male BWF1 mice 
and healthy control BALB/c mice. We found that a significant cluster of genes was 
similarly regulated in the male BWF1 and female BALB/c mice in comparison to the 
disease-prone female BWF1 mice. The fact that a subset of genes varied not by sex or 
stain, but by disease susceptibility suggested that the lower lupus susceptibility of male 
BWF1 mice could be related to differences in splenic immune processes. Subsequent 
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functional analysis of genes upregulated in male BWF1 and female BALB/c compared to 
female BWF1 found similarities in what functional processes were enriched in the two 
disease-resistant groups compared to the disease-prone group. Of particular note was an 
enrichment in the positive regulation of phagocytosis in both the male BWF1 and female 
BALB/c. This was significant because a deficiency in the clearance of apoptotic cells by 
phagocytosis is associated with increased lupus susceptibility [371,491,492]. 
The process by which phagocytes engulf apoptotic and necrotic cells is called 
efferocytosis [370]. This process allows the removal apoptotic debris in a manner that 
promotes anti-inflammatory responses. This is crucial to the maintenance of self-
tolerance, as stimulation of immune responses against apoptotic cells and the self-
antigens they contain could result in autoimmunity [371]. Rapid ingestion of apoptotic 
cells prevents the potentially autoimmune stimulating antigens from being exposed to 
other immune cells and potentially driving immune responses. At the same time, the anti-
inflammatory cytokines produced by the phagocytes suppress nearby immune cells that 
may have been exposed to the apoptotic debris [370-372]. Macrophages are the cells 
primarily responsible for efferocytosis, and defects in macrophage efferocytosis are 
strongly associated with the development of SLE. Macrophages from SLE patients 
exhibit reduced ability to phagocytose apoptotic cells, and accumulation of apoptotic 
cells is seen in SLE patient tissues [370,371,380,493,523]. This defect is also present in 
murine models of lupus, as peritoneal macrophages from female BWF1 mice are 
deficient at efferocytosis compared to healthy control female BALB/c mice [391]. Our 
findings from the RNA-seq suggested that the sex bias of lupus in BWF1 mice might be 
partially due to deficient efferocytic activity in female BWF1 mice. If male BWF1 
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splenic macrophages are like those of healthy control mice and are intrinsically more 
efficient at efferocytosis, we would expect them to express higher levels of genes directly 
involved in the efferocytic process. We examined the pro-phagocytosis genes upregulated 
in male BWF1 compared to the disease-prone female BWF1 mice and we identified one 
gene, LRP1, which is expressed in macrophages and is responsible for binding apoptotic 
cells and promoting their ingestion [405,506]. The other phagocytosis promoting genes 
are either not expressed in macrophages (SFTPA1) or not directly involved in 
phagocytosis (IL2RB, RAC2, and IL1B) [534-538]. Measuring expression in sorted male 
and female BWF1 splenic macrophages showed that male splenic macrophages do 
express higher levels of LRP1. Also, macrophages from androgen depleted lupus-prone 
male BWF1 mice expressed lower levels of LRP1 compared to intact male BWF1 mice. 
Together, these findings support the theory that there could be a sex-based difference in 
splenic macrophage efferocytic efficiency. 
Based on these findings, we compared the ability of female and male BWF1 
splenic macrophages to phagocytose apoptotic cells, and found male BWF1 splenic 
macrophages are more efficient at efferocytosis. Furthermore, this difference was 
androgen dependent, as male BWF1 mice that had undergone androgen depletion by 
castration had splenic macrophage with deficient efferocytosis compared to macrophages 
from intact male BWF1 mice. This finding that male BWF1 mice exhibit increased 
splenic macrophage efferocytosis in an androgen dependent manner sheds new light on 
the causes of sex bias in the lupus BWF1 mouse model. An early study on lupus in the 
BWF1 mouse strain found that while removal of the spleen had no effect on the 
progression of disease in female mice, in the male mice splenectomy resulted in 
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accelerated anti-nuclear antibody development and decreased survival [539]. Our 
findings suggest a possible explanation for this sex-based difference in the effect of 
spleen removal. The spleen is a major site of apoptotic cell clearance [379,387,504,505], 
and reductions in the body’s ability to clear apoptotic cells promote lupus progression 
[371,391,491,492]. The increased disease in splenectomized male mice could, therefore, 
be driven by an increase in the accumulation of apoptotic debris. Since, as our findings 
show, splenic macrophages in male BWF1 mice are more efficient at efferocytosis than 
those from female BWF1 mice, the removal of the spleen would have a bigger impact on 
the overall apoptotic cell clearing ability of the male mice.  
 While we had identified a defect in splenic macrophage efferocytosis in female 
and androgen-depleted male BWF1 mice, the source of the defect was not clear. The 
defect was linked to lower levels of androgen signaling (i.e., due to depletion of 
androgens by castration), which raised the question of whether macrophages, which are 
known to express androgen receptors, could be directly affected by androgens to increase 
phagocytosis of apoptotic cells. However, an examination of the literature shows that this 
is unlikely. Multiple studies have found either that treatment with androgens actually 
suppressed macrophage phagocytic activity [508,540-543], or that androgen treatment 
had no effect on macrophage phagocytosis [544,545]. Estrogen, conversely, generally has 
a pro-phagocytic effect [546,547]. These opposite effects of sex hormones may be why 
macrophages from healthy female rats and mice have been shown to have higher 
phagocytic activity than those from male rats and mice [74,75]. However, it has also been 
shown that castration of male mice decreases peritoneal macrophage phagocytic activity 
[548]. Taken together, this suggests that androgens are important for macrophage 
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phagocytosis, but that this effect is not mediated by a direct androgen-macrophage 
interaction. 
One way that androgens can indirectly influence the immune system is by altering 
intestinal metabolite profiles. Androgens can affect both host and microbial metabolic 
activities, and alterations in metabolite production can have a major on the immune 
system [218,324,436,501,502]. In our studies described in the Metabolite section of this 
dissertation, we explored the functional differences between intact male and female 
BWF1 microbiota by comparing their fecal metabolite levels. We found that in all three 
experiments, male mice had higher levels of phytol (Fig. 30), a metabolite which is 
derived from chlorophyll and exhibits RXR and PPARγ agonist activity [420]. We also 
found phytol abundance was greater in intact than castrated male BWF1 mice (Fig. 31A). 
Once phytol is absorbed from the intestine it is converted to phytanic acid, which readily 
travels in the bloodstream and is an even more potent agonist activity than phytol and 
activates the PPARγ/RXR, PPARδ/RXR, and LXR/RXR heterodimeric signaling 
complexes [393-399,503]. When BWF1 fecal phytanic acid levels were tested, only the 
male feces had detectable levels; it was completely absent from the female and castrated 
male feces (Fig. 31B). 
LXR/RXR and PPARγ/RXR signaling are known to promote efferocytosis via 
many different mechanisms [381,393,397,404,409,410,414,549-560]. Also, our RNA-seq 
data showed that male BWF1 splenic macrophages expressed higher levels of LXR and 
PPARγ-stimulated genes. This made the phytanic acid an obvious candidate for 
investigation as a source of the sex and sex-hormone-based differences in macrophage 
efferocytosis. We investigated the effect of phytanic acid treatment on female BWF1 
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splenic macrophages, and found that it increased their efferocytic activity. We also 
performed these experiments with splenic macrophages from androgen-depleted male 
BWF1 mice, and found similar results. This suggests that treatment with phytanic acid 
might be able to correct the deficiency in efferocytosis that correlates with lower 
androgen signaling. The naturally higher levels of phytanic acid and its precursor, phytol, 
in male BWF1 mice may contribute to the higher level of efferocytosis in male BWF1 
splenic macrophages. This hypothesis was strengthened by the fact that female BWF1 
mice treated with phytanic acid had macrophages with higher efferocytic activity. 
While mammals can convert phytol into phytanic acid, they lack the genes to 
produce phytol [460-462]. Therefore, the intestinal microbiota is the most likely source of 
the increased levels of phytol and phytanic acid seen in intact male BWF1 mice. This fits 
with the findings of recent studies in the literature, which have suggested that the gut 
microbiota could be a source of the sex bias seen in lupus. Studies have found that 
patients with systemic lupus erythematosus and other autoimmune diseases have been 
found to have dysbiotic (disrupted) microbiomes [184,256,257,276-280,282,283]. 
Multiple mechanisms by which the microbiota can influence the immune system have 
been identified, including molecular mimicry of self-antigens, direct interactions with 
intestinal immune cells that induce differentiation, and the production of 
immunomodulatory metabolites [218,436]. Furthermore, sex hormones can significantly 
affect the microbiota, suggesting that BWF1 mouse androgens levels could affect lupus 
progression by influencing the composition and functions of the microbiota [276-
280,282,283,300-302]. This possibility was supported by the findings of two recent 
studies, which showed that the sex bias in the NOD model of Type 1 diabetes was linked 
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to differences in microbiota composition between male and female mice. They found that 
male mice contained a higher abundance of microbes that could protect them against 
developing diabetes, and that in the absence of the microbiota, the sex bias was absent 
[323,324]. One of the studies found that disease was suppressed in female NOD mice that 
received a microbiota transfer from male NOD mice. However, this protective microbiota 
phenotype was dependent on androgen, showing that the immune system, sex hormones, 
and the microbiota are closely interconnected [324]. Also, a recently published paper on 
the SWRxNZB F1 (SNF1) mouse model found differences in microbiota composition 
between intact male, androgen-depleted male, and female mice, but failed to find that 
these alterations significantly affected disease progression. However, the fact that they 
also found androgen depletion didn’t significantly alter disease progression suggests that 
their model may not have been well suited to studying the relationship between sex 
hormones, the microbiota, and lupus [26]. We have also found differences in microbiota 
composition in feces between female and male, and intact and castrated male BWF1 
mice. To investigate whether these differences were connected to the differences in 
efferocytosis, we transferred male microbiota into female BWF1 mice and found it 
improved splenic macrophage efferocytosis. This suggested that the sex differences in 
BWF1 splenic macrophage efferocytosis may be mediated in part by the microbiota. 
These findings have obvious implications for potential SLE therapeutics. 
Increasing macrophage efferocytosis could potentially suppress lupus progression. In 
fact, there is some evidence that glucocorticoid therapy acts in part by increasing 
efferocytosis, but long-term use of glucocorticoid-based therapy is associated with 
irreversible side effects and in some cases can lead to a Th17/Th1 imbalance that 
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promotes inflammation [178,561,562]. However, the agonist activity of phytanic acid is 
too nonspecific for it to be a viable therapy, since it can activate any permissive RXR-
containing heterodimer. For our findings to inform future research, it was crucial to 
understand what pathways are involved in the pro-efferocytic effect of phytanic acid. 
Phytanic acid can stimulate signaling through the PPARδ/RXR, LXR/RXR, and 
PPARγ/RXR complexes [449-453,463], and all of these pathways can stimulate 
macrophage phagocytosis [381,393-400]. However, we conclusively showed that the pro-
efferocytosis effect of phytanic acid is dependent on LXR/RXR and PPARγ/RXR 
signaling but not on PPARδ/RXR signaling. 
This leaves open the question of what LXR and/or PPARγ stimulated genes is 
phytanic acid upregulating to promote phagocytosis. We compared female and male 
BWF1 splenic macrophage expression of canonical efferocytic mediators that are 
stimulated by PPARγ and/or LXR agonists. AXL, MFGE8, and C1QA fit these criteria, 
and defects in their expression are associated with lupus [375,382,393,400,405,522-533], 
but we found no differences in splenic macrophage transcript levels between male and 
female BWF1 mice. We also tested CD36, MERTK, and TIMD4 protein levels, since 
they are well established important mediators of efferocytosis [372,384,393,396,404,408-
410,412,413,513-521]. Of these three, only the pro-efferocytic receptor CD36 exhibited a 
sex-based difference in expression. CD36, a cell surface receptor that binds apoptotic 
cells and facilitates their phagocytosis [408], was expressed at higher levels in male 
BWF1 than female BWF1 splenic macrophages. Macrophages from castrated male 
BWF1 mice also had decreased CD36 expression compared to intact male BWF1 mice. 
CD36 expression can be enhanced by LXR and/or PPARγ signaling, and its expression 
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was highest in male BWF1 mice, which have been found to have higher levels of 
intestinal metabolites, phytol and phytanic acid, which can activate these receptors [420]. 
We found treating splenic macrophages with phytanic acid increased their levels of CD36 
expression, and feeding female BWF1 mice phytanic acid-containing microspheres 
increased splenic macrophage CD36 expression. This suggests that the higher levels of 
CD36 expression in male BWF1 splenic macrophages could be due to higher production 
of phytanic acid and its precursor phytol in the intestine. Furthermore, functional CD36 is 
required for phytanic acid’s enhancement of macrophage efferocytosis, which suggests 
there could be a link between phytanic acid’s ability to upregulate CD36 and its ability to 
improve macrophage efferocytosis. 
In conclusion, we have shown that disease-resistant male BWF1 mice have 
splenic macrophages that are more efficient at efferocytosis than macrophages from 
disease-prone female or androgen depleted castrated male BWF1 mice. This deficiency 
can be ameliorated by treatment with the metabolite phytanic acid, which is more 
abundant in males and activates the efferocytosis-promoting LXR and PPARγ pathways. 
This effect of phytanic acid may be mediated in part by upregulating CD36 expression. 
Transferring microbiota from male BWF1 to female BWF1 mice also increases 
macrophage phagocytosis, which supports the hypothesis that differences in microbiota 
metabolite production between male and female BWF1 mice result in differences in 
macrophage phagocytosis of apoptotic cells. This sex-based difference in efferocytosis 
could contribute to lupus progression, which sheds new light on the source of the sex bias 
in the BWF1 mouse model of lupus and suggests possible avenues of research into new 
treatments for lupus. 
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Figure 32. Splenocyte transcriptome and macrophage gene expression analyses 
indicate that male BWF1 macrophages may have greater efferocytic activity. 
Splenocytes from 16-week-old female and male BWF1, and female BALB/c mice were 
collected and gene expression was analyzed by RNA-seq. (A) Heat map of hierarchically 
clustered differentially expressed genes in splenocytes from female BALB/c, and female 
and male BWF1 mice (n=3). (B) Selected GO:BP pathways enriched in male BWF1 and 
female BALB/c compared to female BWF1 splenocytes. (C) Lrp1 normalized read levels 
in female and male BWF1 splenocytes. (D) F4/80+CD11b+ splenic macrophages from 16-
week-old female and male BWF1 mice were sorted and Lrp1 transcript levels were 
measured by qPCR (n=6). (E) Expression of LRP1 16-week-old female and male BWF1 
CD11b+F4/80+ +splenic macrophages measured by flow cytometry as mean fluorescence 
intensity (MFI) fold difference (n=5). (F) CD11b+F4/80+splenic macrophages from 16-
week-old intact and castrated male BWF1 mice were sorted and Lrp1 transcript levels 
were measured by qPCR (n=6). (G) Expression of LRP1 16-week-old intact and castrated 
male BWF1 CD11b+F4/80+ splenic macrophages measured by flow cytometry as mean 
fluorescence intensity (MFI) fold difference (n=5). *p<0.05, **p<0.01, ***p<0.001 
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Figure 33. Representative histograms of LRP1 and CD36 labeling of female vs male 
CD11b+F4/80+ cells. Splenocytes from 16-week-old female or male BWF1 mice were 
collected and labeled with CD11b, F4/80 and LRP1 or CD36 antibodies and analyzed by 
flow cytometry. Expression of LRP1 or CD36 by CD11b+F4/80+ cells was evaluated. 







Figure 34. Representative gating of CD11b+F4/80+ cells among adherent cells that 
were positive for the apoptotic thymocyte marker CellTraceTM Violet (CTV). 
Splenocytes from 16-week-old female and male BWF1 mice were collected and 
macrophages enriched by selecting for adherent cells. Phagocytosis of apoptotic cells by 
macrophages was assayed by culture with CellTraceTM Violet (CTV)-labeled apoptotic 









Figure 35. Splenic macrophages from disease-prone female or castrated male BWF1 
mice are deficient in their ability to phagocytose apoptotic cells compared to disease-
resistant intact male BWF1 mice. Splenocytes from 16-week-old BWF1 mice were 
collected and macrophages either enriched by selecting for adherent cells or sorted for 
CD11b+F4/80+ cells by FACS. Phagocytosis of apoptotic cells by macrophages was 
assayed by culture with CellTraceTM Violet (CTV)-labeled apoptotic thymocytes for one 
hour followed by analysis of percentages of CD11b+F4/80+ cells that were CTV+. (A) 
Adherent splenocytes from female or male BWF1 mice were labeled with CD11b and 
F4/80 antibodies, and CD11b+F4/80+ cells evaluated for %CTV+ n=6). (B) Sorted 
CD11b+F4/80+macrophages from female or male BWF1 mice were evaluated for %CTV+ 
cells (n=9). (C) Adherent splenocytes from intact male or castrated male BWF1 mice 
were labeled with CD11b and F4/80 antibodies, and CD11b+F4/80+ cells evaluated for 
%CTV+ (n=6-7). (D) Sorted CD11b+F4/80+macrophages from intact male or castrated 
male BWF1 mice were evaluated for %CTV+ cells (n=6). (E) Adherent splenocytes from 
male BWF1 mice implanted with time-release pellets containing vehicle or androgen 
receptor inhibitor, flutamide, were labeled with CD11b and F4/80 antibodies, and 
CD11b+F4/80+ macrophages were evaluated for %CTV+ cells (n=8). Data are reported as 











Figure 36. A male microbiota associated metabolite, phytanic acid, increases the 
ability of adult BWF1 splenic macrophages to phagocytose apoptotic cells. (A) Gene 
expression in female and male splenocytes from 16-week-old BWF1 mice was 
determined by RNA-seq. Metacore Transcription Factor Enrichment analysis shows the 
fold-enrichment of upregulated genes in male vs female splenocytes that are controlled 
by the transcriptional regulators PPARγ and LXRβ (n=3). Splenocytes from 16-week-old 
female (B, C) or castrated male (D) BWF1 mice were collected and macrophages either 
enriched by selecting for adherent cells and labeling with CD11b and F4/80 antibodies 
(B) or sorted for CD11b+F4/80+ cells by FACS (C, D). Cells were pre-treated with 50 μM 
phytanic acid (PA) or ethanol (Vehicle) for 48 hours then phagocytosis of apoptotic cells 
by macrophages was assayed by culture with CellTraceTM Violet (CTV)-labeled 
apoptotic thymocytes for one hour followed by analysis of percentages of CD11b+F4/80+ 
cells that were CTV+ (B, C, D; n=6-7). (E) Female BWF1 mice were treated with PBS 
(Vehicle) or phytanic acid (PA) encapsulated in microspheres 3x per week for 4 weeks 
beginning at 12 weeks of age then splenocytes were collected and sorted for 
CD11b+F4/80+ cells by FACS. Phagocytosis of apoptotic cells by macrophages was 
assayed by culture with CTV-labeled apoptotic thymocytes for one hour followed by 
analysis of percentages of CD11b+F4/80+ cells that were CTV+ (n=8). (F) Twenty-four-
day-old (shortly after weaning) female BWF1 mice were fed cecal contents from adult 
female (negative control) or male (experimental) BWF1 mice, or 24-day-old male BWF1 
mice were fed cecal contents from adult male BWF1 mice (positive control). Mice were 
then fed cecal contents monthly until 16 weeks of age when splenocytes were collected 
and sorted for CD11b+F4/80+ cells by FACS. Phagocytosis of apoptotic cells by 
macrophages was assayed by culture with CTV-labeled apoptotic thymocytes for one 
hour followed by analysis of percentages of CD11b+F4/80+ cells that were CTV+ (n=6). 
Data are reported as fold change (FC) in %CTV+ cells (B-F). *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001  
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Figure 37. Phytanic acid increases macrophage phagocytosis in an LXR/RXR and 
PPARγ/RXR dependent, and PPARδ/RXR independent manner. Splenocytes from 
adult female BWF1 mice were collected and sorted for CD11b+F4/80+cells by FACS. 
Cells were pre-treated with 50 μM phytanic acid (PA), ethanol (Vehicle) and/or nuclear 
receptor (RXR, PPARγ, LXR, PPARδ) inhibitors for 48 hours then phagocytosis of 
apoptotic cells by macrophages was assayed by culture with CellTraceTM Violet (CTV)-
labeled apoptotic thymocytes for one hour followed by analysis of percentages of 
CD11b+F4/80+ cells that were CTV+. (A) 10 μM of RXR inhibitor HX531 (n=10). (B) 10 
μM of PPARγ inhibitor GW9662 (n=10). (C) 5 μM of LXR inhibitor GSK2033 (n=10). 
(D) 10 μM of PPARδ inhibitor GSK0660 (n=10). Data are reported as fold change (FC) 











Figure 38. Male splenic macrophages express higher levels of CD36, and phytanic 
acid increases CD36 expression. Splenocytes from 16-week-old female, male, or 
castrated male BWF1 mice were collected and labeled with CD11b, F4/80, and pro-
efferocytic receptor (CD36, MERTK, or TIMD4) antibodies and analyzed by flow 
cytometry. Expression is shown as mean fluorescence intensity (MFI) fold difference and 
comparisons were done with Student’s t-tests. (A) CD36, MERTK, and TIMD4 
expression in female and male CD11b+F4/80+ cells (n=5). (B) CD36 expression in intact 
and castrated male CD11b+F4/80+ cells (n=5). (C) CD36 expression in female 
CD11b+F4/80+ cells treated with 50 μM phytanic acid (PA) or ethanol (Vehicle), for 24 
hours (n=5). (D) CD36 expression in castrated male CD11b+F4/80+ cells treated with 50 
μM phytanic acid (PA) or ethanol (Vehicle), for 24 hours (n=5). (E) Female BWF1 mice 
were treated with PBS (Vehicle) or phytanic acid (PA) encapsulated in microspheres 3x 
per week for 2 weeks then splenocytes were collected. CD36 expression in 
CD11b+F4/80+ cells was analyzed (n=3). (F) Splenocytes from 16-week-old female 
BWF1 mice were collected and sorted for CD11b+F4/80+ cells by FACS. Sorted cells 
were pre-treated for 48 hours with 50 μM phytanic acid (PA) or ethanol (Vehicle). Then 
they were treated with or without blocking anti-CD36 antibody for 30 mins and 
phagocytosis of apoptotic cells was assayed by culture with CellTraceTM Violet (CTV)-
labeled apoptotic thymocytes for one hour followed by analysis of percentages of 
CD11b+F4/80+ cells that were CTV+. Data are reported as fold change (FC) in %CTV+ 






Figure 39. Expression of pro-efferocytic genes in female and male BWF1 splenic 
macrophages. Splenocytes from 16-week-old female and male BWF1 mice were 
collected and sorted for CD11b+F4/80+cells by FACS. AXL, C1QA, and MFGE8 
transcript levels were measured by qPCR (n=6). 
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Figure 40. Raw Mean Fluorescence Intensity (MFI) data for pro-efferocytic 
expression analysis by flow cytometry. Splenocytes from 16-week-old female, male, or 
castrated male BWF1 mice were collected and labeled with CD11b, F4/80, and pro-
efferocytic receptor (LRP1, CD36, MERTK, or TIMD4) antibodies and analyzed by flow 
cytometry. Comparisons were done using Student’s t-tests. (A) Expression (MFI) of 
LRP1 in female and male CD11b+F4/80+ cells (n=5). (B) Expression of LRP1 in intact 
and castrated male CD11b+F4/80+ cells (n=5). (C) Expression of CD36 in female and 
male CD11b+F4/80+ cells (n=5). (D) Expression of MERTK in female and male 
CD11b+F4/80+ cells (n=5). (E) Expression of TIMD4 in female and male CD11b+F4/80+ 
cells (n=5). (F) Expression of CD36 in intact and castrated male CD11b+F4/80+ cells 
(n=5). (G) Expression of CD36 in female CD11b+F4/80+ cells treated with 50 μM 
phytanic acid (PA) or ethanol (Vehicle) for 24 hours (n=5). (H) Expression of CD36 in 
castrated male CD11b+F4/80+ cells treated with 50 μM phytanic acid (PA) or ethanol 
(Vehicle) for 24 hours (n=5). (I) Female BWF1 mice were treated with vehicle (control) 
or phytanic acid encapsulated in microspheres 3x per week for 2 weeks then splenocytes 
were collected. Expression of CD36 in CD11b+F4/80+ cells was analyzed (n=3). *p<0.05, 
**p<0.01, ***p<0.001 
(A) (B) (C) 
(F) (E) (D) 
(I) (G) (H) 
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Figure 41. Proposed mechanism of phytanic acid enhancement of macrophage 
efferocytosis. Phytanic acid binds PPARγ and RXR and activates signaling through the 
LXR/RXR and PPARγ/RXR heterodimers. This leads to increased expression of CD36 
and other pro-efferocytic genes, which in turn leads to enhanced clearance of apoptotic 
cells. Created with Biorender.com. 
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Figure 42. There are many immune cells involved in lupus progression. Defective 
macrophage clearance of apoptotic cells leads to a buildup of inflammatory nuclear 
antigen-containing debris. Myeloid dendritic cells (mDC) activate T cells and B cells, and 
T cells activate B cells. The apoptotic debris further stimulates anti-nuclear antigen 
responses CD103+ dendritic cells (CD103+ DC) induce regulatory T cells (Treg) that 
produce anti-inflammatory cytokines and suppress the activation/function of T cells. 
Plasmacytoid dendritic cells produce IFNα that promote B cell maturation and antibody 
production. 
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 Table 9. Pro-phagocytosis genes upregulated in splenocytes from male compared to 
female BWF1 mice. 
Gene Symbol Gene Name 
SFTPA1 Pulmonary Surfactant Protein A1 
LRP1 LDL Receptor-Related Protein 1 
IL1B Interleukin 1 Beta 
IL2RB Interleukin 2 Receptor, Beta Chain 
RAC2 Rac Family Small GTPase 2 
HSPA8 Heat Shock Protein 8 
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Table 10. PPARγ-regulated genes upregulated in male compared to female BWF1 
splenocytes 
Gene 
Symbol Gene Name Gene Function 
RPLP1 Ribosomal Protein Lateral 
Stalk Subunit P1 
Ribosomal phosphoprotein 60S subunit 
component 
SLC3A2 Solute Carrier Family 3 
Member 2 
Activator of dibasic and neutral amino acid 
transport, regulates intracellular calcium levels 
ELOVL5 ELOVL Fatty Acid 
Elongase 5 
Fatty acid elongase 1, involved in the 
elongation of long-chain polyunsaturated fatty 
acids 
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Table 11. LXR-regulated genes upregulated in male compared to female BWF1 
splenocytes 
Gene 
Symbol Gene Name Gene Function 
CTSB Cathepsin B Lysosomal cysteine protease with both 
endopeptidase and exopeptidase activity 
that may play a role in protein turnover 
TCF7 Transcription Factor 7 T-cell/lymphocyte high mobility group 
box transcription activator, plays role in 
NK cell and ILC development 
CD3E CD3-Epsilon Critical part of the TCR-CD3 complex 
involved in antigen recognition 
S1PR1 Sphingosine-1-Phosphate 
Receptor 1 
Binds sphingosine-1 phosphate with 
high affinity and induces cell-cell 
adhesion 
FOS FBJ Osteosarcoma Oncogene Regulator of cell proliferation, 
differentiation, and transformation 
ACP5 Acid Phosphatase 5, Tartrate 
Resistant 
Catalyzes the conversion of 
orthophosphoric monoester to alcohol 
and orthophosphate 
LRP1 LDL Receptor Related Protein 1 Apoptotic cell clearance, amyloid 
precursor protein clearance, lipid 
homeostasis, intracellular signaling 
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DISCUSSION
A change in animal facilities coincided with a loss of the previously discovered 
ability of male microbiota to protect against lupus when transferred into female BWF1 
mice, but the protective ability has since been restored (Fig. 23). We compared the 
microbiota from periods when the male microbiota was protective originally (A Tower), 
when it was not protective (CTRB Early), and when the protective ability was restored 
(CTRB Recent). We found that while the female and male microbiota profiles were 
significantly different for all three periods, the degree of significance was higher during 
the A Tower and CTRB Recent periods compared to the CTRB Early period. Analysis of 
specific taxa abundance showed that in the A Tower, Bacteroides was higher in male 
than female BWF1, Clostridium abundance was ~10-20%, and Alistipes was detectable. 
In contrast in the CTRB Early experiments, Bacteroides was almost undetectable or was 
higher in female than male BWF1 mice, Clostridium was considerably higher at 30-40% 
abundance, and Alistipes was completely absent. For experiments in the CTRB Recent 
period, the taxa had returned to abundances more similar to that seen in the A Tower. 
Bacteroides was present and higher in male than female BWF1 mice, Clostridium 
abundance was ~5-15%, and Alistipes was present. Additionally, the same species in 
those genera were predominant as in the A Tower and CTRB Early: B. acidifaciens, C. 
leptum, A. putredinis, and A. timonensis. Bacteroides was the taxon most obviously 
associated with the periods when male microbiota was protective, but for CTRB Early 
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Experiment 4, female BWF1 mice had high Bacteroides but were not protected against 
disease. This could potentially be due to the fact that Clostridium was also high and 
Alistipes were absent in CTRB Early Experiment 4. High Clostridium could potentially 
promote lupus susceptibility or block the actions of beneficial microbiota. It is also 
possible that Alistipes and Bacteroides act cooperatively to suppress lupus. These 
hypotheses were supported by the comparison of cecal transfer experiments from the 
CTRB Early and CTRB recent periods. While high Bacteroides did not correlate with 
protection in the CTRB Early cecal transfer experiment, a high ratio of Bacteroides to 
Clostridium abundances did (Fig. 22B); recipients of male microbiota with a high 
Bacteroides/Clostridium ratio had significantly suppressed disease whereas recipients of 
male microbiota with a low Bacteroides/Clostridium ratio did not, suggesting a possible 
explanation for why high Bacteroides in female mice in CTRB Early Experiment 4 did 
not correlate with protection against disease. C. leptum has been found to be enriched in 
SLE patient gut microbiota compared to healthy controls, and reduction of disease 
activity via standard treatments correlated with reduction of C. leptum abundance [439]. 
Another study found that intestinal retinoic acid synthesis was suppressed by bacteria 
from the class Clostridia, which includes Clostridium [440]. Retinoic acid is important 
for the induction of tolerance-promoting T regulatory cells (Tregs) [441], and SLE is 
associated with lower levels of Tregs [442]. Our lab has also found defects in Treg 
induction due to deficient retinoic acid production (manuscript in preparation). This 
suggests that an overabundance of Clostridia could potentially increase susceptibility to 
lupus by suppressing retinoic acid-dependent Treg induction, resulting in an environment 
that is too pro-inflammatory for the beneficial actions of Bacteroides to have any effect 
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on disease progression. In other words, the beneficial actions of the male microbiota may 
depend on a certain level of Treg induction. This could explain why in the CTRB Early 
cecal transfer experiment, the female recipients of female microbiota were not protected 
from disease despite having high Bacteroides. Further study of the effect of Clostridium 
on retinoic acid production in BWF1 mice will be required. The fact that males during the 
CTRB Early period did not develop disease despite having almost no Bacteroides and 
high Clostridium seems to argue against Clostridium promoting disease progression. 
However, despite having suboptimal microbiota compositions, the CTRB Early male 
mice still were naturally producing androgens. Treating lupus-prone female BWF1 mice 
with testosterone suppresses disease [133], and this effect is likely the reason that the 
CTRB Early male mice did not develop lupus. 
We also found that not only the microbiota compositions but also the 
metabolomic profiles of female, intact male, and castrated male BWF1 mice differed. 
Together with our findings that male microbiota could suppress disease in female BWF1 
mice, this suggested that the taxa that were higher in male than female BWF1 mice might 
produce metabolites that could suppress lupus. We subsequently identified metabolites 
that were consistently higher in male than female BWF1 feces and investigated them for 
whether they had the potential to influence lupus progression. Our results suggested that 
histamine production by the gut microbiota is upregulated in intact male BWF1 mice 
compared to female and castrated male mice. Histamine can have anti-inflammatory 
effects on the intestine, which could prevent the “leaky gut” phenomenon that has been 
linked to increased lupus susceptibility [297,357]. Determining what bacterial species are 
responsible for the increased histamine production could be informative. Lactobacillus 
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reuteri and Lactobacillus gasseri have been shown to produce histamine, but both of 
those were elevated in female mice and so are unlikely to be the cause of elevated 
histamine in male mice [563]. It is unknown whether Bacteroides can produce histamine, 
but a recent study offered some evidence that hints it might. Higher microbiota 
production of histamine has been found to promote other allergic diseases [564], and a 
recent study of children with Immunoglobulin E-mediated cow’s milk allergy (IgE CMA) 
found that Bacteroides was highly elevated in the gut microbiota of children with IgE 
CMA compared to healthy controls [565]. This could potentially indicate that 
Bacteroides is promoting IgE CMA disease by producing histamine, though additional 
studies would be needed to confirm it. If Bacteroides did produce histamine, it would fit 
with our findings that Bacteroides abundance and histamine levels both are higher in 
male than female BWF1 mice. Unfortunately, we do not have metabolite data for the 
CTRB Early cecal transfer experiment where Bacteroides was higher in female recipients 
of female than male microbiota. Analysis of the metabolite profiles from this experiment 
and the CTRB recent experiment could shed additional light on what metabolites are 
associated with disease suppression, higher abundances of Bacteroides, and lower levels 
of Clostridium. There is another possible interpretation of both our data and the IgE 
CMA study, though. It is possible that higher levels of histamine favor higher 
Bacteroides abundance, so the higher levels of histamine in our mice affect lupus 
indirectly by promoting growth of beneficial Bacteroides. 
Another interesting finding was that in every experiment where high Bacteroides 
abundance correlated with disease protection, Alistipes was present. This suggests that 
the successful suppression of lupus in female recipients might require both species to be 
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present in the male microbiota. However, this does not necessarily imply that both 
Alistipes and Bacteroides directly influence lupus. In fact, since Alistipes abundance is 
not higher in CTRB Recent male to female recipients than female to female recipients, it 
is unlikely that it directly suppresses lupus. It could potentially produce a precursor to a 
beneficial metabolite produced by Bacteroides. For example, Alistipes could produce 
histidine, and Bacteroides could convert it into histamine. Alternatively, Alistipes could 
enhance engraftment of Bacteroides in female recipients of male microbiota. It is still 
largely unknown what factors determine whether a microbiota transplant results in a 
temporary change followed by a return to the norm or in a stable engraftment of the 
donor bacteria. However, it is known that the compositions of both the donor and the 
recipient matter, though the effects of specific taxa are still being studied. Several studies 
have found that Alistipes species are among the most likely to stably engraft in the donor; 
these included Alistipes putredinis, which was one of the predominant species of Alistipes 
in our mice [566-568]. It is not clear, though, whether Alistipes higher engraftment ability 
also benefits other taxa in the donor microbiota. To determine whether Bacteroides is 
more successfully engrafted when Alistipes is present or absent as well as the effects of 
Bacteroides and Alistipes on lupus progression, we could transfer monocultures of 
Alistipes and/or Bacteroides into female BWF1 mice and compare both the effect on 
disease and the abundance of the donated strains at different time points. There is also 
some evidence in the literature that higher Bacteroides abundance promotes engraftment 
of donor microbiota. A recent study of the long-term microbiota of patients who had 
received fecal microbiota transfers to treat Clostridium difficile found that the higher the 
abundance of Bacteroides in the donor, the more the microbiota composition of the 
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recipient resembled the original donor composition at one year post transfer [569]. This 
suggests that Bacteroides in BWF1 mice might not be affecting microbiota directly but 
instead promoting the engraftment of other beneficial microbes. However, no other taxa 
besides Bacteroides correlated with suppression of lupus in recipients of male microbiota, 
so this is less likely than Alistipes promoting Bacteroides engraftment. 
We also found that the metabolite, phytol, was consistently higher in male than 
female BWF1 mice for all three metabolomic experiments. This metabolite and its 
product, phytanic acid, can activate the RXR and PPARγ receptors, which means that 
they could potentially suppress lupus progression via several mechanisms. RXR agonists 
are known to increase retinoic acid production [490], so phytol and phytanic acid might 
increase intestinal CD103+ dendritic cell (DC) retinoic acid-dependent induction of 
immunosuppressive Tregs by enhancing CD103+ DC retinoic acid production (Fig. 42). 
This is supported by our lab’s findings that gut CD103+ DCs from female BWF1 mice 
are less effective at inducing Tregs than male-derived gut CD103+ DCs, and have a 
defect in retinoic acid synthesis that can be restored by treatment with phytanic acid 
(manuscript in preparation). RXR and PPARγ agonists are also known to upregulate 
genes promoting macrophage efferocytosis [393,394]. This could improve clearance of 
the apoptotic cell debris that is known to promote lupus progression. We focused our 
efforts on investigating macrophage efferocytosis and found, through transcriptomic and 
protein expression analysis, that the expression of the pro-efferocytosis receptor LRP1 is 
higher in male than female BWF1 splenic macrophages. We then tested the ability of 
splenic macrophages to phagocytose apoptotic cells in vitro and found more efficient 
efferocytic activity in intact male than either female or castrated male BWF1 splenic 
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macrophages. The fact that the intact male BWF1 mice had higher splenic macrophage 
efferocytic activity as well as higher abundance of phytol and phytanic acid suggested 
that there could be a connection between the two. To test this, we treated female BWF1 
splenic macrophages with phytanic acid, and found that this improved their ability to 
phagocytose apoptotic cells in a PPARγ and LXR-dependent manner (Fig. 41). Further 
investigations showed that feeding female BWF1 mice either phytanic acid or male 
BWF1 microbiota improved splenic macrophage efferocytosis, which strengthens the 
connection between the differing male and female microbiota profiles, the higher levels 
of phytol/phytanic acid male compared to female BWF1 mice, and the greater efferocytic 
activity of male splenic macrophages. We also determined that phytanic acid treatment 
upregulated the pro-efferocytic receptor CD36, and that CD36 activity was required for 
the enhancement of efferocytosis by phytanic acid, suggesting a possible mechanism 
(Fig. 41). It is worth noting that when LRP1 binds apoptotic cells, it can enhance PPARγ 
signaling. Since male BWF1 splenic macrophages express higher levels of LRP1, this 
suggests that phytanic acid might be more effective at promoting macrophage 
efferocytosis in male than female macrophages. 
As described in Figure 41, our data indicate that phytanic acid can increase the 
ability of macrophages to phagocytose apoptotic cells by activating PPARγ. However, in 
addition to increasing macrophage ability to sequester self-antigen-containing debris 
away from other immune cells, PPARγ stimulation also promotes macrophage production 
of anti-inflammatory cytokines, including TGFβ and IL-10 [394], and causes the 
macrophages to adopt a more M2-like phenotype [570]. These cytokines can suppress the 
inflammatory responses that drive lupus [394], providing another mechanism by which 
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phytanic acid-activated macrophages can suppress disease. This is not limited to 
macrophages in the spleen, either. Because phytanic acid is readily transported through 
circulation, it may also affect kidney-infiltrating macrophages. M2 macrophages have 
been found to suppress inflammation in chronic kidney disease and promote wound 
healing and tissue remodeling, which can help prevent kidney damage [571]. Phytanic 
acid, therefore, could potentially suppress disease not only by improving clearance of 
apoptotic cells, but also by influencing kidney infiltrating macrophages into an anti-
inflammatory phenotype. The ability of phytanic acid to induce an anti-inflammatory 
phenotype in macrophages could be tested by treating macrophages with phytanic acid or 
vehicle, and then challenging them with LPS and measuring their cytokine production. 
The relevance of these effects on macrophages to lupus progression could be tested by 
feeding female BWF1 mice phytanic acid or vehicle and then isolating kidney infiltrating 
macrophages and comparing production of pro- and anti-inflammatory cytokines.  
Additionally, macrophages are far from the only type of immune cell that is 
affected by PPARγ signaling, and there are many immune cells involved in lupus 
progression (Fig. 42). In dendritic cells, PPARγ stimulation downregulates the 
costimulatory molecules CD80, CD83, and CD40 and upregulates the coinhibitory 
molecule B7H1. This makes the dendritic cells less effective at activating T-cells which 
in turn reduces the activation of B cells by activated T-cells [572]. T cells can also be 
directly affected by PPARγ agonists, as PPARγ stimulation suppresses T follicular helper 
responses, which are important for the maturation of antibody-producing B cells [573]. 
Phytanic acid is unlikely to suppress lupus via interaction with B cells, though, as PPARγ 
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activation has been shown to increase B cell antibody production [574]. Clearly, there are 
many possible mechanisms by which phytanic acid could be affecting lupus progression. 
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CONCLUSION
Our microbiota composition, metabolomic, and macrophage data strongly suggest 
that the microbiota from male BWF1 mice is distinctly different both in composition and 
metabolic activity from the female BWF1 mice. These differences likely play a role in 
the ability of the male microbiota to suppress lupus when transferred into female BWF1 
mice. However, as we found when we compared data from the A Tower, CTRB Early, 
and CTRB Recent periods, when the Bacteroides/Clostridium ratio is low and Alistipes is 
absent like they were in the CTRB Early period, female recipients of male microbiota are 
not protected (Fig. 23). These data illustrate how environmental factors have a major 
impact on microbiota composition. Microbiota function was altered as well, resulting in a 
loss of the ability of the male BWF1 microbiota to suppress disease. These experiments, 
therefore, simultaneously demonstrate the tremendous potential of therapeutic microbiota 
transfers and the inherent challenges of developing a large-scale stable and effective 
treatment based on the entire microbiota profile of a healthy person. Even if a donor 
whose microbiota has the desired effect can be identified, any number of things can cause 
the microbiota profile of the donor to change, and the environment of a human donor is 
much less controlled than that of a laboratory mouse. Ideally, specific beneficial bacterial 
strains can be identified, but here too our results highlight potential pitfalls. Our data 
suggest that high Clostridium may block the therapeutic effect of other bacterial strains, 
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meaning that even a therapy that works in some patients may not work in others if they 
have high levels of a strain that counters the effect of the probiotic bacteria. 
If the therapeutic effect is mediated via the production of an immunomodulatory 
metabolite, it may be possible to bypass the bacteria entirely and design a treatment based 
on that metabolite. In our model we showed the disease suppressing effect of male BWF1 
microbiota may be partially due to higher abundance of the microbial metabolite phytol 
and its derivative, phytanic acid, in male BWF1 mice. By activating PPARγ and LXR 
signaling, phytanic acid can upregulate the pro-efferocytic receptor CD36 and promote 
splenic macrophage efferocytosis. Defective efferocytosis contributes to lupus 
progression, so enhancement of efferocytic activity in macrophages could potentially 
suppress disease. This higher production of an efferocytosis-enhancing metabolite could 
potentially contribute to the lower incidence of lupus in male BWF1 mice. The BWF1 
mouse model mimics the sex-bias seen in SLE patients, raising the possibility that sex-
based differences in the microbiota might also indicate that the microbiota could also 
play a part in women being more susceptible to SLE. 
Looking at the bigger picture, these findings show that treatments that alter the 
microbiota could be useful for managing SLE. This will require greater understanding of 
the complex and numerous mechanisms connecting the immune system and the 
microbiota, and our findings represent a significant step in that direction. Probiotics, 
prebiotics, or other therapeutic modalities designed to encourage the growth of beneficial 
bacteria and/or reduce the prevalence of harmful bacteria may become a standard part of 
the treatment a lupus patient receives.
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